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Thesis Abstract
Parathyroid hormone (PTH) and growth hormone (GH) are known to decline with ageing
and have been associated with the process of apoptosis in the osteoblast and osteocyte
cell populations. The presence of viable osteocytes in bone is an important parameter in
maintaining bone quality while osteocyte death by apoptosis during ageing has been
associated with loss of bone strength. PTH (1-34) administration as part of hormone
replacement therapy (HRT) has been shown to exert positive effects via the stimulation
of bone formation and improved bone microarchitecture, mainly through the inhibition of
osteoblast and osteocyte apoptosis. GH on the other hand has been shown to exert
positive effects on bone formation, but due to financial cost not many clinical trials have
been perfonned. However in vivo studies have demonstrated the positive effects of GH
on osteoblasts and osteocytes with a direct or indirect manner, possibly through the
stimulation of growth factors and mainly IGF-I. Although their potential use as anabolic
treatments has long been recognised and their effects on osteoblasts and osteocytes have
been studied for many years, their effects on the maintenance of the osteocytic population
in vivo are less clear. Work in this thesis has investigated whether recombinant human
parathyroid hormone (rhPTH) and recombinant human growth hormone (rhGH) can
inhibit osteocyte apoptosis, either due to ageing or damage as well as the potential of
these hormones to trigger specific gene response on the osteoblast in the ageing rat
skeleton.
An in vitro study in this thesis has indicated the protective effects of rhPTH and rhGH in
osteocyte cultures following physical injury in vitro. These data have provided evidence
for the first time of effects of these hormones in the repair of cell membranes following
disruption. In this study, physical membrane disruption to MLO-Y4 cells in vitro was
taken to represent physical injury-which is one aspect of microdamage to osteocytes in
bone. These findings may provide a new understanding of how osteocytes sense and
respond to injury and the potential of therapeutical compounds to maintain osteocyte
viability in disease and old age.
rhPTH and rhGH treatment was shown to reduced osteocyte apoptosis in aged female rat
bone, while improved trabecular architecture was observed in response to rhPTH
treatment but not to rhGH. These data point to the potential of these hormones to be used
as anabolic treatments. However the molecular mechanisms by which rhPTH and rhGH
maintain the osteocytic population and lead to bone fonnation are not well understood.
The effects of mechanical loading on the maintenance of the osteocytic population were
investigated in human cancellous bone explants ex vivo in the presence or absence of
rhPTH. Osteocyte viability was increased and a significant reduction in osteocyte
apoptosis was observed compared to unloading conditions after 7 days in culture.
Furthermore alkaline phosphatase a marker of an osteogenic repsonse was increased by
mechanical stimulation in the presence or absence of rhPTH compared to unloading
conditions, indicating a stimulatory effect on osteoblasts. Moreover SOST gene
expression was decreased in the presence or absence of mechanical stimulation following
administration of rhPTH. These data pointed to important anabolic effects induced by
mechanical stimulation in the presence or absence of rhPTH.
Finally a laser microdisection study using the tibias of old female rats presented in this
thesis provides the basis for future studies aimed to identify specific osteoblastic genes
regulated by rhPTH and rhGH at different anatomical sites of bone. Such data would
provide the necessary infonnation to elucidate the molecular mechanisms that regulate
rhPTH and rhGH and their effects on bone.
In this study identification of the anti-apoptotic and protective effects of rhPTH and
rhGH on osteocytes in vivo, in vitro and ex vivo highlighted important infonnation on
their bioactivity in vivo. Moreover an attempt to elucidate the molecular mechanisms
behind rhPTH and rhGH effects on osteoblasts in vivo has been presented and provides
the basis for future studies that may prove useful in identifying specific drug targets for
the treatment of pathological bone.
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Introduction: Bone and Parathyroid and Growth Hormones
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Introduction
1.1 Bone as an organ
Bone is a rigid form of connective tissue that, together with cartilage, makes up the
skeletal system. It serves three main functions; it supports locomotion as a site of muscle
attachment; it protects vital organs, such as the brain and bone marrow; and it functions
as a metabolic tissue, acting as a reserve of calcium and phosphate ions that participate in
serum homeostasis (Baron, 1996, Felsenfeld et al., 1999).
Bone is a dynamic tissue that has the ability to adapt to its architecture through
continuous cycles of modelling and remodelling in order to adapt to structural and
mechanical requirements (Wolf 1982, Turner 1992, Parfitt 1994).
The cells involved in the processes of bone modeling and remodeling are under a
coordinated control in order to attain a balance between bone formation and resorption.
This consists of systemic hormones such as parathyroid hormone (PTH),
1,25dihydroxyvitamin D3 and calcitonin, growth hormone (GH) and steroid hormones as
well as growth factors such as transforming growth factor-(3 (TGF-P), fibroblast growth
factor (FGF's), platelet-derived growth factor (PDGF) and insulin growth factor (IGF).
These hormones and growth factors mainly stimulate and regulate bone formation while
cytokines such as members of the interleukin family and tumour necrosis factor (TNF)
act to stimulate osteoclastic bone resorption (Rodan 1992, Hill P. A., 1998, Sommerfeldt
and Rubin, 2001).
Imbalances in these fine tuned interactions may lead to abnormal turnover cycles,
characterized by insufficient formation of bone resorbing or bone forming cells, increased
resorptive or forming activity or abnormal formation of mineral crystals leading to
diseases such as osteoporosis, Paget's disease, osteolytic and osteoscelrotic bone diseases
(Rodan and Martin 2000, Compston JE, 2007).
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1.2 Bone organisation
Bone consists of hydroxyapatite crystals, collagenous proteins which make up
approximately 85-90% of the total protein in bone(collagen type I) and the remaining 10-
15%f the bone total protein is composed of non-collagenous proteins, either serum
derived or exogenous proteins which bind to hydroxyapatite due to their acidic nature (
Baron 1996). Macroscopically, bones can be divided into flat bones, such as bones of the
skull and scapula, long bones such as the tibia and femur and irregular bones such as
vertebrae, maxillae and cranial bones.
Long bones (Figure 1.1) consist of cortical and trabecular bone (Baron 1996) that
contribute to its function as the load-bearing parts of the skeleton. Cortical bone is a
dense structure forming the outer shell of the long bones and enclosing the medullary
cavity. Cortical bone consists of osteons oriented in the direction of maximal stress; each
osteon is composed of a blood vessel enclosed in a Harvesian canal, which is surrounded
by concentric lamellae of collagen fibres and interstitial bone (areas of cortical bone
surrounded by cement lines that do not contain an osteon). The outer surface of the
cortical bone is called the periosteum and the inner the endosteum (Eihorn 1996).
Trabecular or cancellous bone is a porous network found in the vertebrae and the
metaphyses of long bones. It has a spongy appearance and is composed of a network of
rod and plate-like elements that make the overall organ lighter and allowing space for
marrow; trabecular plates are oriented in such a way to resist mechanical load (Weiner
1999, Sikavitsas et al., 2001) Trabecular bone accounts for about 20% of total bone mass
the remaining 80% is cortical bone, but for about 61% of the bone surface area. The main
role of trabecular bone is to absorb more energy imparted during mechanical load; due to
its structure it is capable of tolerating deformation and distributing mechanical loads from










































Figure 1.1 Schematic diagram of a long bone. Either end of a long bone consists of the
epiphysis, characterised by internal trabecular structure, while the central region known
as the diaphysis consists mainly of cortical bone. Diaphysis and epiphyses are separated
by the metaphysis which includes both trabecular and cortical bone and is found below a




During growth, skeletal architecture is established and controlled by the process of bone
modeling. Modeling can be split into 1. the intramembranous ossification, responsible for
the formation of flat bones and the thickening of long bones and 2. the endochondral
ossification that forms the long bones. During intramembranous ossification,
mesenchymal cells differentiate into preosteoblasts and osteoblasts that synthesize woven
bone. Woven bone is characterized by irregular calcification and arrangement of collagen
fibres and high osteocyte cell density, which is replaced by lamellar bone over time
(Turner 1992, Weiner and Wagner 1998, Sikavitsas 2001).
During the process of endochondral ossification mesenchymal stem cells differentiate
into prechondroblasts and chondroblasts that form a cartilaginous matrix and then
differentiate into chondrocytes that will eventually form the growth plate and engender
longitudinal growth (Parfitt 1976, Carter et al 1996). As chondroblasts continue to
proliferate, chondrocytes move away from the proliferative zone and become
hypertrophic. They then initiate the mineralization process of the cartilaginous matrix and
eventually undergoe apoptosis. This process is controlled by a number of factors such as
parathyroid hormone-related protein (PTHrP), Indian hedgehog (Ihh), and bone
morphogenetic proteins (BMPs) (Strewler 2001). Osteoclasts then come into action to
resorb the calcified matrix, while osteoblasts use the matrix as a template to form the
woven bone (Boyde 1980, Parfitt 1994, Weiner and Wagner 1998, Baron 1996).
1.4 Bone remodeling
Bone remodeling otherwise known as bone turnover is a complex process occurring on
trabecular and cortical bone surfaces. During this process old or damaged bone is
replaced by new (Mundy 1995). Remodeling is essential for bones to adapt to mechanical
strains, repair microdamage and maintain mineral homeostasis; about 2-10% of the whole
adult skeleton is constantly undergoing remodeling (Parfitt 1994, Burr et al. 1985,
Eriksen et al. 2007).
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In endochondral and trabecular bone remodeling the source of osteoblasts and osteoclasts
is the stromal and haematopoietic precursors in the bone marrow, respectively. In
periosteal remodelling osteoblasts are derived from the periosteal mesenchymal cells and
the osteoclasts from the peripheral blood haematopoietic precursors (Rodan 1992,
Prockop 1997, Teitelbaum 2000).
Bone turnover occurs in basic multicellular units (BMUs) (Frost, 1969) and involves a
sequence of events, that include formation and activation of osteoclasts that carry out
bone resorption; osteoblasts replace the resorbed bone by secreting osteoid that over time
becomes calcified returning that site to a quiescent state. The average length required to
complete the remodeling cycle is about 5 months (Recker et ah, 1988) but it differs in
cortical and trabecular bone with the trabecular one being lengthier (Figure 1.2). The
osteoblasts will either line the surface of new bone to either undergo apoptosis or to









Figure 1.2 Remodeling Process. The remodeling process involves two distinct stages:
bone resorption (breakdown) and bone formation. When calcium is needed in the body;
osteoclasts attach to the bone and break it down to release calcium. The osteoblasts then
move in to the cavities that the osteoclasts left and release collagen and proteins in these
cavities and stimulate bone mineralization. Some of these osteoblasts will remain as part
of the matrix and become embedded into the bone to form osteocytes
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1.5 Bone cells
Osteoblasts, osteoclasts, bone lining cells and osteocytes are the four cell types found in
bone. Osteoblasts, osteoclasts and bone lining cells are mainly located at the endosteal
bone surface, whereas osteocytes are found embedded within the mineralized bone
matrix. Osteoclasts are the bone resorbing cells whereas osteoblasts are the bone forming
cells. Osteocytes and bone lining cells are defined by their location but new research
suggests that they may have a role in the balance of bone metabolism.
1.5.1 Osteoblasts
The osteoblasts are fully differentiated mononuclear bone forming cells derived from
mesenchymal stem cells (MSC). These cells arise from the mesenchyme during
development and give rise to a number of different progenitors in the bone marrow
stroma (Prockop 1997). These stem cells will form single colonies known as colony
forming units (CFU's), heterogeneous in size, morphology and differentiation potential.
The CFU's are under the control of different hormones, growth factors and cytokines, as
well as transcription factors that guide CFU's to become osteoblasts, adipoblasts,
chondroblasts, myoblasts or fibroblasts (Ducy et al., 2000).
Osteoblasts are characterized by a round nucleus and a cuboidal shape with prominent
Golgi complexes and a well-developed endoplasmic reticulum (Puzas 1996). They are
also characterized by cytoplasmic processes extending into the osteoid, with which they
communicate with the osteocytes in their canaliculi and gap junctions to communicate
with other osteoblasts (Baron 1996). Their main action is to secrete type I collagen and
non-collagenous proteins of the bone matrix, and regulate the mineralization process,
although the exact mechanism is unknown. The production of collagen is an early event,
taking place after the proliferation of osteoblast precursors, followed by the expression of
alkaline phosphatase (ALP) and reaches maximal levels before mineralization (Yoon et
al., 1987). ALP is an enzyme needed for the mineralization of bone matrix however ALP
is not exclusively expressed in bone and is also found in a wide variety of tissues such as
the liver, spleen, intestine kidney and placenta. In bone ALP is considered as a marker of
osteoblasts at late differentiation stage. During matrix mineralization, a number of genes
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such as osteopontin and osteoclacin are activated and the produced non-collagenous
proteins are deposited in the matrix. In addition to those proteins proteoglycans and
glycoproteins are synthesized and secreted, some of these proteins produced by the
osteoblasts leak into the blood circulation, and different immunoassays are available to
quantitate the bone formation rate e.g by the measurement of alkaline phosphatase
isoenzymes in plasma.
The control of differentiation into an osteogenic lineage is controlled by osteoblast-
specific factors (OSFs). OSF2 or Cbfal (recently renamed Runx2) is a member of the
runt homology domain transcription factor family, which was first identified based on its
ability to regulate osteocalcin (OCN); and has been found to be essential as a
transcriptional activator of osteoblast differentiation (Ducy et al., 2000). The importance
of Runx2 was demonstrated by gene targeting experiments in which Runx-2 deficient
mice developed a cartilaginous skeleton without any osteoblasts with subsequent death of
the animals due to respiratory distress (Komori et al., 1997, Otto et al. 1997). It is the
earliest known marker of osteoblast differentiation and can be stimulated by multiple
signal transduction pathways such as the mitogen-activated protein kinase (MAPK)
pathway, which in turn is stimulated by a number of signals including those initiated by
osteogenic growth factors like bone morphogenetic proteins (BMPs), mechanical loading
and hormones such as parathyroid hormone (PTH) (Franceschi and Xiao 2003).
Nakashima et al. (2002) have identified a novel transcription factor, called osterix (Osx)
that also regulates osteoblast differentiation and bone formation. Osx appears to act
downstream of Runx2. It was shown in the same study that there is no bone formation in
Osx null mice, suggesting that it is essential for osteoblast differentiation. Moreover it
was shown by Celil et al. (2005) that during osteogenic lineage progression, in addition
to BMP-2/Smad pathway, insulin-like growth factor I (IGF-I) and MAPK signaling may
be mediated by Osx.
Osteoblasts and adipocytes are able to transdifferentiate, demonstrating the plasticity of
the progenitors (Park et al., 1999). Surprisingly, the inhibition of gap junctions converts
the osteoblasts into cells with an adipocyte phenotype (Schiller et al. 2001) showing the
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importance of cellular communication during osteognesis. These findings are suggestive
of a bipotential adipocyte-osteoblast precursor cell, and the balance between bone
formation and bone marrow adipogenesis may provide the solution towards a therapeutic
target to prevent or treat conditions with inadequate bone formation and excessive
adipogenesis.
The osteoprogenitors go through three stages that can be divided as 1. proliferation, 2.
extracellular matrix production and 3. mineralization; towards fully differentiated
osteoblasts. During these stages a number a complex markers such as collagen type I,
ALP and non-collagenous proteins are expressed. The diversity of this process suggests
that not all osteoblasts are the same; and they may develop via different regulatory
mechanisms and they may be functionally and even molecularly different from each
other. These differences may explain the different trabecular architecture seen at different
skeletal sites.
1.5.2 Osteoclasts
Osteoclasts are the bone resorbing, multinucleated cells containing an average of 4-20
nuclei. However the number of nuclei per osteoclast is extremely variable, with an
average number 1-6 nuclei in rodents, but more in others species such as cats or humans
with about 7-26 nuclei (Vaananen et al., 2008). In addition, in some pathological
situations like Paget's disease, each osteoclast can contain more than 100 nuclei(Boissy et
al., 2002). They are located on the calcified bone surface, usually at the endosteal site and
they act to resorb the mineral and organic phases in bone or calcified cartilage.
Osteoclasts are characterized by abundant Golgi complexes, numerous mitochondria and
lysosomal vesicle trafficking (Vaananen et al., 2008).
Osteoclasts arise from haematopoietic stem cells within the bone marrow, following the
monocyte-macrophage lineage. Osteoclast differentiation is regulated by a number of
cytokines and growth factors such as osteoprotegerin (OPG), receptor activator of nuclear
factor kappa B ligand (RANKL) and receptor activator of nuclear factor kappa B
(RANK). Following proliferation mononuclear precursors close to the bone surface are
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fused into multinucleated osteoclasts; the mechanisms of fusion and determination of
resorption site are still unknown (Vaananen et al., 2000).
The resorption cycle can be divided into 5 phases that include 1. osteoclast attachment, 2.
osteoclast polarization, 3. formation of the sealing zone, 4. resorption and 5. cell
detachment and death (Vaananen et al. 2000). Once the osteoclast is attached for
resorption it undergoes polarization changes. In the resorbing osteoclast a ruffled border
is fonned, and this area becomes the bone resorbing site that is sealed off from the
surroundings by a sealing zone. The ruffled border area is then acidified by the fusion of
intracellular vesicles and by the V-type ATPase proton pump, ensuring rapid dissolution
of minerals, by migration of the osteoclast along the site destined to be removed, as
migration tracks have been observed in vitro and in vivo (Palokangas et al. 1997). After
the osteoclast has resorbed bone and transported the degraded matrix products into the
extracellular space, it will possibly undergoe apoptosis by the same molecular pathways
as other cell types (Xing and Boyce 2005).
1.5.3 Bone lining cells
The bone lining cells as their name implies are located on the bone surface. These are non
terminally differentiated cells that have been reported to revert to an active osteoblast
phenotype e.g following PTH treatment (Gasser, 1998). The surface of the bone which, is
not undergoing remodeling, is covered by a 1-2 pm thick layer of unmineralized collagen
matrix and a layer of flat elongated cells. These cells other than being called bone lining
cells are known by a number of other names such as 'inactive osteoblasts' and 'surface
osteocytes', suggesting that they are descendents of osteoblasts (Parfitt 1994). There is
very little known of their origin, proliferation, differentiation and function, and they only
contain a few organelles, including endoplasmic reticulum, free ribosomes and
mitochondria (Miller et al. 1980). It has been demonstrated that bone lining cells are in
contact with osteocyte dendrites and that this system regulates ionic flow between bone
and plasma (Rubinacci et al. 1998).
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1.5.4 Osteocytes
Osteocytes (Figure 1.3) are the most abundant cells in bone with approximately ten times
more osteocytes than osteoblasts in adult human bone (Parfitt 1977). Osteocytes are
terminally differentiated osteoblasts that have become embedded within the mineralized
bone matrix (Aarden et al. 1994, Noble BS 2008).
It has been suggested that about 10-20% of osteoblasts will differentiate into osteocytes
(Aubin et al. 1996); however the signals regulating this process are not fully understood.
The evidence for the osteoblast-osteocyte differentiation comes from ultrastuctural
studies, reporting how some osteoblasts are buried inside the matrix (Palumbo et al.
1990). Osteocyte communication within the osteocyte syncytium and other cells on the
bone surface is via dendritic processes that radiate in all directions and pass through the
canaliculi in bone (Palumbo et al. 1990, Aarden et al. 1994).
Osteocyte location and the lack of antibodies directed against specific osteocyte markers,
makes it hard to study their characteristics, and there is limited number of studies to date
describing as such. Avian postmitotic osteocytic-like cells (Van der Plaas et al. 1994)
have been isolated and purified using the mAb OB7.3 antibody (Nijweide and Mulder
1986, 1992) that is thought to be specific for the chicken Phosphate-regulating gene with
homology to endopeptidases on X chromosome (PHEX) endoprotease (Westbroek et al.
2002) likely to be forming part of the osteocyte factor 45/ matrix extracellular
phosphoglycoprotein (OF45/MEPE) signaling pathway (MacDougall et al. 2001, Gowen
et al. 2003). Studies have localized the OF45 mRNA on mature osteoblasts and
osteocytes in the skeleton of rats and mice (Petersen et al. 2000, Igarashi et al. 2002)
suggesting that OF45 might be involved in the mineralization process and the
differentiation of osteoblasts to osteocytes. Other molecules involved in this process
would be matrix metalloproteinases (MMPs), dentin matrix protein-1 (DMP-1), Klotho
gene, TGFb inducible early gene-1 (TIEG), lysophosphatidic acid (LPA) and El 1 which
is a possible marker of the osteocytic phenotype and it has been proposed to regulate
formation and maintenance of the osteocytic as well as the osteoblastic cellular processes
(Wetterwald et al. 1996, Schulze et al. 1999, Hadjiargyrou et al. 2001, Noble BS. 2008).
32
The MLO-Y4 osteocyte-like cell line (Figure 1.4) has been extensively used and lots of
infonnation regarding osteocytic characteristics comes from data based on its use. The
osteocalcin promoter was used to target simian virus (SV) 40 large T-antigen oncogene
into the osteocytes of transgenic mice (Kato et al. 1997). These cells are characterized by
long dendritic processes, high osteoclacin secretion, osteopontin and connexin 43
expression, low collagen type I, low alkaline phosphatase expression (Kato et al. 1997)
and Ell expression (Bonewald, 2007). Other cell lines include the MLO-D1, -D6, -A5
and -C2 osteocyte like cells proposed to represent various stages of the differentiation
form osteoblasts to osteocytes (Kato et al. 2001), but are not yet well characterized.
A number of functions have been proposed for osteocytes, including their role in the
mineralization process (Ikeda et al. 1996) and bone resorption known as osteocytic
osteolysis, as demonstrated by the lacunae size in diseases and collagenase production
(Shimizu et al. 1990, Fuller and Chambers 1995,) although this function remains
controversial (Boyde 1980, Marotti et al. 1990, Van der Plaas et al. 1994). Other studies
have demonstrated an inhibitory signal from osteocytes to neighboring osteoblasts that
negatively regulates bone formation (Marotti et al. 1996). It was only recently that a
number of studies (van Bezooijen et al. 2004; 2005, Poole et al. 2005) identified this
signal to be the protein sclerostin, which belongs to the DAN family of glycoproteins, the
product of the SOST gene responsible for sclerosteosis, a rare skeletal dysplasia
characterized by progressive bone thickening and sclerosis of the skeleton (Brunkow et
al. 2001, Gardner et al., 2005). Sclerosteosis is due to loss of function mutations of the
SOST gene, which encodes for the protein sclerostin that is produced by mature
osteocytes and inhibits bone formation (van Bezooijen et al. 2004). It is hypothesized that
in patients with sclerosteosis and sclerostin deficiency, the bone phenotype is probably
due to increased bone fonnation that is not associated with increased bone resorption,
leading to a positive bone balance and increased bone mass (van Bezooijen et al., 2005).
Although investigations in this field are still ongoing it was initially thought that
sclerostin functions as a BMP antagonist, but it is now known that it antagonizes
canonical Wnt signaling by binding to Wnt co-receptors, low density lipoprotein receptor
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related protein (Lrp) 5 and 6 (Li et al. 2005). Thus high bone mass observed in
sclerosteosis and Van Buchem disease may result from increased Wnt signaling due to
the absence of insensitivity to sclerostin (Sutherland et al. 2004, ten Dijke et al. 2008).
In contrast to this theory, other studies, following examination of the lacunar occupancy
at different stages of remodeling, revealed that forming as well as resorbing osteons
contained higher osteocyte density and lacunar occupancy, when compared to quiescent
osteons (Power et al. 2002). Furthermore evidence has been presented to show that the
controlled death of osteocytes via means of apoptosis may be providing the signals that
direct turnover, since apoptotic osteocytes have been observed in close association with
resorbing areas (Noble et al. 1997, Verborgt et al. 2000, Kogianni et al. 2008) and most
importantly prior to initiation of bone resorption (Noble et al. 2003). However, in order
for the osteocytes to respond to this signal they should be able to sense such a
requirement.
It has been speculated that osteocytes due to their location within the bone matrix as well
as the communicating network they form, may be the mechanosensors (Lanyon 1993,
Klein Nulend et al. 1995, Zhang et al. 1997, Noble et al. 2003) and communicate a
metabolic signal to the bone effector cells (Duncan and Turner 1995, Lean et al. 1996,
Aarden et al. 1996, Klein Nulend et al. 1995, Yellowley et al. 2000).
Several hormones known to regulate the bone turnover process have also been shown to
affect osteocyte survival and function, following binding to their receptors located on the
osteocytes, or via indirect routes. Osteocytes have been shown to undergoe apoptosis in
response to glucocorticoids both in vivo (Weinstein et al. 1998) and in vitro (Kogianni et
al. 2004); respond to PTHrP and PTH binding (Rao et al. 1983, Fermor et al. 1995),
which were shown to alter cx43 expression and induce osteocyte apoptosis possibly
regulating osteocyte communication and survival (Divieti et al. 2001). Osteocytes have
also been demonstrated to respond to intermittent PTH administration by downregulating
expression of sclerostin, which is hypothesized to maintain bone lining cells in a
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quiescent state on the bone surface, therefore allowing lining cells to return to an active
bone forming state (Keller et al. 2005, Poole et al. 2005, Leupin et al., 2007).
1.6 Mechanical loading and bone
Mechanical loading of bone causes the deformation of bone matrix generates strain and
intraosseous fluid flow occurs through the interconnected pore space in the bone. Bone
fluid flow leads to a strain generated streaming potential, which is hypothesized to initiate
the mechanotransduction pathway (Hong et al, 2007). Frost in 1988 introduced the term
mechanostat, which describes the ability of bone to adapt its structure to suit its function.
This process requires bone cells to detect mechanical signals and change bone
architecture accordingly. Bone continuously adjusts to strains by changing its shape,
mass or microarchitecure. For example, reduction in mechanical strain due to disuse like
in cases of prolonged bed-rest, space flight or reduced physical activity in old age results
in increased bone resorption and bone loss (Inman et al. 1999, Bonewald and Johnson
2008), whereas under physiological strains, at a frequency of about 2 Hz, which
corresponds to the stride frequency observed during natural locomotion (Mosley and
Lanyon, 1998) bone mass is maintained.
Mechanical loading is known to control both modeling and remodeling processes, having
an important role in bone structure and shape during growth and its maintenance in adult
life (Rubin 1984, Rubin and Lanyon 1987, Carter 1996, Mosley et al. 1997), however the
mechanism is not completely understood.
Evidence has suggested that bone has an ability to repair accumulated microdamage due
to everyday use (Parfitt 2001) via sensing changes in the distribution of strain within the
bone microenvironment and targeting bone for removal by osteoclasts (Burr and Martin
1993, Parfitt 2002). A number of studies support the same idea, since it was demonstrated
that microdamage induced by loading on canine (Burr and Martin 1993) or rat bone
(Verborgt et al. 2000, Noble et al. 2003) was targeted for removal by osteoclastic cells
more frequently than would have been expected by chance alone (Burr et al. 1985, Mori
and Burr 1993, Burr and Martin 1993, Parfitt et al. 2001) followed by increased
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remodeling activity. The mechanism directing those activities is still unknown, but it is
hypothesized to be mediated by the osteocyte (Kakizaki et al. 1971, Kenzora et al. 1978,
Kamijou 1994, Mori et al. 1997, Marrotti et al. 1998, Hazenberg et al., 2007, Bonewald
and Johnson 2008).
Bone is lost in the absence of loading and maintained or increased in the presence of
loading. The bone cells with potential to sense mechanical strains and translate them into
biochemical signals include bone lining cells, osteoblasts and osteocytes, however due to
their distribution thourghout bone, osteocytes are thought to be one if not the major cell
type to sense mechanical strains (Bonewald and Johnson, 2008). It has been recently
shown that targeted deletion of osteocytes results in bone loss and bone does not respond
to unloading (Bonewald and Johnson, 2008).
But the question is how osteocytes sense mechanical loading, for this reason a number of
models, such as substrate tension and bending, fluid shear and a combination of these
have been developed in an effort to answer this question. There is some controversy
regarding the type of in vitro experimental model that would better mimic the in vivo
environment of loading. The fluid flow that occurs in bone during in vivo situations is
another factor that needs to be considered, since it serves a number of functions such as
nutrient transfer as well as creating fluid shear stress forces on the cell membrane and cell
processes. Current theory has it, that cells are more responsive to fluid shear than to
mechanical strain (Turner et al. 1994, Tan SD et al., 2008). To address these questions an
ex-vivo bioreactor system (Zetos™) has been developed to study the effects of
mechanical loading on bone explants, which is the subject of chapter 4 and will be
discussed in detail there.
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Figure 1.3 The osteocyte. The osteocyte contains a large Gogli apparatus (G), an
endoplasmic reticulum (ER) and a basal nucleus. The osteocytes expresses molecules
involved in the targeting of bone formation and resorption and are under the influence of
hormones, neuronal factors and mechanical stimuli.
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Figure 1.4 MLO-Y4 osteocytes in culture. Representative image of MLO-Y4
osteocyte-like cell line isolated and characterized by Kato et al., 1997, demonstrating
large cytoplasmic extensions which enable contact between neighbor osteocytes. Image
was taken using phase contrast light microscopy. Bar representslO pm.
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1.7 Ageing and microdamage
Osteocyte death has long been associated with ageing (Frost 1960). Certain situations
such as osteoarthritis (Wong et al. 1987) and hip fracture (Dunstan et al. 1990, Dunstan et
al. 1993) have also demonstrated a decrease in osteocyte viability. The general view is
that osteocytes can live for decades (Knothe Tate et al. 2004), but it has been
demonstrated that 40% of osteocytes in ear ossicles which do not receive any mechanical
stimulation during fetal development are dead within the second year of life (Marotti et
al. 1998), emphasizing the importance of mechanical loading in osteocyte survival. It was
later confirmed that osteocyte density indeed declines with age and that the age of bone,
rather than the age of an individual, would be more important in determining the fate of
osteocytes (Qiu et al. 2002).
The age related loss of osteocytes has been associated with impaired bone remodeling,
during the removal of microdamage (Compston 2007). Microdamage is a phenomenon
that occurs in bone as a result of repetitive events of cycling loading; accumulation of
small cracks in the mineralized matrix leads to reduced strength of bones, but bone is
capable of removing the damage by targeted remodeling (Mori and Burr 1993). It has
been suggested that about 10-20% of remodelling in the adult human bone is targeted
while the rest is non-targeted remodelling (Parfitt, 2002). An increase in remodelling has
been reported after the generation of microdamage (Mori and Burr 1993), suggesting that
targeted remodelling involves the active removal of damaged matrix by osteoclasts. The
signals that activate the osteoclastic bone resorption at the damage site are unknown but it
is hypothesized that they originate from the apoptotic death of the osteocytes (Verborgt et
al. 2000, Noble et al. 2003, Kogianni et al. 2008). Osteocyte death was observed to
precede osteoclast invasion in the damaged regions (Noble et al. 2003) and increased
osteocyte apoptosis was associated with the up regulation of the proapoptotic Bax protein




Cell death is a phenomenon conserved throughout evolution and can be classified as
either 1. necrotic death that refers to the morphology seen when cells or tissues die from
severe injury, chemical, physical or toxic. This phenomenon is accompanied by
inflammation and changes in tissue architecture and 2. apoptotic cell death, which is the
programmed cell death, as a result of the induction of an internal suicide program.
Apoptosis is initiated by a variety of stimuli including lack of extracellular survival
factors, administration of steroid hormones, viral infections, oxidative stress, ionising
radiation and DNA damage (Kobayashi et al, 2008). The process of apoptosis is regulated
by the function of several proteins such as the bcl-2 proteins, death receptors, the p53
protein and the caspases (Dragovich et al. 1998). Caspases (Cysteine ASpartate
ProteASES), are cysteine proteases that cleave their target molecules at very specific
sites, following aspartate residues (asp-x). (Allen, et al. 1998, Thornberry et al. 1998).
Caspases play a central role in the apoptotic maschinery as they mediate the apoptotic
process in cells from the initial stages (initiator caspases) to their package in apoptotic
bodies for elimination by phagocytosis (effector caspases). Apoptosis is an essential
homeostatic mechanism for the healthy development and maintenance of tissues e.g
finger formation during fetal development or skin regeneration following sunburn
(Cotman and Anderson 1995); via regulation of the size and function of organs through
the removal of harmful, excess or damaged cells (Hall et al. 1994, Pradhan et al. 1997).
Apoptotic cells are characterized by membrane blebbing, chromatin condensation,
disappearance of the nucleolus, alterations of the cell surface, DNA cleavage and
fragmentation of the cell into apoptotic bodies.
The apoptotic bodies, containing ribosomes, morphologically intact mitochondria, and
cleaved nuclear DNA, are cleared by phagocytosis in order to avoid the generation of an
inflammatory response within the body (Kerr et al. 1972, Savill et al. 1997). Apoptosis
involves an initiating phase, decision, execution and clearing phase (Guchelaar et al.
1997) although the exact sequence of events is not well defined and is thought to involve
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some complex interactions (decision events) between the cells destined to apoptose and
nearby phagocytes (Reddien et al. 2007).
1.9 Apoptosis and bone
In bone tissue there is evidence of both necrotic and apoptotic cell death. Necrosis has
been demonstrated in response to exposure to radiation (Sugimoto et al. 1993), steroid
use (Watanabe et al. 1989), ischemia (Rosingh and James 1968) and leads to the
formation of dead bone separated from healthy bone (Wong et al. 1987). There is also
evidence indicating that bone cells such as osteoclasts, osteoblasts and osteocytes as well
as chondrocytes undergoe apoptosis during development, bone remodelling as well as in
disease indicating that apoptotic cell death is essential for skeletal development and
maintenance throughout life. During endochondral ossification and fracture healing,
when cartilaginous tissue is replaced by woven bone, hypertrophic chondrocytes
undergoe apoptosis (Lee et al. 1998). The mechanism of such actions is unknown but it is
hypothesized to act as a signal to osteoclasts for their removal (Bronckers et al. 2000).
Osteoclasts have been shown to undergoe apoptosis following completion of bone
resorption (Hughes and Boyce 1997, Xing and Boyce 2005) as well as in response to
anti-resorptive agents such as estrogen and bisphosphonates (Kameda et al. 1997, Hughes
et al. 1996, 1995; Papapoulos et al. 1997, Rodan 1998, Rogers et al. 1999). Osteoblasts
on the other hand have also been suggested to undergo apoptosis at the end of the bone
formation cycle in order to regulate the number of osteoblasts present during bone
remodelling (Jilka et al. 1998, Landry et al. 1997) or in response to glucocorticoids in
mouse (Weinstein et al., 1998, Plotkin et al., 1999) and human (Weinstein et al. 1998),
but not in rat (Silvestrini 2000) and to various cytokines in vitro such as TNF-a, IL-1,
IFN-y (Ozeki et al. 2002) and FasL (Kawakami et al. 1997, Jilka et al. 1998).
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1.10 Osteocyte apoptosis
Frost was the first to describe the death of osteocytes in vivo when he observed an
increasing incidence of empty lacunae with increasing age (Frost 1960). The mechanisms
by which osteocytes die was initially thought to be due to necrosis, but recent studies
have provided insight into the apoptotic osteocyte cell morphology, demonstrating DNA
fragmentation, chromatin condensation and cell shrinkage in both pathological and
healthy bones (Noble et al. 1997).
Several studies have reported an association between osteocyte apoptosis and the
regulation of bone turnover in growing bone (Noble et al. 1997). The viability of
osteocytes is affected by the presence or absence of hormones, which influence the
maintenance of bone homeostasis such as glucocorticoids (Weinstein et al. 1998,
Mazzioti et al., 2007) or estrogen (Tomkinson et al. 1997, 1998, Huber et al., 2007).
Intermittent administration of PTH has also been suggested to reduce osteocyte apoptosis
in the mouse vertebra in vivo as well as in MLO-Y4 osteocytes in vitro (Jilka et al. 1999).
During orthodontic tooth movement (Hamaya et al. 2000) or in surrounding areas
induced by fatigue microdamage (Verborgt et al. 2000, Waldorff et al., 2007) large
numbers of apoptotic osteocytes have been observed. Furthermore unloading has been
linked to an increase in osteocyte apoptosis in murine (Aguirre et al. 2006) and rat bone
(Basso et al. 2006) in vivo and in vitro (Bakker et al. 2004), shown in rat bone to be
reversed upon reloading (Basso et al. 2006). Moreover Mann et al. (2006) using an ex
vivo bioreactor system showed that loading reduces osteocyte apoptosis in human
trabecular bone explants. In addition Noble et al (1997) have shown that there is a U-
shape relationship between osteocyte survival and the strains they experience, with
nonnal physiological strains reducing apoptosis, whereas damagingly high levels of
loading induced apoptosis. In the latter case, the transient increase in the proportion of
apoptotic osteocytes in response to high levels of mechanical loading was immediately
followed by subsequent intracortical remodelling providing the first evidence that the
presence of apoptotic osteocytes within bone might regulate specific site-directed
remodelling (Noble et al. 2003). These findings indicate that osteocyte apoptosis is a
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process observed both in normal and pathological bone conditions and it might be
essential in influencing the remodelling process towards specific sites.
1.11 Parathyroid Hormone: background
Parathyroid hormone (PTH) is an 84 amino acid polypeptide secreted by the parathyroid
glands. PTH is essential for the maintenance of calcium homeostasis via direct actions on
its main target organs, bone and kidney, and by indirect actions on the gastrointestinal
tract (Sanders and Harvey, 2008). PTH acts to increase the concentration of calcium in
blood in three ways. It enhances the release of calcium from the bones; it enhances
reabsorption of calcium from renal tubules; and it enhances the absorption of calcium
from the intestine by increasing the production of vitamin D (Vanhouten et al., 2004) The
principal form of biologically active PTH is its intact molecule 1-84 which is the key
endocrine regulator of calcium homeostasis (Poole, 2005) but the Kupffer cells in the
liver cleave it into the 1-34 form and smaller C- terminal fragments.
In the kidney PTH has three major biological functions essential for the regulation of
mineral ion homeostasis: enhancement of active reabsorption of calcium from distal
tubules and the thick ascending limb, inhibition of phosphate reabsorption and
enhancement of calcium absorption in the intestine by increasing the production of
vitamin D (Al-Badr and Martin, 2008). Vitamin D activation occurs in the kidney, where
PTH up regulates the activity of the renal 1-a-hydroxylase, thereby enhancing the
synthesis of vitamin D which in turn increases the intestinal absorption of calcium and
phosphate (Leder et ah, 2005). As a result of these PTH actions blood calcium
concentration rises and blood phosphate concentration declines with the concentration of
extracellular calcium being the most important physiological regulator of the minute-to-
minute secretion of PTH. In figure 1.5 the main actions of PTH are outlined.
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Figure 1.5 Calcium homeostasis and PTH actions In response to low calcium
concentrations in the blood, parathyroid glands secrete PTH. PTH in turn stimulates
release of calcium from bone, stimulating bone resorption, decreases urinary loss of
calcium and indirectly stimulated calcium absorption in the small intestine via






1.12 Parathyroid hormone Receptors and Bone
There are two known parathyroid hormone receptors tenned PTH1R and PTH2R. These
receptors are members of the 7 transmembrane G protein coupled family (Jiippner, 1994).
PTH1R is the classical PTH receptor and is expressed in high levels in the target tissues;
bone and kidney, and regulates calcium ion homeostasis through activation of adenylate
cyclase and phospholipase C (Offermanns et al. , 1996 and Mannstadt et al., 1999,
Pioszak and Xu, 2008). This receptor is also found in a large variety of other fetal and
adult tissues and at high concentrations in growth plate chondrocytes. This makes it very
important in cartilage and bone development, because it mediates the parathyroid
receptor protein (PTHrP) dependent regulation of chondrocyte proliferation and
differentiation (Kroneberg, 2003). PTH2R is primarily expressed in the central nervous
system, pancreas, testis and placenta (Usdin et al., 2002). However most biological
functions mediated through this receptor remain to be determined, it is hypothesized that
it may have a role in the regulation of renal blood flow, as the TIP peptide from brain has
been shown to dilate the renal vessels in a PTH1R indepent manner as well as being
expressed in the intrarenal arterial tree (Usdin et al., 1995, Eichinger et al, 2002).
Recently, three receptors for PTH have been isolated from zebrafish, two of these
receptors are homologues to PTH1R and PTH2R while the third one (PTH3R) appears to
be novel and has not been identified in mammalian cells to date (Juppner, 1999, Gensure
et al., 2004).
The PTH1R seems to be the most important receptor mediating the actions of PTH
(Murray et al., 2005). PTH- dependent regulation of mineral homeostasis is mainly
mediated through the PTH1R receptor (Merendino et al., 1986, Potts and Gardella, 2007).
Most of the PTH1R receptor dependent actions involve activation of adenylyl cyclase
while some actions seem to require phospholipase C-mediated events. PTH receptors on
osteocytes and osteoblasts have been demonstrated in situ by Fermor and Skerry (1995)
and on isolated cells (van der Plas et al., 1994).
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A number of studies have reported that there are no obvious PTH receptors on osteoclasts
and as such the effects of PTH are indirect (Rouleau et ah, 1988).On the other hand there
are reports suggesting that there may in fact be PTH receptors on mature osteoclasts (Teti
et ah, 1991, Agarwala and Gay, 1999, Murray et ah, 2005). Although it has not yet been
resolved whether PTH has direct effects on the osteoclast, it is true that it does have
indirect effects (Ono et ah, 2007). The significance of the PTH1R in bone tissue has been
described via the use of knock out (KO) animal models. Ablation of the PTH1R gene in
mice results in neonatal lethality and severe defects in endochondral bone formation that
is characterized by impaired proliferation and accelerated chondrocyte maturation and
mineralization (Lanske et ah, 1996). Some of these mice survive via chodrocyte specific
expression of constitutively active PTHIRs, but display abnormalities in tooth
development and bone while it has not yet been possible to study the mineral ion
homeostasis (Schipani et ah, 1997).
The primary role of PTH per se and of PTH1R in maintaining the ion homeostasis has
been confirmed via the ablation of the PTH gene (Miao et ah, 2001, 2002), that lead to
hypocalcaemia and hyperphosphatemia, whereas activating mutations in the PTH1R
cause hypercalcemia and hypophosphatemia (Schipani et ah, 1996 and Parfitt et ah 1996)
Mice lacking the PTH gene show abnormalities in mineralization and formation of
primary spongiosa of long bones, which are not observed in PTHrP- null mice and it is
hypothesized to reflect loss of PTH specific actions in bone (Miao et ah, 2001).
1.13 Parathyroid hormone and osteocytes
PTH receptors on osteocytes have been demonstrated in situ by Fermor and Skerry in
1995 and on isolated osteocytes in culture by van der Plas et ah in 1994. A number of
reports (van der Plas et ah, 1994, Liang et ah, 1999) demonstrate the expression of early
response genes such as increase of cAMP, of c-fos, c-jun and IL-6 in response to short
term treatment with PTH in osteocytes. In another study c-fos could only be detected in
osteocytes subjected to mechanical stimulation and PTH treatment, indicating that PTH
supports the mechanical responsiveness of osteocytes (Chow et ah, 1998b).PTH has been
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reported to induce connexin 43 (Cx43) gene expression and gap junctional
communication in osteoblasts (Schiller et al., 1992) and there is some evidence that the
same in terms of Cx43 reorganization is induced by PTH in osteocytic cells (Divieti et
al., 2001). The activation of PTH receptors in osteocytes has been reported to potentiate
calcium influx via stretched activated channels (Miyauchi et al., 2000) suggesting another
mechanism for PTH action. PTH receptors are considered very important in mediating
the effects of mechanical loading and the anti-apoptotic effects of PTH in osteocytes
(Bringhurst, 2002).
Interestingly recent reports have indicated that PTH suppresses SOST gene expression in
vivo and in vitro, and that sclerostin may be the direct target for PTH action, which can
partially explain the anabolic actions of PTH in bone (Bellido et al., 2005, Bellido, 2006,
Keller and Kneissel, 2005)
1.14 Parathyroid hormone and bone cells
Clinical trials in the 1970's and 1980's suggested that PTH could restore bone in
osteoporotic patients (Dempster et al., 1993). Such observations were the start point of
intense research in the past decade on the actions of PTH on bone. Direct PTH
administration to osteoblasts in vitro has led to high levels of cellular gap junction
complexes formed by the cells as well as changes in cell shape. These results emphasize
the importance of the quick response of the cells to PTH which may also explain the
process of the osteoblastic cells as they function in situ. (Massas, Benayahu, 1998).
Further research has indicated that the osteoblast and its progenitors are the primary in
vivo targets for PTH action (Dempster et al., 1993, Ogita et al., 2008), where stimulation
of bone formation occurs primarily in endocortical surfaces (Oxlund et al., 1993). In vitro
studies have shown that PTH promotes the commitment of osteoblast precursors
(Ishizuya et al., 1997, Ogita et al., 2008) and inhibits osteoblast apoptosis (Jilka et al.,
1999). In vivo, PTH induces a transient increase in osteoblast apoptosis (Stanislaus et al.,
2000). The controversy between in vitro and in vivo studies may be explained by the
study of Chen et al. (2002) who demonstrated that PTH has anti-apoptotic effects on
undifferentiated mesenchymal stem cells (MSCs) but is pro-apoptotic to more mature
cells. PTH has also been shown to have an indirect effect on osteoclast activation with a
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follow up calcium release by enhanced bone resorption (Murrils et al., 1990). This action
was later confirmed and explained via the stimulation of the osteoblastic RANKL
expression (Yasuda et al., 1998b) and MCSF synthesis (Suda et al., 1999). With
complicated actions partially understood on both osteoblasts and osteoclasts the net effect
of PTH on the skeleton can either be anabolic or catabolic, depending on the dose of
PTH, the mode of administration, the animal species and the specific skeletal site
(Compston, 2007). Moreover a number of clinical trials demonstrated the efficacy of
rhPTH (1-34) otherwise known as teriparatide as a bone anabolic agent (McLung, 2004).
1.15 Effects of parathyroid hormone on bone tissue
The actions of PTH on bone are complex and only partially understood. For the PTH
actions on bone the presence of several different cells types, including the osteoblasts,
bone marrow stromal cells, hematopoietic precursors of osteoclasts and mature
osteoclasts (Ling et al., 2004, Poole and reeve, 2005) are necessary. PTH administration
leads to the release of calcium near the surface of bone. Continuous administration of
PTH (or increased PTH secretion as seen in primary hyperparathyroidism) leads to an
increased number and activity of osteoclasts, while intermittent administration
paradoxically leads to increased amounts of trabecular bone (Suzuki et al., 2008). The
primary PTH responsive cells in bone are the osteoblasts and its precursors. Tarn et al.
(1982) were the first to identify the differential effects of continuous and intermittent
administration of PTH on net bone apposition rate.
To date, it has been proposed that intermittent PTH administration exerts its anabolic
effects in three steps, 1. stimulation of preosteoblast proliferation; 2. promotion of
differentiation of preosteoblasts and osteoblasts; and 3. via the inhibition of osteoblast
apoptosis (Bijlezikian JP., 2008). It is still unclear whether the proliferation of
preosteoblasts is increased, but in vivo experiments in rats' receiving intermittent PTH
showed an increase in the number of osteoprogenitors indicating that PTH stimulates the
proliferation of osteoblasts (Nishida et al., 1994, Kostenuik et al., 1999).
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Studies in rats and humans, in which histomorphometric and bone formation markers
were evaluated, have shown an increase in bone forming surfaces and markers, following
intermittent PTH administration providing evidence that an increase in differentiation of
osteoblasts is occurring in preference to proliferation (Meng et ah, 1996, Dobnig and
Turner, 1997) . Also recent microarray data from osteoblastic cell lines is supportive of
the hypothesis that PTH exerts its anabolic actions via an increase in osteoblast
differentiation (Qin et ah, 2003, Li et ah, 2007).
The other mechanism with which PTH induces an anabolic response in bone is by
inhibition of osteoblast apoptosis. Daily injections with PTH in adult mice with either
normal bone mass or osteopenia, increased bone formation by preventing apoptosis of
mature osteoblasts (Jilka et ah, 1999). Using a rat model it was shown that intermittent
administration of PTH could both induce an initial transient increase in apoptosis and
inhibit the activities of a group of caspases extracted from entire distal metaphyses
(Stanislaus et al, 2000). These studies highlight the importance of this mechanism in
growing and developing animals, but further research is required to elucidate the
relationship of PTH and osteoblast apoptosis.
PTH affects bone resorption via indirect actions through the osteoblast. Osteoclast
recruitment, differentiation and activation occur via direct interaction between RANKL
on the osteoblast and its receptor RANK on the pre-osteoclast. This interaction can be
inhibited by the decoy receptor OPG and thus, the RANKL: OPG ratio will determine the
degree of osteoclast differentiation and activation (Yasuda et ah, 1998). Recent studies
demonstrated that the various modes of PTH administration regulate the RANKL: OPG
ratio differently, resulting in different effects on bone resorption. Continuous PTH
infusion in rats, sustained a decrease in mRNA for OPG and a prolonged increase in
mRNA for RANKL (Ma et ah, 2001) that was observed over twenty four hours, showing
that continuous administration favors continued differentiation, recruitment and
activation of osteoclasts. Further evidence is provided from studies with cultured marrow
cells; continuous PTH administration produced increased numbers of osteoclasts and
caused a 25-fold increase in the RANKL: OPG ratio. On the other hand when PTH was
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administered intermittently increased osteoblast differentiation markers were
demonstrated, with little effect on the RANKL: OPG ratio (Locklin et al., 2003). PTH
can exert either anabolic or catabolic effects on bone and for these reasons it has become
an intense area of research with the scope of elucidating the mechanism that underlie
those actions and lead to the design of new pharmaceutical compounds.
1.16 Parathyroid hormone related protein
Parathyroid hormone related protein (PTHrP) is a family of proteins produced by most
tissues in the body. A segment of PTHrP is closely related to PTH but its peptides have a
broader spectrum of effects. PTH and some of the PTHrP peptides bind to the same
receptor, but PTHrP peptides also bind to several other receptors (Strewler, 2000). PTHrP
is widely expressed in a number of fetal tissues and has a number of functions such as in
the control of endochondral bone formation, the development of the mammary epithelium
and the eruption of teeth (Kronenberg HM, 2003, Wysolmerski et al., 1998 and Philbrick
et al., 1998)
In cartilage and bone development most of the infonnation in the role of PTHrP comes
from the use of knockout mice. In cartilage the first such experiment was reported in
1994, in which the PTHrP null mouse was a neonatal lethal (Karaplis et al., 1994). The
formation of the cartilaginous growth plate is an essential step for normal linear growth.
The critical control point in this process is the chondrocyte differentiation, to become
terminally differentiated chondrocytes. PTHrP normally regulates the rate of this program
and its deletion results in a rapid progression of this program with the classic
chondrodysplasia phenotype that is lethal at birth (Harrington et al., 2007)
The abnonnalities observed in the endochondral skeleton are a consequence of the
absence of PTHrP regulation of chondrocyte development (Karaplis et al., 1994,
Kronenberg, 2003). It was later reported that heterozygous PTHrP-null mice are normal
at birth but acquire trabecular osteopenia in their long bones from the age of three months
(Amizuka et al., 1996), with subsequent reduced bone formation and mineral apposition,
as well as fonnation and survival of osteoblasts. PTHrP is also expressed in the
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periosteum and in the insertion sites of tendons and ligaments into cortical bone, the
function of PTHrP at those sites is unknown but it is hypothesized that PTHrP may be
induced at those sites by mechanical forces, and serve to regulate localized bone
formation and/or bone formation (Chen et al., 2006).
1.17 Growth Hormone: background
Growth hormone (GH) stimulates growth and cell reproduction in humans and other
animals. It is a 191 amino acids single chain polypeptide hormone and it's a major
participant in growth and metabolism (Figure 1.6). It is synthesized, stored and secreted
by the somatotroph cells of the anterior pituitary gland (Zofkova, 2003). It has a variety
of functions in the body, with the most important being the postnatal longitudinal bone
growth and the increase of height throughout childhood. There are a number of diseases,
such as growth hormone deficiency in children and adults that can be treated through the
therapeutic use of rhGH. Acromegalics due to excess secretion of GH show an increase
in bone remodelling as measured by biochemical parameters of osteoblastic activity such
as alklaline phosphatase (ALP) and osteocalsin production (Ohlsson et al., 1998). The
levels of GH secretion decline with age, by approximately 14% per decade from young
adult life, and the changes in body composition associated with ageing such as reduction
in bone mass are similar to those adults with GH deficiency (Shalet et al., 1998, Velduis
and Bowers, 2003).
GH affects several tissues including the liver, muscle, kidney and bone and its effects are
generally anabolic. GH directly stimulates division and multiplication of chondrocytes as
well as stimulating production of insulin-like growth factor 1 (IGF-1), via its actions on
the liver which is the GH's main target organ and the principal site of IGF-1 production
(Giustina et al., 2008). IGF-1 has growth stimulating effects on a number of target
tissues, making it both an endocrine and autocrine/paracrine hormone, it also exerts its
effects on osteoblasts and chondrocytes which will be discussed later to promote bone
growth (Zofkova 2003).
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In addition to bone growth, GH has other effects on the body; these would include,
increase in calcium retention, increased muscle mass (Corpas et al. 1993) promotion of
lypolysis (Davidson 1987), reduction of glucose uptake by the liver as well as promotion
of gluconeogenesis in the liver and it contributes to the maintenance and function of
pancreatic islets and stimulates the immune system (Chen et al. 1998). Recent studies
have shown that through direct actions on the brain, GH may modulate emotion, stress
response, and behavior (Yoshizato et al. 1998, Abizaid et al., 2008).
The production of GH is modulated by stress, exercise, nutrition, sleep and GH itself
(Barb et al., 2008). However the primary controllers are two hypothalamic hormones and
a hormone from the stomach. The first hormone is the growth hormone-releasing
hormone (GHRH) which is a hypothalamic peptide that stimulates both the synthesis and
secretion of growth hormone. The second one is somatostatin (SS) which is a peptide
produced by several tissues in the body, including the hypothalamus, the main function of
somatostatin is to inhibit growth hormone release in response to GHRH and to other
stimulatory factors such as low blood glucose concentration. Lastly ghrelin is a peptide
hormone secreted from the stomach, ghrelin binds to receptors on somatotrophs and
potently stimulates secretion of growth hormone (Bouillon 1991, Slootweg 1993, Kojima
et al., 1999, Barb et al., 2008).
The mechanism of GH action on bone is not yet clear and there are two hypotheses of
two possible mechanisms of action: the somatomedin hypothesis which states that GH
stimulates production of IGF-I, which in turn stimulates longitudinal bone growth
(Salmon and Daughaday 1957), and the dual effector theory, which states that GH acts on
















Figure 1.6 Diagram of Growth Hormone Actions. Physiological stimuli such as
changes in energy levels and decreased fatty acid concentrations increase GH secretion
from the somatotroph cells within the lateral wings of the anterior pituitary gland. The
major role of growth hormone in growth is to stimulate the liver to secrete IGF-I, which
in turn stimulates proliferation of chondrocytes, resulting in bone growth.
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1.18 GH/IFG-I axis and bone
Growth hormone is probably the most important regulator of IGF-I production (Niu and
Rosen 2005) and the GH/IGF-I axis is the main regulator for growth. There are other
growth systems but appear to play minor role compared to the GH/IGF-I system since it
has been documented that only about 17% of the total body size of an adult mouse can be
attained without the precipitation of GH and IGF-I (Lupu et al. 2001).
The major target of GH is hepatic insulin growth factor I (IGF-I), the endocrine actions of
IGF-I include its role in stimulating chondrocyte proliferation at the growth plate, glucose
homeostasis in muscle and fat as well as skeletal and muscle maintenance (Lupu et al.
2001). IGF-I also stimulates tubular reabsorption of phosphate and can directly regulate
vitamin D activity in the kidney, with subsequent increase in calcium absorption and
transport of phosphate a necessary component of skeletal mineralization (Caverzasio et
al. 1990, Lanfranco et al., 2003, Giordano et al., 2008).
Mohan et al. (2003) demonstrated the contribution of the GH/IGF-I axis to the
development of peak BMD. The skeletal changes in IGF-I knockout (KO), IGF-II KO,
and GH-deficient mice were measured at three different developmental changes; the
prepubertal, pubertal and postpubertal in the femur by dual x-ray absorpiometry. They
demonstrated skeletal growth failure in different degrees in the absence of growth factors.
In summary it was suggested that mice deficient in IGF-I show a greater impairment in
bone accretion than IGF-II or GH deficient mice; and the GH/IGF-I axis but not the IGF-
II, is critical for puberty induced bone growth.
1.19 Growth hormone Receptors and Bone
The first tissue in which GH binding sites were identified was the liver mainly due to the
abundance of receptors located there, however later more tissues that possess growth
honnone receptors (GHRs) were identified including the muscle, adipose, mammary
gland, bone, kidney, embryonic stem cells and immune tissues (Kelly et al. 1991,
Ohlsson et al. 1993, Giustina et al., 2008) and more recently the brain (Yoshizato et al.
1998).
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The GHR is a member of the cytokine/hemopoietic growth factor receptor family (Kelly
et al. 1993).GH signaling via its receptor has been shown to be mediated through
cascades of protein phosphorylation resulting in activation of nuclear proteins and
transcription factors. The GHR itself is not a tyrosine kinase, but after binding of GH to
its receptor an association with a protein JAK2 occurs, JAK2 is then phosphorylated and
in turn it phosphorylates the GHR (Kopchick and Andry 2000).
Barnard et al. (1991) were the first to show specific high-affinity GHRs on the osteoblast
- like cells UMR 106.06. The presence of these receptors was later confirmed in primary
human and mouse osteoblasts (Nilsson et al. 1995, Slootweg et al. 1996). Lobie and
colleagues (1992) demonstrated GHRs on rat chondrocytes, osteoblasts and osteoclasts
while osteocytes were generally found to be immunonegative, while Abu et al. (1997)
reported GHR expression on few osteocytes at remodelling sites. Only recently GHRs
were identified in the frontal bone osteocytes at the onset of the flatfish metamorphosis
(Hildahl et al. 2008).
Evidence as to the function of the GHR in growth development came from the generation
of mice containing a disrupted GHR/GHBP (growth hormone binding protein) gene
through homologous recombination (Zhou et al. 1997). Homozygous mice showed
postnatal growth retardation, dwarfism, and did not display GHRs or GHBPs, these mice
grew to half the size of their non-transgenic littermates, showed lowered IGF-I levels and
increased GH concentrations. Heterozygous mice were slightly smaller compared to non-
transgenic mice and had reduced levels of GHR, GHBP and IGF-I circulation. Female
GHR knockout mice are fertile and they experience delayed puberty, but when IGF-I
replacement therapy is administered it results in advancement of puberty back to normal
levels, highlighting the importance of GH dependent IGF-I production (Danilovich et al.
1999).
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1.20 Growth hormone and bone cells
In bone tissue, growth hormone receptors are active on osteoblast and osteoclasts but not
on mature osteocytes (Lobie et al. 1992). GH stimulates osteoblasts and osteoclasts
directly or indirectly via IGF-I. The effects of GH on the osteoblasts have been studied in
a number of osteoblastic cell lines and primary isolated osteoblasts from various sources,
such as human, chicken, rat and mouse as well as the SaOS-2 human and UMR 106.01
rat osteocarcoma cell line. GH has been demonstrated to induce proliferation of primary
isolated rat, mouse, chicken, human and rat osteosarcoma cells as well as mesenchymal
precursor cells (Ernst and Froesch 1988, Slootweg et al. 1988, Scheven et al. 1991,
Nilsson et al. 1995, Kang et al., 2007).
GH has been demonstrated to act directly on the osteoblast in vitro, while its actions are
partly mediated by IGF-I in vivo. This was demonstrated in calvarial osteoblasts where
the IGF-I receptor was disrupted in vitro and in vivo. GH stimulated IGF-I production
and inhibited osteoblast apoptosis in osteoblasts lacking the IGF-I receptor in vitro. In
vivo wild type mice for the IGF-I receptor treated with GH showed doubling of osteoblast
numbers, while they remained the same in mice lacking the IGF-I receptor. These results
indicate that although direct IGF- lR-independent actions of GH on osteoblast apoptosis
can be demonstrated in vitro, IGF-1R is required for anabolic effects of GH in osteoblasts
in vivo (DiGirolamo et al., 2007). This was also demonstrated via stimulation of
phenotypic functions of osteoblasts such as alkaline phosphatase, osteocalcin, and type I
collagen (Morel et al. 1993, Chenu et al. 1990).
IGF-I is thought to play a role for the GH actions on the osteoblasts. Stimulation of
osteoblastic IGF-I production by GH has been demonstrated by some studies (Morel et al.
1993, Chenu et al. 1990) but not by others (Kanzaki et al. 1995). To identify the
importance of IGF-I in mediating the actions of GH, endogenous IGF-I was sequestered
by an antiserum to IGF in osteoblast-like cells; as a result the proliferative action of GH
was abolished (Ernst and Froesch 1988) demonstrating that local IGF-I is important for
GH induced cell proliferation.
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GH has been shown to increase the number of osteoclasts in the metaphysis if the
proximal tibia of hypophysectomized rats (Lewinson et al. 1993), but the mechanism of
this action is unclear. GHRs have been identified in in mouse marrow cultures (Ranjo et
al. 1996) and in mouse hemopoietic blast cells (Nishiyama et al. 1996). In the study by
Nishiyama et al. (1996) it was found that GH stimulates osteoclastic bone resorption
through both direct and indirect actions on osteoclast differentiation and indirect
activation of mature osteoclasts.
Factors that may mediate the indirect GH-regulated osteoclast formation include IGF-I
and IL-6, both of which are involved in osteoclast formation and have been shown to be
regulated by GH (Nishiyama et al. 1996, Slootweg et al. 1992, Saggese et al. 1995,
Swolin et al. 1996, Mochizuki et al. 1992, Giustina et al., 2008).
It has been shown that IGF-I stimulates activation and formation in cultures of mouse
bone cells (Mochizuki et al. 1992) and that the osteoblasts mediate IGF-I stimulated
formation of osteoclasts in mouse marrow cultures as well as activation of rat osteoclasts
(Hill et al. 1995). The physiology of GH-induced effects on osteoclast is still unclear and
further studies are necessary to try and elucidate the exact mechanisms of GH actions on
the osteoclast.
1.21 Growth hormone and osteocytes
GH receptors have been identified in osteoblasts and osteoclasts but not on mature
osteocytes (Lobie et al., 1992). Only recently GHRs were reported in the frontal bone
osteocytes at the onset of the flatfish metamorphosis (Hildahl et al. 2008). To date the
effects of GH in vitro have been studied in bone tissue cultures which offer the advantage
of preserved intercellular interactions. Stracke et al. (1984) reported that GH increased
ALP activity in the culture medium from embryonal rat tibias in tissue culture. Similar
observations were later confirmed by Maor et al. (1999). Rat cartilage pieces were
cultured on top of collagen sponges in the absence or presence of GH. Three day
incubation with GH caused an increase in DNA synthesis and size of the specimen. The
effect of GH was more pronounced after six days in culture, at which time a network of
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trabeculae was noted throughout the extracellular matrix. The trabeculae contained
osteocyte-like cells and positive staining for osteocalcin and osteopontin provided further
support that the newly formed trabeculae was comprised on bone matrix components.
Utretated cultures lacked bone-like strucures, demonstating that GH directly induced
bone formation in vitro.
Similarly in vivo GH treatment influences bone mass, bone metabolism and mechanical
strength of bones. When GH was administered in hypophysectomized (HX) rats an
increase in bone formation was observed. Furthermore in bone from HX rats a decrease in
mRNA levels of IGF-I was found, and the levels were restored after GH replacement
(Bikle et al. 1995). This observation strongly suggests that GH has a direct effect on bone
cells. In normal rats GH administration has been found to increase cortical bone
(Andreassen et al. 1995). Corresponding to the increased bone mass there is also an
increase in mechanical strength of the whole bone. Due to the absence of evidence
supporting the presence of GHRs in mammalian osteocytes it can only be speculated that
GH exerts indirect effects on them. Future studies are necessary to improve our
understanding of the physiology of GH-induced effect on osteocytes.
1.22 Effects of growth hormone on bone tissue
Postnatal longitudinal bone growth results by the direct effect of GH on bone tissue, as a
result of cell proliferation of chondrocytes in the epiphyseal growth plate. This was
demonstrated after the rate of proliferation decreased following hypophysectomy with
subsequent narrowing of the growth plate. When GH was administered the rate of cell
proliferation and the width of growth plate were restored (Isakson et al. 1985, Nilsson et
al., 2005).
The effect of GH directly on cartilage in vivo was tested by injecting GH locally into the
epiphyseal growth plate of the proximal tibia in hypophysectomized rats. Stimulation of
longitudinal bone growth was demonstrated as well as an increase in the width of the
cartilage in the growth plate suggestive of stimulation of chondrogenesis (Isakosn et al.
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1992). In another study in rats injection of GH locally at the growth plate stimulated
longitudinal bone growth (Isakson et al. 1985).
GH has also been reported to influence bone metabolism by modulating PTH secretion
and its circadian levels (Lancer et al., 1976, Giustina et al., 2008). This effect is partially
mediated by changes in serum phosphate levels (Ahmad et al., 2003). Serum PTH peaks
at around 17.00 hours coinciding with the serum phosphate peak (Estepa et al., 1999),
GH favors phosphate retention via an increase in the renal threshold for phosphate. In
addition both GH and IGF-I activate the renal la-hydroxylase and inhibit 24-
hydroxylase, with an increase in the production of active 1, 25 dihydroxyvitamin D3
(Wei et al., 1997). These mechanisms may contribute to bone mineralization.
Another factor suggested to mediate the effects of GH on longitudinal bone growth is
IGF-I, mainly in its regulation of bone remodeling. IGF-I is hypothesized to have a
mitogenic predisposition on osteoblasts and have been suspected to have potential as a
formation-stimulating drug. In a clinical study it was shown that IGF-I increases
biochemical markers for both bone fonnation and bone resorption (Johansson et al.
1992). In another study of men with idiopathic osteoporosis, GH and IGF-I were
administered and their effects on bone metabolism were compared after 7 days; it was
shown that IGF-I increased biochemical markers for bone fonnation but not bone
resorption while GH increased markers for both bone formation and resorption,
indicating different mechanisms of actions at the cellular level of the two peptides
(Johansson et a. 1996).
In rats IGF-I treatment results in periosteal bone formation and both increased and
decreased bone fonnation has been reported in the cancellous bone (Bagi et al. 1994,
Ibbotson et al. 1992). On the other hand in primates GH but not IGF-I has been shown to
increase bone formation (Sass et al. 1997), while in growth honnone deficiency (GHD)
patients GH treatment increases bone mass but is not clear whether IGF-I has the same
capacity (Ohlsson et al. 1998, Baroncelli et al., 2003).
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1.23 Current Osteoporosis Treatments
HRT is prescribed after menopause to help with the unwanted symptoms of hot flushes;
night sweats; irregular heart beat; mood swings and chronic diseases such as osteoporosis
and to maintain the quality of life of an individual.
A number of treatments are currently available for osteoporosis, which are mainly
focused in preventing bone resorption (Allen et al., 2004). Examples of antiresorptive
medications include estrogens and Selective Estrogen Receptor Modulators (SERMS)
e.g. raloxifene that suppress bone remodelling thus maintaining the function of
osteoblasts and osteocytes; the bisphosphonates, which inhibit osteoclast activity by
inducing osteoclast apoptosis; and finally calcitonin that inhibits osteoclast activity
without affecting the osteoblast collagen production (Stepan et al., 2003). All the above
treatments have been found to reduce fracture risk mainly through their effects on the
osteoclasts (the bone resorbing cells). On the other hand anabolic treatments which have
started receiving a lot of interest recently affect the osteoblasts (the bone forming cells).
Anabolic agents include rhPTH 1-34, rhGH, strontium and statins that directly stimulate
bone formation.
rhPTH (1-34) is the only anabolic agent approved for use for the treatment of
osteoporosis, produced by Lilly referred to as teriparatide. PTH treatment increases bone
turnover, stimulating the osteoblasts to a greater extent than osteoclasts (McCloung et al.
2005). The formation of new bone with PTH improves bone microarchitecture, including
improved trabecular connectivity and enhanced cortical thickness (Misof et al. 2003). It
has also been shown to possibly affect bone size and geometry, with beneficial effects on
bone strength (Parfitt 2002, Burr, 2005). For individuals with severe osteoporosis PTH
might produce more benefits to help in reducing their high risk of fracture, but there is
still no data to support this concept.
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GH is another anabolic agent that when administered in postmenopausal osteoporotic
women and men with idiopathic osteoporosis it was shown to increase the markers for
bone resorption and formation within the first week of administration (Andreassen and
Oxlund 2000). Because of the financial cost for GH treatment there have not been
perfonned many clinical trials, so it has been suggested that GH-releasing factors may be
used for the stimulation of the GH/IGF-I axis. Compared to PTH which is an injectable
treatment the advantage of GH-releasing factors is that they can be administered orally
(Ohlsson et al. 1998).
Moreover in rat studies receiving GH on withdrawal the labeling persists six weeks later
indicating that new bone is preserved upon cessation of treatment contrary to PTH
treatment where bone is quickly resorbed after withdrawal from treatment, and treatment
with antiresorptives should follow to maintain the new bone formed (Ejersted et al.
1998).
1.24 Summary
High osteocyte density has been associated with regions characterised by resorption and
formation activity (Power et al. 2002) while absence of osteocytes is associated with low
occurrence or absence of remodelling surfaces (Marotti et al. 1998) and accumulation of
microdamage in conditions such as ageing (Mori et al. 1997) and osteonecrosis (Kenzora
et al. 1978). In addition, high incidence of osteocyte apoptosis has been associated with a
range of conditions including glucocorticoid treatment (Gu et al. 2005), estrogen
withdrawal (Tomkinson et al. 1997, Weinstein et al. 2000) elevated PTH (Bringhurst
2000), androgen action (Wiren et al. 2006) and both underloaded and overloaded bone
(Noble et al. 2003). My key hypothesis is that rhPTH and rhGH are essential growth
factors in 1) promoting osteocytic cell population survival in ageing and in response to
mechanical stimulation and 2) directing osteoblast bone forming activity in helping to
build new bone. To test these hypotheses I:
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1. Examined the ability of rhPTH and rhGH to promote cell survival of MLO-Y4
osteocyte like cells in vitro to a wound injury model.
2. Examined the ability of rhPTEl and rhGH to promote osteocyte survival in
skeletally mature female rats in vivo.
3. Examined the ability of rhPTH in the presence of absence of mechanical
stimulation to promote osteocyte survival in human bone explants as it has been
previously shown that these two parameters can have a synergistic effect on
osteocyte viability and bone formation. And
4. Examined the ability of rhPTH and rhGH in directing the bone forming activity of
osteoblast cells using LCM and gene microarray at different anatomical sites of
bone (periosteal vs. endosteal) in skeletally mature female rats in vivo.
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CHAPTER 2
The Protective Effects of Recombinant Human Parathyroid and
Recombinant Human Growth Hormones on Osteocyte Plasma
Membrane Repair in vitro
Abstract
Microdamage in bone contributes to fractures and is hypothesized to act as a stimulus for
bone remodeling. Through their apoptotic death, osteocytes are thought to provide signals
that activate osteoclastic bone resorption at the damage site. The cause of osteocyte death
near the microdamage site is unknown but it may be related to either mechanically
sensitive signaling pathways, direct physical damage of the osteocyte itself or the
canalicular system that supplies necessary nutrients and oxygen. In light of a number of
studies suggesting that the rapid repair of plasma membrane disruption is possible and
essential to cell survival in other cell types, here the ability of osteocytes to survive
damage was tested. The rapidity of the repair was estimated using propidium iodide (PI)
and sytox green staining. Also the relationship of osteocyte membrane repair with rhPTH
and rhGH, known to be de-regulated with ageing was investigated.
A cell-wounding model using the osteocyte-like cell line MLO-Y4 was developed. PI
uptake was used to estimate cell wounding and repair over time. For follow-up
experiments PI and Sytox green staining were used to estimate the repair of individual
cells injured over time. MLO-Y4s were incubated in the presence or absence of either
rhPTH or rhGH for one hour after which time they where injured using a sharp blade. As
the repair process is know to be calcium dependent in other cell types, the requirement
for calcium in MLO-Y4 cells in this process in the presence or absence of rhPTH and
rhGH was also investigated.
It was found that large numbers of osteocytes were capable of re-sealing their plasma
membrane within the first minute following mechanical injury in the presence or absence
of rhPTH and rhGH. Interestingly the repair process was accelerated following
incubation with either rhPTH or rhGH, in the presence or absence of calcium in the
growth media, but the mechanisms of this process are unknown. These findings may
provide a new understanding of how osteocytes sense and respond to injury and the
potential of therapeutic compounds to maintain osteocyte viability in disease and old age.
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2.1 Introduction
In the skeleton the number of viable osteocytes decreases with age (Frost 1960, Dunstan
et al. 1993), and it is likely that this age-related decrease is occurring in the proportion of
bone that is not being actively remodeled (Chan and Duque 2002). In the elderly there is
more damage accumulating and less healthy bone with the sites of lower osteocyte lacuna
density containing more damage (Noble 2003). Microdamage occurs in bone as a result
of normal functional and repetitive loading due to every day use with subsequent
accumulation of small cracks in the bone matrix (Reilly and Currey, 2000, Qui et al.
2005, Nagaraja et al. 2007) that is increased during strenuous exercise (Brukner 1966).
Osteocytes are extremely sensitive to alterations in the local physical enviromnent
(Skerry et al., 1989) and are thought to be involved in microdamage detection and
remodeling (Parfitt 1993, Bentolila et al. 1998).
Bone is capable of removing the accumulating microdamage through the actions of the
osteoclasts and the osteoblasts, during bone remodeling (Burr and Martin, 1993; Mori
and Burr, 1993; Parfitt, 2001), which is impaired in the ageing skeleton for reasons that
still remain unknown (Compston 2007). Osteocytes are vital in bone remodeling and
produce signal molecules to regulate this process. Mechanotransduction is the process by
which cells in a living tissue - such as osteocytes -perceive physical stimuli and respond
with biochemical signals (Dodd et al., 1999). Osteocytes respond to altered load through
changes in gene and protein expression (Dodd et al., 1999). Mechanical stimuli within the
physiological range maintain osteocyte viability (Noble et al. 1997, Plotkin et al., 2005).
On the other hand, excessive strains result in microdamage and osteocyte apoptosis
(Verborgt et al., 2000, Noble et al., 2000, 2003). The mechanism by which microdamage
induces cell death is debated. Previously studies have suggested that apoptosis may occur
as a result of direct physical damage to the cell membrane (Colopy et al. 2004, O'Brien et
al. 2005), activation of mechanically sensitive signaling pathways or damage to the light
chain shifting (LCS) and disruption of nutrient and oxygen provision (Frost 1960,
Knothe-Tate 1998, Dodd 1999). However these factors cannot be considered in isolation.
It is hypothesized that osteocyte death is associated with the production of signals
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involved in the activation of the remodeling process. However, controversy arises over
whether signaling molecules are generated following osteocyte apoptosis. It has recently
been demonstrated that induction of bone damage is associated with an increase in
osteocyte death by apoptosis. This was demonstrated by Noble and colleagues (1997,
2003) using the rat model of fatigue fracture, where osteocyte apoptosis was associated
with cortical bone resorption induced by mechanical loading, pointing to the hypothesis
that osteocytes provide signals that activate osteoclastic bone resorption at the damage
site through their apoptotic death (Noble et ah, 2000). Ruptured osteocyte processes may
also secrete compounds, which diffuse throughout the matrix and stimulate osteoclasts
(Hazenberg 2007). In support of this theory Kurata and colleagues (2006) demonstrated
the release of molecules such as RANKL, which induces osteoclastogenesis following
osteocyte damage.
As mentioned earlier it has been suggested that apoptosis may occur as a result of direct
physical damage to the cell membrane (Colopy et al. 2004, O'Brien et al. 2005).
However recent reports demonstrated the ability of cells to repair membrane disruptions
following physical injury within seconds (McNeil and Steinhardt 1997, McNeil and
Terasaki 2001) due to the inherent 'self-sealing' capacity of biological membranes
(McNeil 2002). Such a response is vital for cell survival, and has been found to be
calcium dependent. The 'Patch Hypothesis'- first proposed by Terasaki and colleagues
(1997) describes de-novo barrier formation and membrane fusion, triggered by the
entrance of extracellular calcium following cell injury. A number of vesicles accumulate
and fuse with one another to form a patch vesicle which fuses with the phospholipid
bilayer, providing a reparative protein barrier (McNeil and Steinhardt, 2003). In bone
rapid resealing of membrane disruptions would be vital in maintaining osteocyte viability
and bone quality as well as removal of damage and remodeling.
In light of studies suggesting that the rapid repair of plasma membrane disruption is
possible and essential to cell survival in other cell types (McNeil and Kirchhausen 2005),
the ability of MLO-Y4 osteocyte-like cells to survive physical damage was tested and the
rapidity of the repair estimated for the first time in osteocytes. The ability of rhPTH and
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rhGH to influence the repair process of the damaged cell membrane was also tested. Both
PTH and GH affect bone growth and maintenance either directly or indirectly. PTH has
been shown to increase bone mass by adding bone on both endosteal and periosteal
envelopes as well as affecting the bone remodeling process, similarly GH influences bone
growth and skeletal maintenance either directly or indirectly via stimulation of IGF-I
production (Reijnders et al. 2007, Sundeep et al. 2008).
Loss of osteocytes in bone is associated with an impairment of the damage repair system,
with older people having more damage. PTH and GH decline with ageing thus possibly
influencing the repair system. Moreover they have been found to modify calcium
channels; PTH has been demonstrated to activate the calcium channels in rat and chicken
osteocytes (Miyauchi et al. 2000, Selim et al. 2005). GH on the other hand has been
shown to increase intracellular calcium concentrations about twofold within two minutes
of addition in adipocyte cultures (Shikha et al., 1998). Taking into account that in other
cells types such as skin cells and the sea urchin, the repair process has been shown to be
calcium dependent (McNeil and Kirchhausen 2005), a possibility that these hormones
may be able to influence the repair process in a calcium dependent manner arises.
In this study membrane-disruption to MLO-Y4s in vitro was taken to represent direct
physical injury to osteocytes in vivo. The purpose of this study was to investigate the
hypothesis that direct physical damage to osteocytes causes' cell death (Colopy 2004,
O'Brien 2005) and the effect of rhPTH and rhGH with the process of cell membrane
resealing following physical injury. Staining techniques were used to demonstrate the
ability of MLO-Y4 cells to survive and rapidly repair following physical membrane
disruption. These findings provide us with an insight of how osteocytes respond to injury
as well as the potential of therapeutic compounds to maintain osteocyte viability in
disease and old age.
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2.2 Materials and methods
All chemicals were purchased from Sigma, UK, unless otherwise stated. All tissue
culture reagents were purchased form Invitrogen, UK and all tissue culture plastics from
Corning, UK. All tissue culture procedures were performed in a laminar flow hood (class
2) receiving HEPA-fdtered air, using sterile equipment.
2.2.1 Cell culture and maintenance
The murine long-bone derived osteocyte-like MLO-Y4 cell line was cultured in Modified
Eagles Medium Alpha (a-MEM) supplemented with 5% foetal bovine serum (FBS), 5%
newborn calf serum (NCS), 1% penicillin/streptomycin (P/S) and 1% L-glutamine (Kato
et al., 1997). Cells were grown in continuous monolayer culture in sterile 75 cm2 tissue
culture flasks. Flasks were coated with 0.1M collagen type I from rat tail prior to use.
Growth media were stored at 4°C and wanned to 37 °C prior to use. Cells were
maintained in an incubator at 37 °C in a 95% humidified atmosphere of 02:C02 in the
ratio of 95%:5%. Subculturing was performed twice weekly upon reaching 90%
confluency. The cell monolayer was detached with addition of 1ml of trypsin solution at
2.5mg/l for 5 minutes, followed by addition of 10ml of growth medium, lml of the cell




The ML0-Y4 osteocytes were plated at a density of 3.5 x 104 cells per ml in 24 well
plates, 24 hours prior to experimentation. Following appropriate treatment cells were
returned to the incubator at 37°C for the appropriate time following individual treatment.
Experiments were carried out a minimum of three times, and each treatment was
represented by 4 wells in each experiment. Cells were observed in 6 fields per well
resulting in 24 fields per treatment group using a x20 magnification lens for all estimates
allowing similar numbers of cells to be counted per field in all experiments using an
inverted microscope fitted with DXM 1200 camera (Nikon UK Limited). All compounds
used for cell treatments were diluted in complete a-MEM media.
2.2.3 Hormone treatments
The MLO-Y4 cells were pre-treated for one hour with rhPTH and rhGH (both provided
by NOVARTIS) diluted in a- MEM medium supplemented with 5% FBS, 5% NCS, 1%
P/S and 1% L-glutamine at the concentrations of 50nM/ml and lOOng/ml respectively
followed by cell injury. Cells were also pre-treated for one hour prior to injury with TGF-
b3 at concentrations of lng/ml, lOng/ml and 50ng/ml and Vitamin C at concentrations of
1 pM/ml, 50pM/ml and lOOpM/ml for one hour prior to injury.
2.2.4 Serum deprivation
The MLO-Y4 cells were grown to confluency in complete a- MEM media prior to
incubation for 16 hours in low serum a- MEM media, which contained 0.1% FBS, 1%




Hanks balanced salt solution
Inorganic balanced salt solutions in tissue culture have long been used and their functions
can be divided into four principal ones: 1. serve as irrigating, transporting and diluting
fluids while maintaining intra- and extracellular osmotic balance, 2. provide cells with
water and certain bulk inorganic ions, 3. provide principal source of energy combined
with a carbohydrate for cell metabolism and 4. provide a buffering system to maintain the
medium within the physiologic pH range (Hanks, 1976). For the purposes of the
experiments presented here Hanks solution which contains all necessary salts except
calcium chloride was used to deprive cells of extracellular calcium. Hanks salt solution
was supplemented with 5% FBS, 5% NCS, 1% P/S and 1% L-glutamine.
The MLO-Y4 cells were incubated in Hanks media for half an hour prior to initiation of
cell treatments with rhPTH and rhGH. Following experimental treatments cell injury was
induced and cell repair over time was estimated.
For follow up experiments calcium chloride diluted in Hanks at a final concentration of
1.6mM (which is the final concentration of calcium chloride in a- MEM media was
sterile filtered and added in cultures pre-treated with Hanks pre- and post- injury.
2.2.6 Cell injury
A cell-wounding model was developed for the injury of the MLO-Y4 osteocytes. Cells
were injured using a sterile sharp blade and a cut was induced in the middle of the well to
disrupt plasma cell membrane of cells below the blade (figure 2.1) in order to follow up
repair over time at different time points from 0 seconds - 15seconds (T(0)), 5minutes, 30
minutes and 24 hours. Following those time points, repair was also followed up at shorter
time points from 0 seconds - 16 seconds (T (0)), to 1 minute, 2 minutes, 3 minutes, 4
minutes and 5minutes.Cells at a distance of 0.2mm either side of the cut were counted for
the analysis.
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Figure 2.1 Induction of injury in MLO-Y4 cells in culture. Representative image of
injured MLO-Y4 cells in culture (A, B). Cells were injured by cutting through the middle
of the well using a sharp blade. Cells were stained with PI to identify those with a
compromised plasma membrane (B). Cut was found to induce cell injury (C).Arrows
indicate injured cells on the cut. Bar represents 100 pm.
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2.2.7 Determination of Cell repair over time
2.2.7.1 Propidium Iodide stain
For the identification of cells with a compromised cell membrane i.e. cells that have not
repaired over time following the experimental procedure propidium iodide (PI) stain was
used. PI is a compound that stains nuclear DNA, giving a red fluorescent image when
subjected to UV light illumination at 535nm. PI is most often used to differentiate
between necrotic and apoptotic cells while being excluded from healthy cells, with an
intact cell membrane (Lecoeur 2002). PI is rapidly taken up by cells and binds to DNA
by intercalating between the bases with little or no sequence preference and with a
stoichiometry of one dye per 4-5 base pairs of DNA (Moore et al. 1998). Once the dye is
bound to nucleic acid, its fluorescence is enhanced 20- to 30- fold fluoresces as bright
red. For the T (0) 100 pi of PI were added in the culture media prior to injury at a final
concentration of 2.5ng/ml diluted in a- MEM media. In separate wells for the follow up
time points PI was added after injury was induced, to identify cells with a compromised
cell membrane over time (figure 2.2). Following experimental treatments, cells were
fixed in 4% paraformaldehyde for 10 minutes, washed three times in PBS and air-dried.




For total cell number counts on the cut 4',6- Diamino-2- phenylindole (DAPI) compound
that stains nuclear DNA, and fluoresces as bright blue when subjected to UV light
illumination at 358nm was used. DAPI is a stain that is rapidly taken up by cells and
forms enhanced fluorescent complexes with double-stranded DNA due to either forming
a highly energetic interaction or stable hydrogen bonds with the minor groove of the
double helix (Cowden et ah, 1981). Following experimental treatments, and staining with
PI as described above cells were incubated with DAPI at a concentration of 2.5ng/ml for
5-10 minutes, washed in PBS and examined by fluorescence microscopy and digital
image capture. Four wells represented each time-point in each 24-well plate and eight
fields per well were taken, which resulted in 192 fields counted per plate. Each
experiment was repeated at least three times.
Percentage of non-repaired cells (%) =
Number of PI positive cells
X 100
Number of DAPI stained cells
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Figure 2.2 MLO-Y4 cells in culture post injury. PI was added in media following
injury in MLO-Y4 cells in culture (A) to identify the cells with a compromised plasma
membrane (B). Cells were then fixed and DAPI stained (C) for total cell counts on the
cut. Arrows indicate cells injured on the cut. Bar representslOO pm.
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2.21.3 SYTOX green stain
To follow the course of repair of individual cells, two membrane permeant dyes were
used, one to identify the cells damaged at start (PI) and a second one to determine
whether repair of the cells damaged at start occurred (Sytox green) (Figure 2.3). Sytox
green is a nucleic acid stain that rapidly penetrates cells with compromised plasma
membranes while being excluded from live cells. It stains nuclear DNA and fluoresces as
bright green when subjected to UV light illumination at 490nm. Sytox green is most often
used in dead-live assays to identify necrotic cells (Roth et al. 1997). Following
experimental treatments lOOpl of PI was added to the bathing media prior to injury for
each of the different time points to identify the number of cells injured at the start.
Following incubation with PI for 15 seconds cells were washed with a - MEM media to
remove excess PI. For the T (0) time point cells upon removal of PI were immediately
stained for 10 seconds with lOOpl Sytox green at a final concentration of lpM/ml diluted
in a-MEM media and then fixed in 4% parafonnaldehyde . For the later time points cells
were washed and then placed back in the incubator in a- MEM media. At the end of each
experimental time point media were removed and cells were incubated for 10 seconds in
Sytox green prior to being fixed in 4% paraformaldehyde and were then examined using
fluorescence microscopy. Cells that were PI positive and Sytox negative were cells that
were injured and then repaired their membrane thus excluding Sytox green stain. PI
negative and Sytox green positive were considered as uninjured cells that later became
penneant to the dye, possibly undergoing unrelated death into the dish.
Percentage repaired cells (%) = (PI +ve) + (PI +ve / Sytox +ve)
PI + Svtox -ve ) x 100
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1) ML0-Y4s in culture 2) PI Addition 3) Sytox Green Addition
Figure 2.3 Double staining experiments. A. MLO-Y4s in culture. B. Addition of PI
prior to induction of injury, followed by removal of the media and cells were washed, and
fresh media replaced for the set time intervals prior to staining with Sytox green C.
Addition of Sytox green and incubation for about 10 seconds prior to removal and fixing
with PFA. Arrows indicate cells injured on the cut and did not repair. Bar represents 100
pm.
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2.2.7.4 In situ analysis of osteocyte DNA fragmentation using Nick
Translation technique
To identify cells undergoing apoptosis a DNA nick translation technique, (Noble et al.
1995; 1997) was used. Only the larger number of single DNA breaks, associated with
apoptosis rather than necrosis, were detected. The technique allows the identification of
early DNA breaks prior to loss of the DNA content and prior to plasma membrane
permeabilisation (Petit et al., 1995).The cells were fixed in 4% paraformaldehyde
(Sigma, UK) for 10 minutes and then washed in phosphate buffer saline (PBS) (Oxoid,
UK) for 5 minutes three times. For the positive control a well was treated with
deoxyribonuclease I (DNase) at a concentration of 0.2 mg/ml in PBS (Sigma, UK) for 30
minutes to induce DNA breaks (figure 2.4). All wells apart from the negative control
(figure 2.5) that was treated with the following reaction mixture in the absence of DNA
polymerase I, were treated with a reaction mixture that consisted of 3 mmol/L
digoxigenin (DIG)-labelled dUTP (DIG-11-dUTP); 3 mmol/L each of dGTP, dATP, and
dCTP; 50 mmol/L Tris HC1, pH 7.5; 5 mmol/L MgC^, 0.1 mmol/L dithiothreitol, 0.5
mL/100 ml DNA polymerase I for 45 minutes at 37 °C in a humified chamber. At the end
of the incubation period all wells were washed in PBS and incubated with fluorescein
isothiocyanate (FITC)-labelled anti-DIG antibody (all reagents obtained from Roche
Diagnostics Corporation, UK) and 5% normal sheep serum (Sigma) in PBS, for 1 hour in
a humidified chamber at room temperature (RT). After washing in PBS all wells were
stained for nuclear DNA with DAPI (Sigma, UK) at 2mg/ml for 10 minutes, washed
thoroughly in PBS and mounted with fluorescent mounting medium (DAKO, UK). Wells
were visualized by fluorescent microscopy using a DXM1200 camera mounted on
Eclipse E800 microscope (Nikon) using 20X/0.50 D/0.17WD2.1 magnification lens
(x20). Osteocytes stained positive for both the FITC label and DAPI were considered as
osteocytes containing fragmented DNA.
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A. FITC B. DAPI C. Combined
Figure 2.4 In situ demonstration of a positive control for the nick translation
method. MLOY-4 cells in tissue culture wells were treated with the nick translation
mixture. All nuclei stained green for the FITC signal (A, C) since the cells were
incubated with deoxyribonuclease I (DNase) in order to produce DNA breaks prior to
reaction with the nick translation mixture (x 20). Nuclei were stained blue with DAPI
(B). Bar represents 10 pm.
A. FITC B. DAPI C. Combined
Figure 2.5 In situ demonstration of a negative control for the nick translation
method. MLOY-4 cells were treated with the nick translation mixture in the absence of
polymerase I. Nuclei were stained blue with DAPI (B). No FITC signal was observed
indicating the inability of oligonucleotides to be incorporated into the DNA breaks in the
absence of DNA polymerase I and be recognized by the anti-DIG-FITC labelled antibody
(A, C) (x 20). Bar represents 10pm.
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2.2.8 Statistical Analysis
For all data analyses the statistical software package SPSS 14.1 for Windows was used.
All data was checked for normal distribution by applying the Kolmogorov-Smirnov test.
In cases where the randomly selected sample data were shown to have a normal
(Gaussian) distribution (95% of data would fall within plus or minus 1.96 standard
deviations from the mean value) parametric statistical tests such as one-way Analysis of
Variance (ANOVA) and the post-hoc Tukey-Kramer and Bonferroni test were performed
to detennine statistical significance between the treatment groups. The Tukey-Kramer
post hoc test was employed in all statistical analyses to determine significance between
the treatment groups as it allows for comparison of more than two means without
introducing the type I error associated with multiple t-tests (Zar 1984, Fielding and
Gilbert 2000). Results are expressed as means ± SEM. p<0.05 was considered to be
statistically significant, representative of n=3 experiments.
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2.3 Results
2.3.1. MLO-Y4 cells repair their cell plasma membrane in a time dependent-
manner.
ML0-Y4 osteocytes were injured using a sharp blade as described in the methods section
§2.2.6 and PI was added prior to injury for the 0 seconds - 30 seconds time point and then
in other culture wells post injury at 5 minutes, 30 minutes and 24 hours. It was found that
large numbers of osteocytes were capable of re-sealing their plasma membrane following
injury in a time dependent-manner (figure 2.4). The number of cells counted per field was
at the range of 25-35 cells. Between 0 seconds - 30 seconds 19 % ± 1.79 of the cells had
been damaged as demonstrated by PI uptake; however repair was increased over time so
that only 11 % ± 0.93 (p<0.05) were damaged at 5 minutes, 6 % ± 0.35 (p<0.001) at 30
minutes and only 3% ± 0.32 cells still damaged after 24 hours. Whereas the pre-cut
control cultures were found to be at 2 % ± 0.18, indicating that the damage was caused


















5mins 30m ins 24hrs
Figure 2.4 MLO-Y4 osteocyte like cells repair their plasma cell membrane in a time
dependent manner. Osteocytes were plated and allowed to set overnight prior induction
of injury in control media. Cell injury was induced at time 0 and PI was added for the 0-
30 seconds' time point prior to induction of injury and then at the time points of
5minutes, 30 minutes and 24 hours, to identify cells that remained leaky to PI (cells that
did not repair over time). By 24 hours the PI positive cells reach similar levels as that of
the pre-cut cultures. Graphs represent mean percentages of PI positive cells ± SEM f
represents p<0.05 compared the previous time point.
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2.3.2. Incubation of MLO-Y4 cells prior to injury with rhPTH or rhGH
enhances the repair process.
Following the observations that MLO-Y4 cells repair their cell membrane over time, the
prospect of rhGH and rhPTH influencing the cell repair process was examined. MLO-Y4
osteocytes were pre-treated for an hour with the known anti-apoptotic doses of 50nM/ml
rhPTH or lOOng/ml rhGH. Following incubation with these hormones, physical injury
was induced and PI was added at 0seconds-30seconds time point and then post injury at 5
minutes, 30 minutes and 24 hours. At the end of each experimental time point cells were
fixed and stained with DAPI for total cell counts on the cut (Figure 2.5). It was found
that rhPTH significantly increased the cell repair at the earliest time point compared to
control cultures (10% ±0.15 vs. 19% ±0.17 respectively, p<0.05) with the repair
increasing over time so that at 5 minutes (6% ± 0.26 vs. 7 % ± 0.28, p>0.05) cells were
still damaged in the rhPTH-treated cultures compared to the control cultures. Both the
control and rhPTH-treated cultures reached similar levels of repair by 24 hours (1%
±0.11 vs. 3 % ±0.11) respectively (figure 2A). Similarly rhGH significantly increased the
cell repair process over time compared to the control (12% ±0.17 vs. 19% ± 0.17,
p<0.05) at 0seconds-30seconds, and (6 % ± 0.14 vs. 7 % ± 0.28, p>0.05) still damaged at
5 minutes in the rhGH treated cultures compared to the control. By 24 hours both rhGH
and control cultures reached similar levels of repair (2% ± 0.08 vs. 1% ±0.11, p>0.05)
respecyively still being damaged (Figure 2B).
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Figure 2.6 Representatives of Bright field, PI and DAPI staining experiments from
Osecs - 30 sees to 24 hours. Cells were stained with PI post induction of injury to
identify cells with a compromised plasma membrane and with DAPI following fixation
of cells for total cell counts on the cut, in different cultures for each time point. A. 0 secs-
30 sees time point, B. 5 minutes time point, C. 30 minutes time point and D. 24 hours
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Figure 2.6 MLO-Y4 osteocytes like cells repair their plasma cell membrane faster in
the presence of rhPTH or rhGH. Cells were pre-incubated for 1 hour with either 50nM
rhPTH or lOOng/ml rhGH followed by cell injury. Cells repaired their cell membrane
faster in the presence of rhPTH (A) or rhGH (B). Graphs represent mean percentages of
PI positive cells ± S.E, * = p<0.05 denote significant differences of control cultures
compared to rhPTH or rhGH treated cultures at the same time point, t represents p<0.05
compared to the same treatment at the previous time point.
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2.3.3. Pre-incubation of MLO-Y4 cells with TGF- 03 and Vitamin C do not
induce the same response as that of rhPTH and rhGH.
MLO-Y4 cells were pre-incubated with TGF- 03 (Figure 2.7A) in a range of doses (1, 10
and 50ng/ml) and with L-ac™rbic acid (vitamin C) (10, 50 and 100 pM) (Figure 2.7B).
Repair of cells over time was similar at all time points in both treated and untreated
cultures, except the 5 minutes time point for the 100 pM of vitamin C compared to
control at that time point ( 12% vs. 20%, p<0.05). No significant differences were found
between the pre-treated cultures with TGF- 03 and vitamin C in terms of cell repair over
time when compared to the control cultures.
2.3.4. Cell membrane repair upon induction of mechanical injury in the
presence or absence of rhPTH and rhGH occurs within the first minute.
The resealing of cell membranes has been reported to occur within a few seconds
(McNeil et al. 2005). From the data presented in this study it was observed that the repair
was taking place within the first 5 minutes with significant differences noted at the T(0)
in pre-treated cultures with rhPTH and rhGH compared to the control (figure 2.8 A, B).
To define more specifically the time period at which repair occurred PI was added every
minute over a 5 minute time period, followed by fixation of cells and DAPI staining for
total cell counts. Repair was significantly accelerated at 0secs-30secs in the cultures pre-
treated with rhGH and rhPTH compared to the control cultures (14% ± 0.86, 12% ± 0.69
vs. 23% ± 2.01, p<0.05, respectively). At 1 minute cell plasma membrane was
significantly accelerated in the presence of rhGH and rhPTH compared to control cultures
(9% ± 0.26, 8% ± 0.28 vs. 15% ± 1.00, p<0.05, p<0.001, respectively). Similarly at 2
minutes repair was also accelerated in the presence of rhGH and rhPTH compared to
control cultures (7% ± 0.57, 6% ± 0.28 vs. 12% ± 1.13, p<0.05, respectively). At 3
minutes statistically significant differences were noted between the rhPTH tretated
cultures and the control cultures (5% ± 0.30 vs. 8% ± 1.14, p<0.05). For subsequent time-
points no statistically significant differences were noted between rhPTH and rhGH
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Figure 2.7 TGF-b3 and Vitamin C do not induce the same response as that of
rhPTH and rhGH in cell repair. Osteocytes were incubated in the presence of TGF-b3
(A) and Vitamin C (B) for 1 hour prior to induction of injury. Cell injury was induced as
described in methods. Graphs represent mean percentages of PI positive cells ± SEM, * =
p<0.05 denote significant differences for the lOOpM of Vit. C compared to control at the
same time point, t represents p<0.05 compared to the same treatment at the previous time
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Figure 2.8 MLO-Y4 cells plasma membrane repair occurs within the first five
minutes. MLO-Y4 cells were incubated for 1 hour in the presence of rhPTH and rhGH
prior to induction of injury. The majority of cells repair their plasma membrane within
the first minute of induction of injury with a significant effect of rhGH (A) and rhPTH
(B) compared to control cultures (p< 0.05). Graphs represent mean percentages of PI
positive cells ± SEM, * = p<0.05 and ** = p< 0.001 denote significant differences when
hormonal treatments compared to control cultures, t represents p<0.05 compared to the
same treatment at the previous time point.
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2.3.5 Cell repair is enhanced in the presence of rhPTH or rhGH as shown by
double staining with PI and Sytox green.
In order to identify cells injured at the start of the time course and subsequent repair of
these cells, double staining experiments using PI and Sytox green were carried out. PI
was added in the bathing media prior to induction of injury to identify cells damaged at
start. Cells were stained with Sytox green at the end of each time point to identify cells
that did nor repair over time (Figure 2.9) from Osecs - 30 sees up to 24 hours (figure
2.10D) and 0 sees - 30 sees to 5 minutes (figure 2.1 ID) time periods. These experiments
provided evidence of a constant cell number injured at each time point in the presence or
absence of rhPTH or rhGH (figure 2.10A-C, figure 2.11A-C), with no significant
differences noted between the numbers of cells injured initially at each time point.
Similarly to previous experiments at 0secs-30secs cell membrane repair was statistically
significant enhanced in the presence of rhGH or rhPTH compared to control cultures
(31% ± 1.71, 34% ± 0.86 vs. 24 % ± 1.69, p<0.05, respectively). At 5 minutes in the
presence of rhGH or rhPTH cell repair was statistically enhanced compared to control
cultures (70% ± 0.52, 68% ± 0.59 vs. 58% ± 0.74, p<0.05, respectively). For the time
points at 30 minutes and 24 hours no statistically significant changes were noted between
control and treated cultures. Most of the cell membrane repair was noted to occur within
the first minute post injury and pre-incubation with either rhPTH or rhGH significantly
accelerated the repair process compared to control cultures as shown in figure 2.1 ID. At
the 0secs-30secs time point post injury statistically significant differences were noted
between the cultures pre-treated with rhGH or rhPTH to control cultures (29% ± 1.71,
32% ± 0.86 vs. 16% ± 1.69, p<0.05, respectively). At 1 minute statistically significant
differences were noted between the rhGH or rhPTH treated to control cultures (52% ±
0.26, 51% ± 0.27 vs. 30% ± 1.15, p<0.05, respectively). Repair of cell membrane repair
continued to occur for up to 3minutes however no statistically significant differences







Figure 2.9 Representatives of the double staining experiments with PI and Sytox
green from Osecs - 30 sees to 24 hours. Cells were stained with PI prior to induction of
injury and at follow up time points with Sytox green prior to fixation. A. 0 sees- 30 sees
time point, B. 5 minutes time point, C. 30 minutes time point and D. 24 hours time point.
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Figure 2.10 Double staining of MLO-Y4 cells in response to rhPTH and rhGH
treatment from 0 sees- 30secs to 24 hours. Cells were stained with PI prior to injury to
identify the cells injured at each time point. For each time point media was removed and
cells stained with Sytox green prior to fixation to identify cells that did not repair their
plasma membrane over time. Graphs A, B and C show the average number of cells
positively stained with PI and Sytox green in the absence of rhPTH or rhGH (A), in the
presence of rhGH (B) and in the presence of rhPTH (C) for PI and Sytox green, these
graphs demonstrate a constant number of cells injured at each different time point (PI
linear relationship) and a decrease in the number of damaged cells (Sytox positive) over
time. Repair is accelerated at earlier time points in the presence of rhGH (D) and rhPTH
(E). Graphs represent mean percentages of repaired cells ± SEM, * = p<0.05 denotes
significant differences when treatments compared to control cultures at the same time
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Figure 2.11 Double staining with PI and Sytox green in response to rhPTH and
rhGH treatment from 0 sees - 30secs to 5 minutes. Repair of cells following physical
injury from 0secs.-30secs to 5 minutes. Most of the repair occurs within the first minute
post injury and pre-incubation with rhGH (D) or rhPTH (E) accelerates the process.
Graphs A, B and C show the average number of cells positively stained in the absence
(A) of rhPTH or rhGH, in the presence of rhGH (B) and in the presence of rhPTH (C) for
PI and Sytox green, these graphs demonstrate a constant number of cells injured at each
different time point (PI linear relationship) and a decrease in the number of damaged cells
(Sytox positive) over time. Graphs represent mean percentages of non-repaired cells ±
SEM, * = p<0.05 denote significant differences when hormonal treatments compared to
control cultures at the same time point, f represents p<0.05 compared to the same
treatment at the previous time point.
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2.3.6 rhPTH and rhGH exert protective effects upon induction of injury in
serum-deprived osteocytes.
MLO-Y4 osteocytes were incubated in 0.1% FBS for 16 hours, in order to deprive cells
in culture from growth factors, after which time they were incubated for an hour with
rhGH (figure 2.12A) or rhPTH (figure 2.12B). Injury was then induced followed by PI
and DAPI staining. In more detail at 0secs-30secs cells in the 0.1% FBS cultures did not
repair following injury when compared to control, 0.1% FBS+rhGH and control+rhGH
cultures (27% ± 0.59 vs. 19% ± 0.71, 16% ± 0.74, 12% ± 0.17, respectively, p<0.001).
Similarly at 5 minutes cells in 0.1% FBS cultures did not repair following injury when
compared to control, 0.1% FBS+rhGH and control+rhGH cultures(24% ± 0.45 vs. 10% ±
0.31, 10% ± 1.07, 6% ± 0.14, respectively, p<0.001). At 30 minutes cells in 0.1% FBS
cultures did not repair following injury when compared to control, 0.1% FBS+rhGH and
control+rhGH cultures(21% ± 0.39 vs. 8% ± 0.24, 3% ± 0.15, 3% ± 0.011, respectively,
p0.05). At 24 hours cells the same as in previous time points was observed with the cells
in 0.1% FBS cultures not repairing following injury when compared to control, 0.1%
FBS+rhGH and control+rhGH cultures (24% ± 0.23 vs. 4% ± 0.37, 3% ± 0.45, 3% ±
0.14, respectively, p<0.001). Similarly to rhGH in the presence of rhPTH at 0secs-30secs
cells in the 0.1% FBS cultures did not repair following injury when compared to control,
0.1% FBS+rhPTH and control+rhPTH cultures (27% ±0.17 vs. 18% ± 0.47, 11% ± 0.47,
10% ± 0.15, respectively, p<0.001). At 5 minutes cells in 0.1% FBS cultures did not
repair following injury when compared to control, 0.1% FBS+rhPTH and control+rhPTH
cultures (24% ± 0.43 vs. 11% ± 0.26, 7% ±0.18, 6% ± 0.30, respectively, p<0.05). At 30
minutes as before cells in 0.1% FBS cultures did not repair following injury when
compared to control, 0.1% FBS+rhPTH and control+rhPTH cultures (21% ± 0.68 vs. 9 %
± 0.11, 3.2% ±0.13, 3% ± 0.27, respectively, p<0.05). Similarly at 24 hours cells in 0.1%
FBS cultures did not repair their plasma membrane when compared to control, 0.1%
FBS+rhPTH and control+rhPTH cultures (24% ± 0.23 vs. 8% ± 0.37, 3% ± 0.23, 2% ±
0.13, respectively, p <0.001). Pre-incubation of low serum cultures with rhPTH or rhGH
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Figure 2.12 Pre-incubation with rhPTH and rhGH following overnight incubation
of MLO-Y4 osteocytes in low serum enhances cell membrane repair. Osteocytes were
incubated overnight in 0.1% FBS followed by pre-incubation of an hour with either
rhPTH or rhGH. Following injury cells in low serum controls did not repair as cells in
control media (a-MEM) or those pre-incubated with rhGH (A) or rhPTH (B) in control or
0.1% FBS media. Graphs represent mean percentages of PI positive cells ± SEM, * =
p<0.05 and ** = p< 0.001 denote significant differences of treatments and control
cultures compared to 0.1% FBS cultures at the same time point, t represents p<0.05
compared to the same treatment at the previous time point.
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2.3.7 Effects of extracellular calcium removal in cell membrane repair on
cultures of MLO-Y4 osteocytes.
The repair process is calcium dependent in other cell types (Terasaki et al., 1997); the
same hypothesis was tested in osteocyte cells in culture. Cells were incubated in HANKS
solution (which is an inorganic balanced salt solution, containing all necessary salts
except calcium chloride) for half an hour prior to induction of injury followed by PI and
DAPI staining. It has been previously reported that the removal of extracellular calcium
causes dissociation of cell-cell contacts and changes in cell shape, such as retraction and
rounding (Xin et al., 2005). Such changes didn't appear to occur in the cultures examined
in these experiments following light microscopy observation. Extracellular calcium
deprivation was found to significantly affect the repair process at all time points, when
compared to controls (Figure 2.13). At Osecs. - 30 seconds the percentages of injured
cells in the calcium deprived cultures were significantly higher compared to the control
(51% ± 0.47 vs. 19 ± 0.71, respectively, p<0.001). At 5 minutes there was a significant
decrease in the controls compared to calcium deprived cultures (10% ± 0.31 vs. 41% ±
1.23, respectively, pO.OOl) with the same observation at 30 minutes (4% ± 0.64 vs. 38%
± 1.45, respectively, p<0.001). To test these findings calcium chloride at a final
concentration of 1.6mM was added in the HANKS calcium deprived cultures pre- and
post- injury (Figure 2.14), to test if the cell repair can reach similar levels as that of the
controls. These findings showed no significant differences between addition of calcium
chloride prior or post injury, however there were significant difference noted between the
calcium deprived (HANKS) and the calcium deprived with addition of calcium chloride
cultures. There were also significant differences noted between the HANKS treated
cultures with addition of calcium chloride compared to the control media cultures for the
early time points. In table 2.1 the mean percentages ± SEM of damaged cells are












0-30secs 51%±0.47 33%±1.28 32% ±0.33 27% ±0.96 pO.001
5 mins 36% ±3.46 18% ±0.54 16% ±0.23 13% ±0.61 pO.OOl



















Figure 2.13 Extracellular calcium is important for cell membrane repair following
injury. Cells were incubated for 30 minutes with HANKS media to deprive them from
extracellular calcium. Cell repair in the calcium deprived cell cultures was compromised
and no significant differences were noted between the time points. Cells in control media
repaired their cell membrane following injury in a time dependent manner and significant
differences in cell repair were noted between the time points. Graphs represent mean
percentages of PI positive cells ± SEM, ** = p< 0.001 denote significant differences of
control media cultures compared to HANKS calcium deprived cultures at the same time
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Figure 2.14 Addition of calcium chloride in HANKS calcium deprived cultures
accelerates the repair process. Cells were incubated for 30 minutes with HANKS media
to deprive them from extracellular calcium. Calcium chloride at a final concentration of
1,6mM was added in the HANKS cultures prior (PI) and post injury (AI) and repair was
documented. There were no significant differences noted between addition of calcium
chloride prior or post injury, however there were significant difference noted between the
calcium deprived (HANKS) and the calcium deprived with addition of calcium chloride
cultures. Also there were significant differences found between the HANKS treated
cultures with addition of calcium chloride compared to the control media cultures for the
early time points. Graphs represent mean percentages of PI positive cells ± SEM, ** = p<
0.001 denote significant differences of all treatment cultures compared to HANKS
calcium deprived cultures at the same time point, t represents p<0.05 compared to the
same treatment at the previous time point.
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2.3.8. Effects of rhPTH and rhGH on cell membrane repair in the absence of
extracellular calcium.
Following deprivation of extracellular calcium in HANKS media cells were pre-treated
with rhPTH or rhGH, at the end of the incubation injury was induced. The calcium
deprived cultures treated with rhGH (Figure 2.15A) and those treated with rhPTH (Figure
2.15B) showed significant differences compared to the HANKS cultures. However the
repair process of these cultures could not reach same levels of repair as that of control or
control in the presence of rhPTH or rhGH. In more detail at 0secs-30secs statistically
significant differences in cell membrane repair were noted between the HANKS cultures
compared to the HANKS+rhGH, control and control+rhGH cultures (50% ± 0.47 vs.
24% ± 1.17, 19% ± 0.71, 13% ± 0.17, respectively, p=0.001). Similarly at 5 minutes
statistically significant differences were noted between the HANKS cultures compared to
the HANKS+rhGH, control and control+rhGH cultures (37% ±2.16 vs. 18% ± 0.61, 7.%
± 0.31, 6% ± 0.14, respectively, p=0.05). At 30 minutes statistically significant
differences were noted between the HANKS cultures compared to the HANKS+rhGH,
control and control+rhGH cultures (33% ± 1.79 vs. 16% ± 0.55, 6% ± 0.24, 3% ± 0.11,
respsectively, p<0.05). Similarly to rhGH treatment, rhPTH treatment resulted in
statistically significant differences at 0secs-30secs between the HANKS cultures
compared to the HANKS+rhPTH, control and control+rhPTH cultures (50% ± 0.47 vs.
26% ± 0.58, 19% ± 0.71, 10% ± 0.15, respectively, p=0.001). At 5 minutes statistically
significant differences were noted between the HANKS cultures compared to the
HANKS+rhPTH, control and control+rhPTH cultures (37% ±2.16 vs. 18% ± 0.28, 7% ±
0.31, 5% ± 0.30, respectively, p=0.01). Similarly at 30 minutes differences were noted
between the HANKS cultures compared to the HANKS+rhPTH, control and
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Figure 2.15 Pre-incubation of calcium deprived cultures with rhPTH or rhGH
affects the repair process. Cells were calcium deprived in HANKS media followed by
pre-incubation with rhPTH or rhGH for an hour. Following addition of rhGH (A) or
rhPTH (B) in calcium deprived cultures the repair process was significantly accelerated
as cells repair in a time dependent manner when compared to calcium deprived cultures.
However the repair process of these cultures could not reach same levels of repair as that
of control or control in the presence of rhPTH or rhGH. Graphs represent mean
percentages of PI positive cells ± SEM, ** = p< 0.001 denote significant differences of
all treatment cultures compared to HANKS calcium deprived cultures at the same time
point. | represents p<0.05 compared to the same treatment at the previous time point.
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2.3.9. Osteocyte apoptosis using in situ nick translation technique.
Following observations that osteocytes were not dying immediately following injury, due
to necrosis, in situ nick translation technique was used to define whether they were
undergoing apoptosis at later time points. But due to the model used to induce cell injury
it was not clear which cells were undergoing apoptosis since all visible cells on the cut
were stained positive for all time points examined (figure 2.16).
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Figure 2.16 Nick translation representatives for all three treatment groups.
Representative images of MLO-Y4 -osteocyte like cells following injury in vitro at
different time points. Following fixation cells were reacted with the nick translation
mixture in order to identify apoptotic osteocytes (FITC-green). Red arrows identify
apoptotic osteocytes. Bar = 100 pm.
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2.4 Discussion
It is widely accepted (McNeil, 1997, 2001, 2002) that cell membranes are 'self-sealing'
in a number of different cell types, in support of this concept, experimental conditions
using laser wounding, electroporation or needle scratch have been developed that allow
cell membrane disruprions to reseal in the laboratory, (McNeil and Kirchhausen, 2005).
The biological question of interest presented in this chapter, however, is whether MLO-
Y4 cells have the capacity to reseal and survive cell membrane disruptions in vitro and
whether this process is affected by the presence of rhPTH and rhGH.
Before this work, observations in vivo supported the hypothesis that direct cell injury
causes osteocyte apoptosis (Colopy et al. 2004, O'Brien et al. 2005). These studies
reported death of osteocytes due to disruptions near microcracks, however they did not
apply techniques to study osteocyte apoptosis and base all conclusions to light
microscopy and as such no secure conclusions can be made to link microdamage to cell
death. Alternative interpretations of these results are of course possible, because the
perturbations inflicted might have introduced unintended effects. Here it is shown that
MLO-Y4 cells are able to survive and repair following physical membrane disruption.
A simple in vitro model for injuring cells in culture was developed. Briefly cells were
injured using a sharp blade in vitro in 24-well plates by making a light scratch over the
cell surface.The MLO-Y4 osteocyte like cell line was used, due to the difficulties of
obtaining large numbers of primary osteocytes. Cell repair was followed at different time
points and it was found that whilst scalpel damage induced significant injury, osteocyte
repair was rapid, the majority occurring within the first few minutes following damage.
Such rapid repair is confirmed by previous studies (McNeil 1997, 2001, 2002), which
describe a resealing response, occurring within seconds following cell injury to prevent
loss of cytoplasmic contents, calcium influx and subsequent cell death (McNeil 2000).
Although repair occurred in the absence of these hormones, following incubation for an
hour with rhPTH or rhGH was shown to have a beneficial effect, reducing the number of
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injured cells dramatically within the first five minutes. The choice of concentrations for
both compounds was based on what has been published before in the literature regarding
the known anti-apoptotic effective concentrations of these hormones in vitro (Kassem et
al. 1993, Jilka et al. 1999). In order to determine whether the effect of rhPTH and rhGH
in accelerating the repair process was specific to those two compounds, TGF-J33, a
growth factor regulating a broad range of biological processes as well as wound healing
(Janssens et al. 2005) and Vitamin C- a potent antioxidant (Padayatty et al., 2003) were
also used over the time period of 24 hours in the same experimental context as that of
rhGH and rhPTH. Antioxidant compounds such as vitamin C, vitamin E and estrogen
protect osteocytes from apoptosis induced from oxidant attack (Mann et al., 2005). These
compounds did not induce the same response as rhPTH or rhGH, indicative of the
protective effects these hormones have on osteocytes in culture. However there was a
significant difference observed at the highest concentration of vitamin C when compared
to the control cultures at the 5 minute time point, which is suggestive of the possibility
that longer incubation periods or higher concentrations of antioxidant compounds may be
able to elicit protective effects to osteocytes.
To estimate cell wounding and repair over time three different tracking dyes were used.
In initial experiments cell wounding and repair was estimated using PI staining, which
stained cells with a compromised cell membrane at different time points and DAPI stain
was used to estimate the total cell numbers for 0.2mm of either site of the cut. For follow
up experiments due to the inability to determine initial percentages of damaged cells,
questions arose over the nature of the beneficial effect seen in the presence of rhPTH and
rhGH. For instance, whether rhPTH and rhGH allowed cells to heal more quickly, or
increased resistance of cells to scalpel damage. Double staining experiments using PI and
Sytox green helped to clarify this point. It was found that the initial number of damaged
(PI positive) cells was similar in the presence and absence of rhPTH and rhGH. Therefore
it could be concluded that rhPTH and rhGH were most likely increasing the overall rate
of repair following damage.
103
Pre-incubation for an hour with rhPTH and rhGH had a significant effect on the rapidity
of the cell membrane repair when compared to control cultures. Cell repair was followed
at a number of different time-points, from 30 seconds to 24 hours at initial experiments.
The majority of cells repaired within the first five minutes. Following this observation
shorter experiments from 30 seconds to 5 minutes were carried out. In these experiments
rhPTH and rhGH had a similar effect in accelerating the repair process when compared to
the control cultures. To my knowledge there is no such report of similar effects in the
literature, thus more studies are needed to investigate these findings. However there are a
number of studies in the literature reporting the repair process of cell membrane in vitro
in different tissues such as endothelium, skeletal, cardiac muscle and skin (McNeil 1993,
1997, 2001, 2002). At the cell level, most of the studies of membrane repair have been
perfonned in sea urchin fibroblasts (McNeil and Terasaki 2001, McNeil 2000) and the
repair process was reported to occur within the first 5 seconds of induction of injury to
these cells. Nevertheless in neurons it has been reported that repair can take as long as 90
minutes. In this study the repair was increased over time with 18.5% of the cells that had
been damaged as demonstrated by PI uptake at 0 seconds - 30 seconds increasing over
time with only 3% of cells still damaged after 24 hours.
The mechanism of this rapid membrane resealing has been shown to be calcium
dependent (McNeil et al. 2003). According to the patch hypothesis influx of calcium into
the cytosol through the membrane disruption elevates cytosolic calcium locally. The
cytoskeleton then breaks down and although the precise repair mechanism is still
unknown, current reports propose that resealing is directly mediated by the delivery of
intracellular membrane to the cells surface (Idone et al., 2008). According to these
models the vesicles fuse with one another, forming a larger patch vesicle that fill up the
disrupted site (McNeil et al. 2000) or decrease plasma membrane tension to elicit an
exocytotic addition of vesicles to the plasma membrane (Togo et al. 2000). The force
required to allow a decrease in membrane tension comes from the adherence of a
phospholipid bilayer to the underlying cytoskeleton, thus disruption elicited exocytosis is
proposed to promote lipid flow and hence resealing (Miyake and McNeil 2003).
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In the present study the involvement of extracellular calcium in the resealing process in
the absence or presence of rhPTH or rhGH was tested. Preliminary data is suggestive of
calcium being involved in the resealing process of MLO-Y4 cells. When injury was
induced in HANKS (calcium chloride absent) cultures the cells where unable to repair the
membrane disruption when compared to the control cultures, but interestingly upon
addition of calcium chloride in these cultures the repair process was restored close to
control levels. It has been reported in other studies that resealing of small disruptions
such as those induced by electroporation do not require extracellular calcium and have
been reported as spontaneous sealing of the membrane without the participation of
internal membranes (Fein and Terasaki, 2005). However in the study presented here the
disruptions were of a higher magnitude than those of electroporation induced disruptions.
Another possibility that would explain these findings is that the membrane added during
wound sealing adds enough calcium permeability to change the membrane potential. On
the other hand if we suppose that calcium is not involved in the resealing process the
possibility that the penneability is present in the plasma membrane before injury but is
inactivated and the injury does not produce a large enough signal to activate penneability
can provide an alternative explanation to these findings. While calcium was not directly
linked to the response to rhPTH and rhGH in this study, both of these honnones have
been reported to affect calcium trafficking. Studies of calcium trafficking in the presence
of PTH and GH have demonstrated an effect by those hormones. Nanomolar
concentrations of PTH and GH have been shown to increase calcium in target cells within
a couple of minutes (Gesek and Friedman 1992, Samra et al. 1992, Gaur et al. 1998).
Such observations may explain the effect of rhPTH and rhGH in calcium deprived
cultures and the rapidity of disruption repair. The calcium content has not been quantified
in this study and such an investigation would be useful in providing more in depth
information regarding the involvement of calcium in cell repair in MLO-Y4 cells. These
findings highlight the importance of physiological levels of extracellular calcium for the
repair of cell membrane disruptions.
Both PTH and GH have been reported to have anti-apoptotic effects and stimulate growth
factor production, including IGF-I (Herndon et al. 1995, Eriksen et al. 1996, Aarts et al.
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2001, Compston 2007). PTH has been reported to enhance the survival of serum deprived
chondrocytes and save them from apoptosis (Aarts et al. 2001), GH on the other hand has
been reported to stimulate IGF-I production and affect wound healing and tissue repair,
however, the mechanism by which it improves wound healing remains in question
(Herndon et al. 1995). Cells deprived of growth factors undergoe cell death and apoptosis
(Goyeneche et al. 2006). The effect of growth factor deprivation in cell membrane repair,
via means of serum starvation of cells overnight was investigated. Serum deprived
cultures showed a slower repair over time compared to control cultures. When cells were
pre-treated with rhPTH and rhGH the repair process was significantly improved
compared to serum deprived cultures in the absence of rhPTH or rhGH and similar to
control cultures pre-treated with rhPTH and rhGH. These data suggest that rhPTH and
rhGH can enhance the repair process even in serum starved cells after a short incubation
period. This response may be related to the stimulation of cells to produce growth factors
either within their cytosol or in the extracellular fluids. Upon disruption they stimulate
potential signals to enter into the wounded cell; and possibly expression of other genes
that either facilitate cell survival against the disruption injury or promote tissue recovery
or protect the tissue from mechanical stresses. Support for this hypothesis comes from
studies of basic fibroblast growth factors (bFGF and aFGF) (McNeil and Steinhardt
1997). When these polypeptides are found in the extracellular environment they are
potent growth factors and when they are localized in cytosolic and nuclear compartments
of cells, they have been shown to be released into extracellular medium upon disruption
of membranes which are survived by the cell, possibly due to the release of these factors.
Evidence has been presented to suggest that when mechanical forces are experimentally
imposed upon osteocyte-like cells wounding of the plasma cell membrane occurs, which
is survived by the cell. Staining with PI and Sytox green has identified wounding and
repair of cells over time. Both rhGH and rhPTH had a protective effect over osteocytes in
culture and accelerated the repair process following injury. It can be concluded that about
80% of these cells survive injury and efficiently repair their cell plasma membrane, and
are fully capable of both locomotion and proliferation as documented by our real-time 24
hour long time-lapse videos. However this is a preliminary study and a number of
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limitations were identified in the design of the experiment. It is clear that the repair
process is rapid and in order to accurately determine the time-frame, further work is
required to characterize the initial time point. In the present study the initial time point
was defined as the first 30 seconds but as reported in other studies (McNeil and Terasaki
2001, McNeil 2000) repair can occur within the first 5 seconds of induction of injury.
This could involve time-lapse microscopy of individual cells damaged by laser, or
experimentation with other dyes that would be taken up faster by the cells.
The present study was carried out using an MLO-Y4 osteocyte-like cell line which does
not represent primary osteocytes as such it is important that future work is undertaken on
well characterized primary cells, obtained from sequential digestion, to confinn the
observations made here. Moreover these cells do not express calcium channels in their
resting phase but they do upon hormone stimulation (Gu et al., 2001), thus further studies
would be useful to identify the exact mechanism of cell repair and calcium trafficking in
MLO-Y4 cells. These experiments show that rhPTH and rhGH increase the rate of repair
following damage, but do not address the final outcome, in terms of whether cells are
actually saved through this acceleration of healing and as such we can only speculate as
to the benefit of accelerated repair in vivo. Though it is clear that the cells are not dying
immediately (by necrosis), we cannot rule out the possibility of apoptosis. However as
documented in 24 hour time-lapse movies of wounded cells, these cells are able to heal
their cell membrane and survive injury. In this study an attempt to study the fate of all
cells wounded was made using the in situ nick translation techinque , however due to the
scalplel damage caused to the plastic of the well it was hard to identify the cells on the
cut following in situ nick translation staining. Thus an improved injury model would be
necessary to study the fate of these cells following injury.
Plasma membrane disruption is a frequent and physiological event, and rapid resealing is
therefore a fundamental biological adaptation (McNeil, 2005). The present work
establishes the hypothesis that MLO-Y4 cells are able to repair following injury and the
rate of the repair process is accelerated in the presence of rhPTH and rhGH, by
mechanisms that are still unknown. It is hypothesized that osteocyte death related to
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microdamage may not be due to the physical damage of the osteocyte itself, but it may be
related to either mechanically sensitive signaling pathways, direct physical damage of the
canalicular system that supplies necessary nutrients and oxygen. In vivo the osteocyte
network is vital for the detection of microdamage and activation of the remodeling
process for its removal (Burr and Martin 1993, Mori and Burr 1993, Dodd et al. 1999,
Parfitt 2001) therefore accelerated repair via the use of therapeutical compounds may be
beneficial in maintaining the structural integrity of bone.
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CHAPTER 3
Recombinant Human Parathyroid and Recombinant Human
Growth Hormone Inhibit Osteocyte Apoptosis In Aged Female
Rats. Implications for Bone Quality Maintenance in the Ageing
Female Rat Skeleton
Abstract
Parathyroid and growth hormone has been previously shown to exert positive effects on
bone, including the maintenance of osteocytes, via inhibition of their apoptotic cell death.
This study has investigated the effects of these hormones on osteocyte viability and
apoptosis. Their effect on bone architectural changes as well as sclerostin expression by
osteocytes in aged female rats was also tested.
Eighteen, virgin female Sprague-Dawley rats aged 15 months were divided into three
treatment groups. The control group received vehicle by gavage (n=6), the second group
received rhPTH (1-34) at a dose of 50 pg/kg (n=6) once daily, and the third group
received rhGH once daily at a dose of 2.5 mg/kg (n=6), by subcutaneous injection. Tibias
and femurs were removed; snap frozen and examined histologically at 14 days following
the start of treatment. For all three groups in the region of secondary spongiosa
osteocytes were examined for viability using the lactate dehydrogenase enzyme activity
assay (LDH assay), for apoptosis using an in situ nick-translation (NT) technique and for
sclerostin expression using immunostaining. There was a trend towards a decrease in
osteocyte apoptosis in response to rhPTH and rhGH treatments but the difference was not
statistically significant. Moreover a trend towards a decrease in osteocytes expressing
sclerostin was observed, with no statistical significance noted. Architectural changes in
the trabecular bone were also documented using the femurs of the same animals by
means of three-dimensional micro-computed tomography. Significant changes compared
to the control group in trabecular architecture were observed in the rhPTH treated group
but not in the rhGH group.
These observations demonstrate that these hormones can exert inhibitory effects upon
osteocyte apoptosis and rhPTH can improve the trabecular architecture in aged animals,
pointing to their potential to be used as anabolic treatments.
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3.1 Introduction
In the previous chapter evidence has been presented regarding the effects of rhPTH and
rhGH in MLO-Y4 osteocyte-like cells. Both compounds have been shown to exert a
protective effect on osteocytes following physical injury in vitro, pointing to a potential
use of these compounds to protect the osteocytic population in ageing and disease states.
In the study presented here the effects of these hormones on osteocytes were examined in
vivo in aged skeletally mature female rats.
Osteocyte loss via apoptosis or necrosis has long been associated with the ageing process
(Dunstan et al. 1993, Frost 1960), and as a consequence their presence within bone has
been associated with its ability to respond to mechanical stimuli (Lanyon et al. 1993),
remodel efficiently and repair accumulated microdamage (Burr et al. 1985, Parfitt 2001,
Noble et al. 2003). These findings indicate that bone quality is closely associated with the
presence of osteocytes and the communicating network they form through their
cytoplasmic processes within the bone matrix (Dunstan et al. 1993).
Osteocyte death by apoptosis has been associated with a range of conditions including
glucocorticoid treatment ( Gu et al. 2005), estrogen withdrawal (Tomkinson et al. 1997,
Weinstein et al. 2000), elevated PTH (Bringhurst 2000), androgen action (Wiren et al.
2006) and both underloaded and overloaded bone (Noble et al. 2003).
Osteocytes possess receptors for a number of hormones including the receptors for PTH
(Divieti, 2005). On the other hand GH receptors have only been shown on osteoblasts and
osteoclasts but not on mature rat osteocytes (Lobie et al. 1992), leading to the assumption
that it affects them indirectly, possibly via stimulation of growth factors, mainly being
IGF-I. Moreover GH levels decline by approximately 14% per decade from young adult
life, and the associated reduction in bone mass similar to that seen in adults with growth
hormone deficiency is indicative of influencing the skeleton (Shalet et al., 1998).
In animal studies an increase in bone mass in both ovariectomized and normal rats
following administration of GH and PTH has been documented (Andreassen, H. Oxlund,
112
2001, Alexander et al. 2001). Combined treatment with PTH and GH has been shown to
stimulate enhanced bone formation mainly at the endocortical surface, which was found
to be greater than that induced by PTH administration alone, whereas GH treatment has
been shown not to influence the endocortical surface (Adreassen and Oxlund, 2000). In
studies of post menopausal women administration of GH and intermittent PTH have
shown an increase in bone turnover as well as a reversal of bone loss induced by estrogen
deficiency in the case of PTH (Saaf et ah, 1999, Alexander et al. 2001).
Anabolic treatments have become the focus of intense research lately due to their
potential to stimulate bone formation. The only anabolic agent currently approved for the
treatment of osteoporosis, is teriparatide; the human PTH analog 1-34. Its use has been
associated with an increase in bone density and bone turnover (Girotra et al., 2006). The
mechanisms underlying the anabolic effects of PTH are not well understood but
depending on the mode of administration it exerts either anabolic (intermittent
administration) or catabolic (continuous administration) effects. When intermittently
administered, PTH appears to increase bone mass by stimulating the osteoblasts at all
levels of their life cycle including recruitment, proliferation, differentiation and apoptosis
(Wang et al., 2006). Intermittent administration of PTH in accelerated senescence
resistant mouse strain (SAMR 1) mice has also been shown to decrease apoptosis in
osteocytes (Jilka et al., 2002). Similar anti-apoptotic effects were observed in MLO-Y4
osteocyte-like cells (Bringhurst, 2002). These findings indicate that PTH exerts complex
actions in bone and a net positive or negative outcome dependant on the kinetics of PTH
exposure. Further identification of novel genes involved and studies of their molecular
mechanisms of action are required to elucidate PTH effects on bone.
Recently, the SOST gene and its protein product, sclerostin, have been identified as
potent negative regulators of bone formation (Keller and Kneissel, 2004). SOST is
expressed by mature osteocytes and its protein product sclerostin has been proposed to
act as a signal directed to osteoblasts or to lining cells; following completion of
mineralization in the matrix surrounding the osteocyte in order to limit further osteoblast
activity (Poole et al. 2005) and/or to indirectly activate osteoclast resorption. In the
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present study sclerostin expression via means of immunostaining in the osteocytes was
investigated in the three treatment groups analyzed, as it has been reported to be involved
in the PTH anabolic response (Li et al. 2005, Poole et al. 2005, van Bezooijen et al.
2005).
In contrast to the effects exerted by PTH, the anabolic effects of GH are not direct to the
osteocytes, since the GH receptor is found only on the surface of osteoblasts and
osteoclasts but not on the mature osteocytes (Andreassen, H. Oxlund, 2001). GH is the
most important regulator of IGF-I production (Niu and Rosen, 2005), which is known to
stimulate chondrocyte proliferation at the growth plate as well as skeletal and muscle
maintenance (Lupu et al., 2001). IGF-I not only exerts proliferative effects on tissues but
also anti-apoptotic effects, as has been demonstrated in cell cultures of some tumors
(Granerus et al. 2001). IGF-I production may provide some insight as to the mechanism
of GH effects on osteocytes. IGF-I receptors have been shown on osteocytes which may
explain the indirect anti-apoptotic effect of GH via IGF-I production (Okazaki et al.
2003). GH administration has been shown to increase bone formation and resorption and
to enhance cortical bone mass and mechanical strength, these effects are thought to be
mediated by the GH-IGF-I axis (Adreassen and Oxlund, 2001).
In this study the use of rhPTH and rhGH on the maintenance of osteocyte viability and
prevention of the increase in the proportion of osteocytes undergoing apoptosis in aged
intact female rats, was investigated. Finally the architectural changes in the trabecular
bone following short term hormonal treatment were examined.
In order to detect changes in osteocyte viability methods to detect both osteocyte
apoptosis and viability were employed. Apoptotic osteocytes were identified by the use
of the Nick Translation (NT) technique (Noble et al. 1997), while viable osteocytes at the
time of sampling were determined by using the Lactate Dehydrogenase Assay (LDH)
(Noble et al. 2003). Architectural changes in the trabecular bone were analysed by means
of three-dimensional micro-computed tomography (pCT).
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3.2 Materials and Methods
3.2.1 Animals
Eighteen, female Sprague-Dawley rats were purchased (Harlan UK Ltd., Shaws Farm,
Blackthorn, Bicester, Oxon, UK) at the age of three months and allowed to age until the
age of 18 months. A standard rodent diet (RM1; Special Diet Services Ltd, UK) and tap
water were available ad libitum, with twelve hours light (6:00 a.m. to 6:00 p.m.) and
twelve hours darkness. Animal experimentation was conducted in compliance with
national ethical guidelines.
The animals were grouped into three treatment groups, so that each group contained 6
animals. Group 1, the control group, which received vehicle (1% Carboxy-
methylcellulose) by gavage using a stomach tube. Group 2 received rhPTH fragment 1 -
34 (provided by NOVARTIS, Basel, Switzerland) once daily at a dose of 50 pg/kg body
weight via subcutaneous injection, dissolved in 0.15M saline.Group 3 received rhGH
(provided by NOVARTIS) once daily at a dose of 2.5 mg/kg body weight via
subcutaneous injection, dissolved in distilled water. The animals were weighed every day
prior to treatment and the dose of the compounds was adjusted in accordance with the
actual body weight. The duration of the experiment was fourteen days.
At the end of the experimental period all animals were killed by exsanguination the tibias
were harvested and dissected free of muscle, immersed in 5% polyvinyl alcohol (Sigma,
UK) and frozen to -70°C in super cooled hexane (BDH, UK), prior to storage and
analysis. Transverse cryostat sections of 7pm thickness were cut onto ultra pure tape for
sections (Taab Laboratories, UK) from the left tibia from the control, the rhPTH and the
rhGH groups and were then transferred to Super frost slides(Western Laboratory
Services, UK) for further analysis. Three sections of each sample were used in order to
determine each of the measurement criteria. These sections were spaced at least three
sections apart to avoid sampling the same osteocyte nucleus twice.
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3.2.2 Cell viability assessment in situ
Viable osteocytes at the time of sampling were identified in cryostat sections by means of
their lactate dehydrogenase (LDH) activity.Lactate dehydrogenase is a cytoplasmic
enzyme that catalyzes the oxidation of L-lactate to pyruvate via the reduction of
nicotinamide adenine dinucleotide (NAD+)to NADH (Stryer L. 1995).
LDH
L-lactate + NAD+ « > Pyruvate + NADH+ H+
The metabolic activity of the cells was assessed by their capacity to convert NBT to a
coloured product since the colour is the outcome of metabolic activity (Widholm, 1972).
The proton atom (H+) released during the reduction of NAD+ to NADH reduces NBT to
give a dark blue coloured product only in the metabolically active cells with intact cell
membranes. Histochemical staining was undertaken using the method of Noble and
Stevens (Noble and Stevens 2003). 7pm unfixed tissue sections were incubated in 1.75
rng/ml disodium salt (a-nicotinamide adenine dinucleotide, NAD) (Roche Diagnostics
Corporation, UK), 60 mmol/L lactic acid, 3 mg/ml nitroblue tetrazolium (NBT) (Sigma,
UK) and 40% Polypep (Sigma, UK), pH 8.0, for 3h at 37°C in a humidified chamber.
Finally, sections were rinsed in warm water to remove the reaction mixture, fixed in 4%
paraformaldehyde for 10 minutes, washed in PBS and then mounted in DAKO mounting
medium (Fisher Scientific Ltd, UK). Sections were examined under transmitted light and
the number of dark blue stained LDH positive osteocytes (figure 3.1), considered to be
viable per bone area (mm2), and was quantified using the BIOQUANT OSTEO software.
Images were captured with a DXM1200 camera mounted on Eclipse E800 microscope
(Nikon) using 20X/0.50 / 0.17WD2.1 magnification lens.
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Figure 3.1 Histochemical reaction of LDH enzyme in rat sections in situ.
Representative image of a section obtained from a control animal and stained for LDH
activity. Viable osteocytes were distinguished by the presence of LDH activity in cells.
Blue arrow identifies a viable LDH-positive osteocyte. Bar represents 100pm.
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3.2.3 In situ analysis of osteocyte DNA fragmentation using Nick
Translation technique
The percentage of osteocytes demonstrating significant levels of DNA fragmentation was
determined using a DNA nick translation technique, (Noble et al. 1995; 1997). Only the
larger number of single DNA breaks, associated with apoptosis rather than necrosis, were
detected. The technique allows the identification of early DNA breaks prior to loss of the
DNA content and prior to plasma membrane permeabilisation (Petit et al., 1995).The 7
pm thick cryostat sections were fixed in 4% paraformaldehyde (Sigma, UK) for 10
minutes and then washed in phosphate buffer saline (PBS) (Oxoid, UK) for 5 minutes
three times, prior to demineralisation in 0.25 mol/L ethylenediamine tetra-acetate
(EDTA) (Sigma, UK) in 50 mmol/L Tris HCL, pH 7.4, for 10 minutes. The sections were
then washed in PBS. For the positive control a section was treated with
deoxyribonuclease I (DNase) at a concentration of 0.2 mg/ml in PBS (Sigma, UK) for 30
minutes to induce DNA breaks (figure 3.2). All sections apart from the negative control
(figure 3.3) that was treated with the following reaction mixture in the absence of DNA
polymerase I, were treated with a reaction mixture that consisted of 3 mmol/L
digoxigenin (DIG)-labelled dUTP (DIG-11-dUTP); 3 mmol/L each of dGTP, dATP, and
dCTP; 50 mmol/L Tris HC1, pH 7.5; 5 mmol/L MgCh, 0.1 mmol/L dithiothreitol, 0.5
mL/100 ml DNA polymerase I for 45 minutes at 37 °C in a humified chamber. At the end
of the incubation period all sections were washed in PBS and incubated with fluorescein
isothiocyanate (FITC)-labelled anti-DIG antibody (all reagents obtained from Roche
Diagnostics Corporation, UK) and 5% normal sheep serum (Sigma) in PBS, for 1 hour in
a humidified chamber at room temperature (RT). After washing in PBS all sections were
stained for nuclear DNA with DAPI (Sigma, UK) at 2mg/ml for 10 minutes, washed
thoroughly in PBS and mounted with fluorescent mounting medium (DAKO, UK).
Sections were visualized by fluorescent microscopy using a DXM1200 camera mounted
on Eclipse E800 microscope (Nikon) using 20X/0.50 / 0.17WD2.1 magnification lens
(x20). Osteocytes stained positive for both the FITC label and DAPI were considered as
osteocytes containing fragmented DNA.
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A. FITC B. DAPI C. Combined
Figure 3.2 In situ demonstration of a positive control for the nick translation
method. A section of cortical bone was taken from the tibia of a control animal. All
nuclei stained green for the FITC signal (A, C) since the section was incubated with
deoxyribonuclease I (DNase) in order to produce DNA breaks prior to reaction with the
nick translation mixture (x 20). Nuclei were stained blue with DAPI (B). Bar represents
100 pm.
A. FITC B. DAPI C. Combined
Figure 3.3 In situ demonstration of a negative control for the nick translation
method. Sections were treated with the nick translation mixture without the presence of
DNA polymerase I. Nuclei were stained blue with DAPI (B). No FITC signal was
observed indicating the inability of oligonucleotides to be incorporated into the DNA
breaks in the absence of DNA polymerase I and be recognized by the anti-DIG-FITC
labelled antibody (A, C) (x 20). Bar represents 100 pm.
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3.2.4 Quantification of osteocyte viability and apoptotic criteria
Transverse cryostat sections 7 jam thick were obtained from the secondary spongiosa
region moving towards the diaphysis for 2.5 mm. To calculate the percentage of
apoptotic osteocytes three non-consecutive sections from each biopsy were used. Using
the nick translation technique the number of apoptotic osteocytes relative to the total
number of cells that stained positive for DAPI was calculated to give the percentage of
apoptotic osteocytes. Adjacent sections from the same area were used to determine the
density of viable osteocytes (the number of LDH positive osteocytes per mm2) using the
in situ LDH viability assay. A minimum of eight non-overlapping fields of view were
randomly selected from each of the sections so that more of 70% of the total bone area
was analyzed.
The following criteria were used to calculate the percentage of apoptotic osteocytes and
the percentage of viable osteocytes following the treatments described above.
Percentage of apoptotic osteocytes (%) =
Average number of FITC positive osteocytes
X 100
Average number of PI stained osteocytes
Density of viable osteocytes (mm2) =
The number of LDH positive osteocytes
The area of bone in the field of measurement per mm2
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3.2.5 Sclerostin staining
For the identification of sclerostin-positive osteocytes in the rat tibia 7 pm thick cryostat
sections were fixed in 4% paraformaldehyde (Sigma, UK) for 10 minutes and then
washed in phosphate buffer saline (PBS) (Oxoid, UK) three times for 5 minutes, prior to
demineralisation in 0.25 mol/L ethylenediamine tetra-acetate (EDTA) (Sigma, UK) in 50
mmol/L Tris HCL, pH 7.4, for 10 minutes. The sections were then washed in PBS and
incubated in 0.3% H2O2 (Sigma, UK) in methanol for 15 minutes at room temperature.
Sections were then washed in PBS three times for 5minutes prior to incubation for 1 hour
in 10% normal rabbit serum in PBS. The sections were then incubated with 1:100 diluted
goat polyclonal anti-mouse sclerostin antibody in PBS (R&D Systems) at 4°C overnight
in a humidified chamber. For the negative control (Figure 3.4) sections were incubated in
goat serum diluted at 1:100 in 2% normal rabbit serum. At the end of the incubation
period sections were washed three times for 5 minutes in PBS and incubated for 1 hour at
room temperature with 1:200 diluted rabbit-anti goat-HRP (Autogen Bioclear). Sections
were then washed with PBS and immunodetection was performed using DAB chromogen
for 20 seconds. After washing in PBS all sections were stained for nuclear DNA with
DAPI (Sigma, UK) at 2mg/ml for 10 minutes, washed thoroughly in PBS and mounted
with fluorescent mounting medium (DAKO, UK). Sections were visualized by light and
fluorescent microscopy using a DXM1200 camera mounted on Eclipse E800 microscope
(Nikon) using 20X/0.50 / 0.17WD2.1 magnification lens (x20). Osteocytes stained
positive for sclerostin were considered as osteocytes expressing sclerostin (Figure
3.5).The following criteria were used to calculate the percentage of sclerostin positive
osteocytes:
Density of sclerostin positive osteocytes (mm2) =
The number of sclerostin positive osteocytes
The area of bone in the field of measurement per mm2
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A. SOST B. DAPI
Figure 3.4 Immunohistochemical demonstration of a negative control for sclerostin
staining. Sections were treated with the goat serum diluted at 1:100 in 2% normal rabbit
serum mixture without the presence of sclerostin antibody. Nuclei were stained blue with
DAPI (B). No sclerostin signal was observed (A). Bar represents 100 pm.
A. SOST B. DAPI
Figure 3.5 Immunohistochemical reaction of sclerostin expression in rat section. A
section of trabecular bone was taken from a control animal. Osteocytes stained positive
for sclerostin are brown as indicated by the arrow (A) Nuclei stained positive for DAPI
(B). Bar represents 100pm.
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3.2.6 Micro-computed Tomography (micro-CT)
The rat femurs and not the tibias, (due to the fact that the tibias were all embedded in
PVA and could not fit into the scanner), were removed from -80°C storage and placed in
a plastic tube mounted vertically in the Skyscan 1172 for micro-CT imaging. The system
is composed of a sealed microfocus X-ray tube and a CCD camera. Images were obtained
at 60V and 167pA. Specimens were studied packed with dry ice to remain frozen during
scan, since it could take from 10 up to 20 minutes for a scan to complete as time passes.
The pixel size used was 10pm with a rotation of 360° .The area of interest scanned was
for 2mm towards the diaphysis with reference to the growth plate as the starting point.
Reconstruction was carried out using the Skyscan Nrecon software. Trabeculae were
selected with reference to the growth plate. A cross sectional slice was selected as
growth plate reference slice, by moving slice by slice from the end of the growth plate
through to the metaphysis and selecting the cross sectional level at which the primary
spongiosa is obvious. Such a reference slice can be identified in all the scans. The regions
of interest were selected with reference to the growth plate reference slice. Within the
trabecular region separation from the cortical bone was performed using a free hand
drawing tool for separating the regions of interest. The trabecular region commenced
about 0.215- 1.74 mm from the growth plate in the direction of the metaphysis. After
defining the region of interest (ROl) 2D and 3D histomorphometric parameters were
obtained.
Microstructural measurements were obtained using a processing algorithm to produce
binary images separating the trabecular and intertrabecular regions(marrow space). For
2D analysis, the total tissue area (TA: mm2), bone perimeter (B.Pm: mm) and bone area
(BA: mm2) are determined directly from the ROI, while the trabecular number (Tb.N:
/mm) was calculated as a derived parameter using Parfitt's definitions (1987), according
to the parallel plate model, following the equation: Tb.N 5 (BV/TV)/Tb.Th
Tissue volume (TV: mm3), bone volume (BV: mm3), bone surface (BS: mm2), and the
Tb.N (/mm) were directly measured. The fractional bone volume was obtained by BV/TV
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(%).'Trabecular thickness (Tb.Th) was then obtained following the equation of the
parallel plate model: Tb.Th 5 2/ (BS/BV)
Trabecular separation (Tb. Sp) was also obtained by the parallel plate model following
the equation: Tb.Sp 5 (1/Tb.N) 2 Tb.Th
3.2.8 Histomorphometry
Bone histomorphometry provides information regarding bone structure and remodeling
process in a location within bone biopsies (Chavassieux and Delmas 2006).
Histomorphometric indices are divided into primary such as measurements of bone
surface (BS), volume (BV) (Parfitt 1987) and the derived measurements some of which
would include mineralizing surface (MS) or bone formation rate (BFR/BS).
Using light microscopy, the bone surfaces were traced on sections from the samples
maintained in the Zetos™ system and analysis of bone surface (BS) was earned out using
the bone histomorphometry software BIOQUANT OSTEO (Bioquant Image Analysis
Corporation, USA). The sections used were collected from the 2.5mm distance and were
stained for alkaline phosphatase activity as described earlier and measurement of bone
surfaces was performed using the formula:
BS (mm) = Total Bone Surface - Artificial edges
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3.2.9 Statistical Analysis
For all data analyses the statistical software package SPSS 14.1 for Windows was used.
All data was checked for normal distribution by applying the Kolmogorov-Smirnov test.
In cases where the randomly selected sample data were shown to have a normal
(Gaussian) distribution parametric statistical tests such as one-way Analysis of Variance
(ANOVA) and the post-hoc Tukey-Kramer and Bonferroni test were performed to
determine statistical significance between the treatment groups. For comparison between
percentages of osteocyte apoptosis used in this study, the square root of each percentage
was transformed into its arcsine, which enabled the distribution of the data to be nearly
normal allowing therefore the use of parametric tests. Tukey-Kramer post hoc test was
also employed in all statistical analyses to determine significance between the treatment
groups as it allows for comparison of more than two means without introducing the type I
error associated with multiple t-tests (Zar 1984, Fielding and Gilbert 2000). Results are
expressed as means ± SEM p<0.05 was considered to be statistically significant.
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3.3 Results
3.3.1 Recombinant human parathyroid hormone (rhPTH) and recombinant
human growth hormone (rhGH) treatment increases osteocyte viability in
the rat tibia.
Following fourteen days of treatment with rhPTH at 50 pg/kg/day and rhGH at 2.5
mg/kg/day (Figure 3.6) was associated with significant increases in the number of viable
osteocytes in both treatment groups. rhPTH treatment increased osteocyte viability to 506
± 3.2 compared to 345 ± 5.4 in the control (p= 0.001). Similar effects to rhPTH treatment
were observed with rhGH treatment which also increased osteocyte viability to 460 ± 9.1
compared to 345 ± 5.4 in the control (p<0.05) (figure 3.7).
3.3.2 Recombinant human parathyroid hormone (rhPTH) and recombinant
human growth hormone (rhGH) treatment reduces osteocyte apoptosis in
the rat tibia.
Treatment with rhPTH (50 pg/kg/day) and rhGH (2.5 mg/kg/day) resulted in a small
decrease in the percentage of osteocytes undergoing apoptosis in the tibia (figure 3.8);
however no statistically significant differences were observed. The proportion of
osteocytes undergoing apoptosis was decreased to 0.52% ± 0.05 in the rhPTH treatment
group and 0.56% ± 0.06 in the rhGH treatment compared to 0.59% ± 0.02 in the control






Figure 3.6 LDH representatives for all three treatment groups. Representative
images of sections obtained from the secondary spongiosa of a control animal, an rhGH
treated animal and an rhPTH treated animal, and stained for LDH activity. Viable
osteocytes were distinguished by the presence of LDH activity in cells. Black arrows




















Figure 3.7 The number of LDH positive osteocytes per bone area following 14 days
of treatment with rhPTH and rhGH. The number of viable osteocytes (LDH positive
cells) per bone area (mm2) 14 days post-hormone treatment. Hormone treatment
increased the numbers of viable osteocytes. Sections were studied for the presence of
cellular LDH activity. Results are expressed as the number of total osteocytes displaying
positive staining for LDH ± SEM * = p<0.05 and ** = p<0.001 denote significant
differences when compared to control.
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A. FITC B. DAPI C. Combined
Figure 3.8 Nick translation representatives for all three treatment groups.
Representative images from the secondary spongiosa of rat sections treated with rhGH
and rhPTH in vivo for 14 days and reacted with the nick translation mixture in order to





















Figure 3.9 The percentage of osteocytes displaying evidence of DNA fragmentation
in situ after 14 days of rhPTH and rhGH hormonal treatment. rhPTH and rhGH
treatment resulted in a trend towards a decrease in the percentage of osteocyte
undergoing apoptosis in situ after 14 days of treatment. Sections were obtained from the
secondary spongiosa of the tibia and studied for the presence of fragmented DNA
material using an in situ nick translation technique. Results are expressed as the mean
percentage of total osteocytes displaying positive staining for fragmented DNA ± SEM.
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3.3.3 Trabecular structure parameters measured using micro-computed
tomography (pCT).
Trabecular structure parameters were measured using pCT as described in §3.2.6.
Trabecular bone volume (BV/TV) and trabecular thickness (Tb.Th) were greater in the
rhPTH and rhGH treatment groups compared to the control group (figure 3.10).
Trabecular separation (Tb.Sp) was lower in the rhPTH and rhGH compared to the
control. Analysis by means of pCT revealed that BV/TV was significantly greater in the
rhPTH group compared to the control group (46% ± 7.41 vs. 20% ± 5.81 respectively,
p<0.05). In contrast no significant difference was found in the BV/TV measurement
between the rhGH treatment group and the control group (31% ± 3.17 vs. 20% ± 5.81,
respectively, p>0.05). Trabecular thickness (Tb.Th.) was significantly greater in the
rhPTH treatment group compared to the control (122pm ± 10.38 vs. 81pm ± 12.1
respectively, p<0.05), whereas no difference was observed between the rhGH group
treatment and the control group (95pm ± 0.61 vs. 81pm ±18.1 respectively). Trabecular
separation (Tb.Sp.) was significantly lower in the rhPTH treatment group compared to
the control (168pm ± 2.9 vs. 251 pm ±1.71 respectively, p<0.05), whereas no significant
difference was found between the rhGH treatment group and the control group (195pm ±




Figure 3.10 Two-dimensional images of the femoral metaphysis using micro-
computed tomography. Representative 2D images derived from the pCT analysis for
































control rh PTH rhGH
Figure 3.11 Effects of rhPTH and rhGH treatment on the three-dimensional
structure in trabecular bone of the distal femur. rhPTH treatment significantly
increased BV/TV and Tb.Th and decreased Tb.Sp compared to the control. No significant
differences were found between the rhGH treatment and the control. Results are
expressed as mean percentages of individual indices ± SEM * = p<0.05 denote
significant differences when compared to control.
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3.3.4 The effect of rhPTH and rhGH on osteocyte sclerostin expression.
Sclerostin was located in osteocytes, whereas lining cells and osteoblasts were negative.
The immunostained osteocytes were mainly located in the inner bones areas, while a few
positive osteocytes were visible near the endosteal surfaces. Treatment with rhPTH
(50pg/kg/day) and rhGH (2.5mg/kg/day) resulted in non significant differences in the
numbers of osteocytes expressing sclerostin, when compared to control (53 ± 1.16, 64 ±
7.17 vs. 63 ± 4.1, respectively, p>0.05) (figure 3.12). Figure 3.13 shows representative



















Figure 3.12 The number of sclerostin positive osteocytes per bone area in the rat
tibial metaphysis. The number of sclerostin positive osteocytes was not significantly
altered between treatment groups. Sections were studied for the presence of sclerostin
expression, via means of immunostaining. Results are presented as numbers of sclerostin
positive osteocytes ± SEM.
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Figure 3.13 Representative images for sclerostin staining for the three treatment
groups. Representative sections of trabecular rat bone stained for sclerostin expression in
rat osteocytes. Arrow identifies sclerostin positive osteocytes. Bar represents 100pm.
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3.4 Discussion
In the previous chapter evidence has been presented to demonstrate the protective effects
of rhPTH and rhGH in osteocyte-like cells in vitro. In the study presented here the effects
of these compounds were tested in vivo. Evidence has been presented to show that short
term hormone treatment can promote osteocyte viability as well as improving bone
architecture, in the aged female rat.
The decline of osteocyte numbers has been related with ageing and disease states such as
osteoporosis, with the number of viable osteocytes in the human femur declining from
90% in the first decade to 20% in the 9th decade (Dunstan et al. 1993), resulting in
skeletal fragility and increased fracture incidence. Anabolic treatments such as PTH and
GH hold much promise in restoring bone mass and architecture. To test this hypothesis in
the present study rhPTH and rhGH were administered in aged female rats.
In this study a decrease in osteocyte apoptosis from age-related apoptosis in the tibia of
female rats following rhPTH treatment was observed; but the differences were not
statistically significant. A possible explanation for this finding lies on the short duration
of the experiment or the advanced age of the animals. It seems possible that the gain in
bone volume as noted by the micro-CT analysis was primarily due to an increase in
trabecular thickness, possibly due to an increase in osteoblast number and to a lesser
degree in osteoblast activity, as it was previously shown in older animals, where PTH
treatment rapidly activated bone lining cells to express the osteoblast phenotype (Dobnig
and Turner, 1995). Several other studies in adult and aged rats have shown that the
increase in bone mass induced by PTH is predominantly due to trabecular thickening
(Turner et al. 1998, Wronski et al.1999, Kneissel et al. 2001) and not due to the
suppression of osteoblast and osteocyte apoptosis. These data suggests that the process of
ageing and the increase in quiescent bone surfaces covered with bone lining cells forms
the basis for the anabolic effects of PTH on bone. Support for this hypothesis comes from
reports where the PTH-induced bone gain appears to result from direct activation of bone
lining cells on cancellous and cortical surfaces (Gasser 2003).
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At present the molecular mechanisms of PTH anabolic actions are not fully understood.
However the recently identified gene SOST and its protein product sclerostin have been
recognized as potent negative regulators of bone formation (van Bezooijen RL. 2007,
Bellido et al. 2005, Keller and Kneissel 2005, Li et al. 2005, Boyden et al. 2002,
Brunkow et al. 2001). In the present study sclerostin expression in the secondary
metaphyseal trabeculae of the rat tibia was investigated. rhPTH treatment resulted in a
decrease in the number of sclerostin positive osteocytes with no statistically significant
differences noted. Sclerostin positive osteocytes where located in the inner zone of bone,
which is in agreement with previous studies (van Besooijen et al. 2006, Poole et al. 2005,
Silvestrini et al. 2007), supporting the finding that it is only expressed by mature
osteocytes. This finding is suggestive of the possibility that sclerostin down regulation
may not have an important role in mediating the anabolic effects of rhPTH in skeletally
mature animals. On the other hand bone architectural changes occurred in the rhPTH
treated group, as shown by the bone formation indices via means of micro-CT. Although
no fluorescent markers of bone formation had been administered and no secure
assessment of the degree of bone formation could be formulated, an enhancement in bone
architecture in rhPTH treated rats was shown by a significant rise in trabecular thickness
together with a tendency towards a rise in BV/TV and towards a fall in trabecular
separation. It is possible to hypothesize that PTH-mediated sclerostin reduction could be
critical in regulating bone remodeling. However no secure conclusions can be drawn
regarding the role of sclerostin from the data presented in this study since sclerostin is a
delayed secreted product of osteocytes (Poole et al. 2005) and possibly SOST gene
expression and protein quantification may provide more information regarding its effect
in vivo. Along the same line rhGH treatment did not change the number of sclerostin
positive osteocytes compared to the other treatment groups, there is no other report in the
literature regarding rhGH and sclerostin expression and further studies are necessary to
confirm these findings.
On the other hand rhGH treatment has been reported to increase the markers for bone
resorption and formation within the first week of administration in postmenopausal
osteoporotic women and men with idiopathic osteoporosis (Andreassen and Oxlund
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2000, Andreassen et al. 1996). Fluorochrome labeling has shown that GH induces
periosteal bone deposition at the diaphysial bone surfaces of long bones without
influencing the endocortical surfaces of these bones (Andreassen et al, 2000). On
withdrawal from GH the labeling persists six weeks later indicating that new bone is
preserved upon cessation of treatment contrary to PTH treatment where bone is quickly
resorbed after withdrawal from treatment (Ejersted et al. 1998). In line with these
findings, in this study improvements in bone volume, trabecular separation and thickness
where observed as indicated by micro-CT analysis of the femurs, compared to control,
following rhGH treatment; however these differences where found not to be statistically
significant. This may be explained by the fact that in old rats no linear growth occurs and
as such treatment with rhGH does not influence bone volume or trabecular thickness.
However rhGH administration in this study had a significant effect on osteocyte viability,
with a non statistically significant effect on apoptosis. This finding as for rhPTH
treatment could be due to the duration of the experiment or the age of the animals. In
addition as mentioned earlier mature osteocytes do not possess GH receptors and as such
rhGH administration is unlikely to stimulate osteocytes directly. However in vitro and in
vivo studies have revealed that GH can stimulate bone turnover either directly and/or
indirectly through local IGF production, since it increases osteoblast number and activity
(Neuberg et al. 1997, Wong et al. 2000, Ueland 2004, Niu and Rosen 2005). In bone, no
reports exist so far to report any anti-apoptotic effects of IGFs on osteocytes; however the
targeted overexpression of IGF-I in osteoblasts has been shown to increase the osteocyte
lacunae occupancy without changing the osteoblast number, suggesting that IGF-I plays
an autocrine role in osteocyte generation and life spun (Zhao et al. 2000).
In conclusion, treatment with rhPTH and rhGH increased osteocyte viability and resulted
in a decrease in osteocyte apoptosis associated with ageing, with no statistical
significance; and an improvement of trabecular architecture. The rhPTH effect was more
marked than that of rhGH in terms of osteocyte viability and decrease in apoptosis as
well as in micro-CT indices measured. These differences may be partially explained by
the fact that osteocytes possess receptors for PTH but not for GH, thus GH treatment
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exerts indirect effects to the osteocytes possibly through the GH/IGF-I axis, in vivo.
Evidence to a GH protective effect in vitro via a potential stimulation of growth factors
has also been presented in chapter 2, where osteocyte-like cells in low serum effectively
repaired their plasma membrane and survived injury following treatment with rhGH.
Although the exact signaling pathways of the effects of these hormones on bone were not
investigated in this study, the current hypothesis that osteocytes are important in
maintaining bone quality and affecting bone formation, possibly through the secretion of
sclerostin (Keller and Kneissel 2005, Bellido et al. 2005) and resorption (Noble et al.
2003), receives lots of interest. However in this study no conclusions can be drawn
regarding the effect of sclerostin in the skeletally mature rat; further studies are needed to
determine whether changes in the osteocyte-derived sclerostin are involved in the control
of bone formation by other hormones, locally produced growth factors, or mechanical
stimuli as discussed in chapter 4; and whether regulation of other osteocyte products by
PTH or GH are involved in the effects of these hormones in bone. Finally it should be
noted that the original study design for this in vivo study was not intended for the analysis
presented in this chapter but for the microarray study discussed in chapter 5. For this
reason a number of experimental weaknesses can be identified. Firstly no fluorescent
markers were administered so as to measure bone formation rate in the ageing rat
skeleton following hormone treatment, to avoid disturbance of the cells of interest. Also
the tibias were used for two different studies and as such only one tibia was available for
analysis in each study, and because of the original study design the tibias were not




The Influence of Mechanical Stimulation and Recombinant
Human Parathyroid Hormone on Osteocyte Apoptosis and Bone
Viability in Human Trabecular Bone
Abstract
Data presented in the previous chapters have demonstrated the beneficial effects of
rhPTH administration on the viability and apoptotic death of murine osteocytes in vitro
and rat osteocytes in vivo. In this study the effect of an anabolic regime of rhPTH on the
viability of osteocytes and osteoblast in human trabecular bone explants ex vivo in the
presence and absence of mechanical stimulation using a 3D bioreactor system (Zetos™)
was investigated.
Bone cores 10mm x 5mm in size prepared from human femoral head explants were
incubated in the bioreactor for 7 days and subjected either to disuse conditions,
physiological loading regime on a daily basis or rhPTH treatment every day as a 4 hours
pulse in the presence or absence of mechanical loading. Following 7 days in culture;
osteocyte viability as determined by LDH activity, apoptosis as determined by in situ
nick translation technique, sclerostin and SOST gene expression and osteoblast alkaline
phosphatase activity were measured.
Results suggested that application of mechanical loading at physiological levels improved
osteocyte viability and significantly reduced osteocyte apoptosis compared to disuse
conditions. Administration of rhPTH reduced osteocyte apoptosis in the presence and
absence of mechanical stimulation. Furthermore application of mechanical stimulation
did not change the numbers of osteocytes expressing sclerostin in the presence or absence
of rhPTH compared to T (0) controls. Similar observations were made under unloading
conditions in the presence or absence of rhPTH compared to T(0) controls. On the
contrary the relative SOST gene expression (mRNA) decreased in the presence or
absence of mechanical stimulation following administration of rhPTH.
These data have indicated that application of physiological loading in human bone using
the bioreactor system inhibited osteocyte apoptosis and increased alkaline phosphatase




Wolffs law states that bone has the ability to adapt to its loading environment, (Wolf J.,
1892); this is done through the remodeling process that is mediated by the bone cells-the
osteoblasts, the osteocytes and the osteoclasts. Osteocytes have been shown to be able to
sense the strains produced in their surrounding environment and produce or modify
molecules such as nitric oxide (NO), prostaglandin (PGE2) and collagen type I gene
expression (Pitsillides et al. 1995, Ajubi et al. 1999). Production of these signals have a
subsequent effect on the function of bone effector cells and regulation of the bone
remodeling process in order to allow the skeleton to adapt efficiently to daily mechanical
requirements (Burger et al. 1995, Lanyon 1993, Mullender and Huiskes 1997).
Studies have reported an age-related decline in osteocyte viability (Frost 1960, Dunstan
et al. 1993, Qiu et al. 2005) which may result in reduced or impaired response in
detection of mechanical strain and microdamage and lead to inappropriate bone
remodelling, accumulation of microdamage in bone (Mori et al. 1997), loss of bone
architecture and increased fracture risk (Burr et al. 1985, Parfitt 1993). The mechanism
by which osteocytes may regulate the remodeling process is not fully understood. There
are a number of reports in the literature which have provided evidence to suggest that the
death of osteocytes through apoptosis might be providing the signals to regulate bone
remodeling (Kaneko et al. 1997, Noble et al. 1997, Verborgt et al. 2000, Noble et al.
2003, Kogianni et al., 2004, Aguirre et al. 2006, Kogianni et ah, 2008) since osteocyte
apoptosis has been documented to be associated with increased resorptive activity in
response to estrogen deficiency (Tomkinson et al. 1997, 1998) and exposure to
glucocorticoids (Weinstein et al. 1998, Kogianni et al., 2004). Moreover it has been
suggested that a U-shaped relationship exists between the survival of osteocytes and the
loads produced in their environment in a way that low or excessive strains lead to
osteocyte apoptosis following microdamage (Noble et al. 2003). This hypothesis might
provide evidence for a possible causal mechanism by which signals derived from
apoptotic osteocytes can regulate bone architecture (Noble et al. 2003).
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For the growth, maintenance and repair of bone a number of non-mechanical agents such
as PTH, which increases bone mass by adding bone on both endosteal and periosteal
envelopes is necessary. However, hormone release appears to decline with age and that
may be affecting the sensitivity of bone cells to mechanical loading (Jee and Tian, 2005).
In this study the effect of rhPTH in the presence or absence of mechanical loading was
tested. A line of evidence is available to show the effectiveness of combining PTH with
mechanical loading. Gasser and colleagues (1998) reported that unloaded vertebral
bodies in rats responded poorly to PTH administration, while Chow et ah, (1998) found a
synergistic effect of PTH and mechanical loading. Moreover it was found that trabecular
bone density was higher in the regions of lumbar vertebrae under the highest compressive
loading forces in women (Cann et al., 1997).
Mechanical loading improves bone mass and strength by stimulating the addition of new
bone onto bone surfaces experiencing high strains, whereas sites experiencing small
strains remain quiescent. At the cellular level the mechanisms involved in directing new
bone formation to the high strain regions of a loaded bone are unclear (Robling et al.
2006). However significant progress has been made in understanding some of the basic
mechanisms of mechanotransduction in bone. An important finding is the requirement for
Wnt signaling through Lrp5 in mechanically induced bone formation, as mice with a loss
of function mutation in Lrp5 were unable to respond anabolically to mechanical
stimulation (Sawakami et al. 2006), suggestive of Wnt/Lrp5 signaling being an integral
part of the mechanotransduction cascade in normal bone tissue.
Sclerostin, the protein product of SOST gene is a potent inhibitor of bone formation
(Robling et al. 2008). Mutation in the SOST gene causes sclerosteosis and Van Buchem
disease (Brunkow et al. 2001), patients with such mutations exhibit high bone mass.
Sclerostin was originally characterized as a BMP antagonist but more recently it has been
shown to bind to LRP5/6 (Li et al. 2005). Consequently, sclerostin raises the possibility
for regulating mechanically induced signaling through the Lrp5 receptor; moreover
sclerostin expression is specific to mature osteocytes (Poole et al. 2005, van Bezooijen et
al. 2005) which are hypothesized to be the mechanosensor in bone, due to the population
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density, distribution and extensive communication networks within bone (Cowin 2002).
However there is little data to support this hypothesis (Cowin 2002) and as such the
discovery of an osteocyte specific factor that has been shown to be mechanically
regulated (Robling et al. 2008, 2006) and can reach the osteoblasts, with known effects
on the Wnt/Lrp5 mechanotransduction signaling pathway , could be an alternative
explanation for osteocytic mechanotransduction. In this study the regulation of
SOST/sclerostin in the presence or absence of mechanical stimulation in a bioreactor
following rhPTH administration was investigated in human osteocytes.
Studies have shown that the application of mechanical loading that produced strains
within the physiological range appeared to preserve osteocyte viability compared to the
unloaded conditions in vivo (Noble et al. 2003) and ex vivo (Lozupone et al. 1996) as
well as to provide an osteogenic stimulus required by the bone tissue in order to maintain
its structure and function (Frost 1988, Lanyon 1996, Robling 2000). When mechanical
stress was applied on osteoblast-like cells, increased calcium content and ALP activity as
well as DNA content was reported to be increased (Winter at al., 2002) showing that
loading affects the osteoblast behavior as well.
Although there are a number of studies reporting the effectiveness of combining PTH
with mechanical load in animals, such studies prove difficult to undertake in human bone
due to inability to obtain human bone explants before and after exercise and maintaining
viable cultures of bone explants ex vivo (Jones et al., 2003).
These difficulties can now be partially overcome by the use of the Zetos™ culture system
that allows the bone cells to interact with each other and the extracellular matrix; while
the controlled application of mechanical loading or the administration of hormones and
growth factors might enable the study of bone remodeling and growth factor or hormone
interactions in normal and pathological bone in a controlled environment (Jones et al.
2003, Davies et al. 2006). The Zetos™ culture system can provide a better understanding
of skeletal physiology as the bone structure can be maintained in its 3D structure in near
to physiological environment with a constant supply of nutrients and oxygen (Jones et al.
2003).
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This study has investigated the effects of the controlled perfusion of rhPTH in an
intermittent mode (anabolic action) in the presence or absence of mechanical loading; on
the maintenance of the osteocytic population as well as SOST and sclerostin expression
along with osteoblastic alkaline phosphatase activity in human bone after 7 days in
culture in the Zetos ™ bioreactor.
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4.2 Materials and Methods
Unless indicated otherwise, all reagents were purchased from Sigma, UK. Preparation
and culture of bone tissue was performed in a sterilised environment using sterile
equipment.
4.2.1 Zetos™ description
The Zetos1 M system consists of two parts; a set of diffusion chambers in which cancellous
bone cores are maintained; which is connected to growth media supply via a peristaltic
pump; and a computer-controlled loading device used to apply daily physiological
mechanical stimulation to individual cores (Figure 4.1) (Davies et al. 2006). The system
is designed to do three things: 1. apply all sorts of mechanical waveforms-frequencies
and amplitudes to investigate mechanotransduction in bone and cartilage, 2. ensure the
mechanical properties of the biological material and 3. maintain the material in as good a
codition as possible. The bone cores are compressed axially by a piezoelectric actuator
(PZA). Strain gauges on the PZA and a force sensor above it provide output signals of
expansion and applied force, respectively. Force and specimen deformation are recorded
and the bone stiffness determined (Jones et al. 2003).
Within the diffusion chambers individual bone cores are housed and supplemented with
control media, and subjected to daily mechanical loading. Chambers contain a loading
piston at the top plate which transmits the loading force to the bone core while the bottom
plate is open in order to measure bone deformation at the bottom of the plate. The
growth media is pumped continuously around the system by the use of a perfusion pump
that can supply media to multiple chambers simultaneously. The loading device is
controlled by a computer programme that can apply a defined load to the bone cores
(Jones et al. 2003).
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Figure 4.1 The Zetos™ system. The Zetos™ bioreactor consists of a loading device
controlled by a computer and diffusion chambers perfused with media through individual
reservoirs with the aid of a peristaltic pump (A). Zetos™ bone loading champer (B) and
cross section of a bone specimen in a loading champer (C).
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4.2.2 Preparation of human biopsies for culture
Excised femoral head tissue was obtained, with written consent and with the approval of
the local ethical committee, from patients undergoing elective arthoplasty. A total of
three patient samples were collected (Table 4.1).
The samples were collected in sterile PBS and transferred to the lab following surgery,
with processing taking place within 2 hours. Femoral heads were first cut into 8mm slices
in thickness using an Exackt 310 diamond-coated band saw (Figure 4.2). All preparation
was performed under sterile conditions and during cutting and drilling the bone was
irrigated with cold PBS in order to minimize heat-induced damage to the tissue and to
prevent the bone from drying out (Davies et al. 2001). Cylindrical bone cores at 10mm in
diameter were drilled from each of these 8 mm-thick slices (Figure 4.2) using a diamond-
coated hollow drill (developed in house), while their height was adjusted to 5mm (±
2pm) with the Exackt 310 diamond coated band saw. The bone cores were then
thoroughly washed three times for 10 min in Hank's Balanced Salt Solution (HBSS) at
37°C, and subsequently washed for 20 min in HBSS supplemented with the antibiotics
Penicillin/Streptomycin (50IU/ml) (Invitrogen, UK), gentamycin (lOmg/ml) and the
antimycotic amphotericin B (4pg/ml). Cores from each individual patient were assigned
into four groups (cores from each individual patient were used for one experiment);
explants that were subjected daily to mechanical stimulation (n=3), explants that received
daily rhPTH treatment and subjected to mechanical stimulation (n=3), explants that
received daily rhPTH treatment in the absence of mechanical stimulation (n=3) and
explants that did not receive neither rhPTH nor mechanical stimulation (n=3).
4.2.3 Controls of the study
As described in § 4.2.2, bone core samples that were left untreated were included in the
Zetos ™ chambers in order to provide negative controls for mechanical stimulation or
rhPTH treatment. Besides the untreated controls that were incubated in the Zetos™
bioreactor for 7 days, the study was provided with additional control samples that were
not included in the Zetos™ chambers. Three bone cores from each patient T (0) were
frozen immediately in cold hexane at the end of the harvesting procedure to provide an
indication of the tissue state at the start of the experiments and to act as positive controls
for cell viability assays.
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Patient 12 3
Gender Male Female Male
Age 46 57 60






















Figure 4.2. Schematic overview of the experimental setup using the 3D bioreactor
system (Zetos™). Human trabecular bone cores were drilled from 8 mm-thick bone
slices obtained from each individual human femoral head and housed within the diffusion
chambers. Cores were assigned into four different treatment groups and maintained in the
Zetos™ bioreactor for a period of 7 days. Following that period, cores were frozen and
sections were collected from each core for subsequent analysis for osteocyte viability,
apoptosis, alkaline phosphatase indices, sclerostin expression and SOST gene expression.
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4.2.4 Maintenance of bone cores in the Zetos ™ system
Individual cores were inserted in the diffusion chambers and were left overnight at 37 °C
to settle prior to initiation of the experiment. Each diffusion chamber was connected to
individual media reservoir via a peristaltic pump system allowing continual perfusion
(7ml/hour) of the bone tissue with culture media. Individual bone cores were perfused
with Dulbecco's Modified Eagle medium (DMEM) (Gibco, UK) containing 10% FCS,
lOmM HEPES, 2mM L-glutamine (Gibco, UK), (lOpg/ml) L-ascorbic acid-2-phosphate,
5mM (3-glycerophosphate disodium hydrate, 0.14mM NAHCO3 and Penicillin (50 IU/ml)
Streptomycin (50pg/ml) (Gibco, UK). The bone cores were maintained in an
environmental chamber set at 37°C for 7 days with media being replaced daily in order to
provide adequate oxygen supply and clear out the cores receiving rhPTH treatment.
Throughout the experimental period, the pH of the media in each diffusion chamber was
closely monitored (~ pH 7.25) in order to ensure a physiological pH value during the
maintenance of the cores in the Zetos™ bioreactor.
4.2.5 Loading of the samples
A daily compressive mechanical loading of 5 minutes duration was applied to the bone
cores on a daily basis; a 1 minute static load to ensure that the core is placed properly in
the chamber followed by a 3 minute dynamic load. The applied forces resulted in strains
of 3000 pstrain at a frequency of 1 Hz, in a waveform that corresponded to physiological
jumping movement, based on preliminary studies in bovine bone (Figure 4.3), (Mann et
al. 2004, 2006).
4.2.6 Treatment with rhPTH
rhPTH was prepared from an initial stock of lOmM and was further diluted to 7pM in
normal medium. Samples then received treatment with rhPTH at lpl/ml in normal
medium to give a final concentration of 7nM. Treatment was administered at the
beginning of the experiment (day 1) and was supplied as a 5 hour pulse every 24 hours





Figure 4.3. Waveform diagram for the jumping stimuli. The waveform shown above












Figure 4.4 Schematic representation of the rhPTH treatment regime. rhPTH was
administered as a 5 hour pulse in 24 hours.
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4.2.7 Sample processing
After 7 days in the bioreactor, cores from each individual experiment were taken out of
the champers and immersed in 5 % polyvinyl alcohol and snap frozen in hexane (BDH,
UK) prior to storage at -70 °C. Transverse cryostat sections of 7pm in thickness were cut
from the chilled material using an ultra pure tape for sections (Taab Laboratories, UK)
and transferred to Superfrost slides (Western Laboratory Services, UK) for further
analysis. The use of the ultra pure tape allowed better adhesion of the bone sections onto
the slides. In order to broadly identify appropriate regions for subsequent analysis 6
sections were randomly collected from distances 0-0.5mm and 1-2.5mm from the upper
surface of the bone cores as outlined in table 4.2 and figure 4.5.
4.2.8 Cell viability assessment in situ
Osteocytes that were viable at the time of sampling were identified in cryostat sections by
means of their lactate dehydrogenase (LDH) activity as described in §3.2.2. The number
of LDH positive osteocytes, representing the viable osteocytes, was expressed as a
percentage of LDH positive osteocytes over the total number of cells. LDH staining was
performed on four consecutive sections taken at 1 mm and 2.5 mm distances through
each of the bone cores and six image fields were analyzed per section.
Percentage of viable osteocytes (%) =
The number of LDH positive osteocytes
X 100
The number of DAPI stained osteocytes
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No of No of Total no of No of Total no of
Treatments cores sections sections/ fields/ fields
/treatment /distance/ distance/ Section/ /distance
/patient patient treatment/ patient /treatment/
patient patient
TO 3 4 12 6 72
Unloaded 3 4 12 6 72
Unloaded+rhPTH 3 4 12 6 72
Loaded 3 4 12 6 72
Loaded+rhPTH 3 4 12 6 72
Table 4.2. Outline of sections collected and fields analysed from each distance. Four
sections were collected from each distance per core and six fields of view were analysed






Figure 4.5. A schematic representation of the bone core. Bone cores are cylindrical in
shape, 5 mm in height and 10 mm in diameter. (The arrows point to some of the distances
away from the core surface at which cryostat sections were obtained in order to carry out
the analysis).
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4.2.9 In situ analysis of osteocyte DNA fragmentation using Nick
Translation technique
The percentage of osteocytes demonstrating DNA breaks and therefore considered to be
apoptotic was investigated using in situ DNA nick translation technique (Noble et al.
1997), as previously described in 3.2.3. Counterstaining was performed using DAPI, at
2.5ng/ml in order to enable identification of total osteocyte numbers in each section.
Sections were then visualized by fluorescence microscopy in order to determine the ratio
of the apoptotic osteocytes (FITC positive) over the total number of osteocytes (DAPI
stained osteocytes). NT technique was employed on four consecutive sections per biopsy
and a minimum of six fields of view were analyzed per section taken at 2.5mm distance
through the bone cores covering in principle more than 70% of the total bone area at 20x
magnification.
Percentage of apoptotic osteocytes (%) =
Number of FITC positive osteocytes
X 100
Number of DAPI stained osteocytes
4.2.10 Alkaline Phosphatase Staining
Alkaline phospatase (ALP) is a protein attached to the plasma membrane via a glycosyl-
phosphatidinositol linkage (Noda, 1987) and catalyses the hydrolysis of phosphate
monoesters.
R-0-P03 + H20 ► R-OH + HP04-
ALP is a widely used marker of the osteoblast and has been suggested to participate in
bone mineralization (Waymire et al., 1995). ALP positive bone surfaces were detected in
7pm cryosections taken at the 2.5 mm region of interest. ALP staining was performed on
four consecutive sections taken at 2.5mm distance through each of the bone cores and six
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image fields were analyzed per section. Sections were incubated at room temperature for
15 minutes in a solution of 1 mg/ml Fast Blue containing 40 pi (v/v) Naphthol-ASMX-
mix, made in distilled water. The reaction was inhibited by washing the sections with
PBS, followed by fixation in 4% paraformaldehyde for 10 minutes at room temperature.
The percentage of ALP positive surface to total bone surface per field of view was
measured using Bioquant Osteo Histomorphometry software (Bioquant Image Analysis
Corporation, USA).
Percentage of alkaline phosphatase +ve area (%)
= (total bone area-alkaline phosphatase +ve area) *100
4.2.11 Sclerostin Staining
The percentage of osteocytes expressing sclerostin was investigated via means of
immunostaining with a polyclonal anti-human sclerostin antibody (R&D Systems) as
previously described in 3.2.5 (Figures 4.6, 4.7). Counterstaining was performed using
DAPI, at 2.5ng/ml in order to enable identification of total osteocyte numbers in each
section. Sections were then visualised by light and fluorescent microscopy in order to
determine the ratio of the osteocytes expressing sclerostin over the total number of
osteocytes (DAPI stained osteocytes). Sclerostin immunostaining was employed on four
consecutive sections per biopsy and a minimum of six fields of view were analyzed per
section taken at 2.5mm distance through the bone cores. The following criteria were used
to calculate the percentage of sclerostin positive osteocytes:
Percentage of sclerostin positive osteocytes (%) =
The number of sclerostin positive osteocytes
X 100
The number of DAPI stained osteocytes
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A. Sclerostin B. DAPI
Figure 4.6 Immunohistochemical reaction of sclerostin expression in sections of
human bone explants. A section of trabecular bone was taken from a T (0) control
sample. Osteocytes stained positive for sclerostin are brown as indicated by the arrow (A)
Nuclei stained positive for DAPI (B). Bar represents 100pm.
A. Sclerostin B. DAPI
Figure 4.7 Immunohistochemical demonstration of a negative control for sclerostin
staining. Sections were treated with non-immune goat serum control diluted at 1:100 in
2% normal rabbit serum mixture in the absence of sclerostin antibody. Nuclei were
stained blue with DAPI (B). No sclerostin signal was observed (A). Bar represents 100
pm.
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4.2.12 RNA extraction from bone cores
For RNA extraction the bone cores were pulverized in liquid nitrogen using a mortar and
pestle and the bone powder suspended in Trizol (Invitrogen).The homogenized sample
was then incubated for 5 minutes at room temperature to allow the dissociation of
nucleoproteins. The mix was then centrifuged (eppendorf centrifuge 5417R) to remove
any debris and the supernatant was transferred to a new tube. 0.2 ml of chloroform were
added and the samples vortexed for 15 seconds and incubated at room temperature for 2-
3 minutes prior to centrifugation at 4°C for 15 minutes at 12,000 x g. The mixture then
separates into a lower phenol-chloroform phase containing the DNA, an interphase that
contains protein and a colorless upper aqueous phase containing the RNA. The upper
aqueous phase was carefully aspirated into a new tube taking care to avoiding the
interphase. An equal volume of isopropanol was added and the sample placed at -20 °C
for a minimum of 20 minutes in order to precipitate the RNA. Following centrifugation at
12,000 x g for 10 minutes at 4°C the RNA was visible as a gel-like pellet at the bottom of
the tube. The supernatant was then removed and the pellet was washed three times with
lml of 75% ethanol at 7,500 x g for 5 minutes at 4°C. All leftover ethanol was removed
after the final wash and the pellet was allowed to air-dry for approximately 10 minutes.
The RNA pellet was then dissolved in 25 pi of RNAse free water. The RNA sample was
then transferred on ice and stored immediately at -80°C.
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4.2.13 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
RNA samples were reverse transcribed to generate cDNA using the WT-Ovation1M RNA
Amplification System (NuGEN) according to manufacturer's recommendations.
First Strand cDNA Synthesis Protocol
In a 2 pi of total RNA sample, 2pl of Strand Primer Mix (A 1-2) reagent were added and
the tube(s) was placed in a thermal cycler at:
65° C for 5 minutes
Cool to 4° C.
The tubes were then placed on ice and 6 pi of a master mix consisting of 5 pi First Strand
Buffer Mix (A2-2) 0.5 pi of Nuclease Free Water (Dl) and 0.5 pi of First Strand Enzyme
Mix (A3).The tubes were then placed in a chilled thermal cycler at:
4 ° C 1 minute
25 ° C 10 minutes
42 ° C 10 minutes
70 °C 15 minutes
4 ° C for ever
Following that the tubes were placed on ice to continue immediately with the second
strand cDNA synthesis.
Second Strand cDNA Synthesis Protocol
A master mix combined of 9.75 pi of Second Strand Buffer Mix (Bl-3) and 0.25 pi
Second Strand Enzyme Mix (B2-2) was prepared and 10 pi were added to each of the
First Strand Reaction tubes, mixed well by pippeting and placed in a thermal cycler for:
4 ° C 1 minute
25 ° C 10 minutes
50 0 C 30 minutes
70 ° C 5 minutes
4 ° C for ever
Samples were then placed on ice to continue immediately with Post Second Strand
Enhancement Step.
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Post Second Strand Enhancement Protocol
2 pi of the master mix combined of 1.9 jj.1 Second Strand Buffer Mix (Bl-3) and 0.1 (rl of
Reaction Enhancement Enzyme Mix (B3) were added to each of the Second Strand
Reaction tubes, mixed by pippeting and placed on a chilled thermal cycler for:
4 ° C 1 minute
37 ° C 15 minutes
80 0 C 20 minutes
4 0 C for ever
Samples were then placed on ice to continue with the SPIA Amplification.
SPIA Amplification Protocol
A master mix combined of 5 pi SPIA Buffer Mix (C2-4), 5 pi of SPIA Primer Mix and
10 pi SPIA Enzyme Mix was prepared and 20 pi were added to each of the Enhanced
Second Strand reaction tubes, mixed and placed on a thermal cycler for:
4 ° C 1 minute
47 0 C 60 minutes
95 ° C 5 minutes
Samples were then placed on ice, prior to application of the Purification of Amplified
cDNA Protocol.
Purification of Amplified cDNA Protocol
The Zymo Research DNA Clean and Concentrator -25 system was used for purification
of the cDNA derived from the WT-Ovation™ RNA Amplification System.
320 pi of DNA Binding Buffer were added into the 40 pi of the amplified cDNA
followed by vortexing. The mix was loaded onto the Zymo-Spin II Column and
centrifuged at 10,000 x g for 10 seconds. The flow through was discarded and the sample
was washed with 200 pi of 80% ethanol and then centrifuged at 10,000 x g for 10
seconds. The flow through was then discarded and another 200 pi of 80% ethanol were
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added and the sample centrifuged at 10,000 x g for 30 seconds. The flow through was
then discarded and the tip of the column was blotted onto filter paper to remove any
residual wash buffer. The column was then placed in a clean 1.5 ml tube and 30 pi of
nuclease free water were added and allowed to stand for 1 minute at room temperature
prior to centrifuging at 10,000 x g for 30 seconds to elute the purified cDNA. The sample
was then vortexed and placed at -20 °C until further use.
4.2.14 Quantitative Real-Time PCR Expression Analysis
Quantitative real-time PCR expression analysis was performed using an AB1 Prism 7900
HT sequence detection system, TaqMan® Universal PCR Master mix, human 18 S rRNA
pre-developed TaqMan® assay reagent for normalization and TaqMan® Assay-on-
Demand™ products for human SOST (primers custom designed in house by Dr. Val
Mann) were all purchaced from Applied Biosystems. All samples were run in triplicates.
The TaqMan® Universal PCR Master mix was used for all the reaction components
except primers, probe, and template. The final primer concentrations were 900 nM, and
final probe concentrations were 50 nM. Cycling conditions were 50°C for 2 min, 95°C
for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. The data were collected
and analyzed by the ABI Prism 7700 Sequence Detection System Software, version 2.1.
The quantity (measured in copies/pl) was determined by the standard curve method, in
which a standard curve generated by serial dilution (lx, 1:10, 1:100, 1:1,000, and
1:10,000) of a double-stranded fragment of known concentration was run with the
unknown samples. No-template negative controls were constructed by substitution of
nuclease-free water for cDNA. The quantity of each unknown was determined by plotting
a standard curve (Threshold Cycle (Cx) vs. Starting Quantity) and calculating from the Cx
of each sample the amount amplified. The normalized value was determined by




Bone histomorphometry was earned out as described in §3.2.8. Histomorphometric
indices are divided into primary such as measurements of bone surface (BS), volume
(BV) (Parfitt 1987) and the derived measurements some of which would include
mineralizing surface (MS) or bone formation rate (BFR/BS).
Using light microscopy, the bone surfaces were traced on sections from the samples
maintained in the Zetos™ system and analysis of bone surface (BS) was carried out using
the bone histomorphometry software BIOQUANT OSTEO (Bioquant Image Analysis
Corporation, USA). The sections used were collected as described earlier and
measurement of bone surfaces was performed using the formula:
BS (mm) = Total Bone Surface - Artificial edges
4.2.16 Statistical analysis
All data analyses were performed using the statistical software package SPSS for
Windows 14.1. All data were checked for normality. In cases where the randomly
selected sample data were shown to have a nonnal (Gaussian) distribution, the one-way
Analysis of Variance (ANOVA) followed by the Tukey-Kramer and Bonferroni post hoc
test were performed to determine statistical significance between treatment groups. For
percentages or proportions that were not normally distributed the square root of each
proportion was transformed into its arcsine which allowed the distribution of the data to
be nearly normal enabling the use of parametric tests. Results were considered significant
when p<0.05 denoted by * .The results are presented as means ± SEM.
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4.3 Results
4.3.1. The effect of mechanical loading on osteocyte viability in the
presence or absence of rhPTH at 1 and 2.5 mm distances.
In order to provide positive controls for the viability of osteocytes prior to the
introduction of the cores to the Zetos 'M system, three samples were frozen immediately
following the harvesting procedure, as described in methods, and were termed time zero
(TO) controls. For each of the other treatment groups' three cores were introduced in the
bioreactor and subjected to mechanical stimulation on a daily basis for 7 days. The
treatment groups were divided in those that were maintained in the presence (termed as
Load) (LD) or absence (termed as Unloaded) (UL) of mechanical stimulation and those
maintained in the presence of mechanical stimulation and rhPTH alone treatment (termed
as Loaded + PTH) (PTHLD) and those that received rhPTH treatment but no mechanical
stimulation (termed as Unloaded + PTH) (PTH). After 7 days, all bone cores were
removed from the bioreactor and were analyzed for cell viability using the LDH activity
in order to determine any changes in the number of viable osteocytes following treatment
as described above (Figure 4.9).
As shown in figure 4.8(A-C) at 1mm for patient 1 (PI) (Figure 4.8A) osteocyte viability
in the unloaded sample was significantly lower to the T (0) control (30%± 2.63 vs. 87%±
11.1, p=0.016), while mechanical stimulation significantly increased osteocyte viability
when compared to unloaded (53%± 4.09 vs. 30%± 2.63, p=0.018). rhPTH treatment
significantly increased osteocyte viability in the absence or presence of mechanical
stimulation when compared to unloaded (82%± 10.2 vs. 30%± 2.63 p=0.018, 58%± 4.44
vs. 30%± 2.63, p=0.033). For patient 2 (P2) (Figure 4.8B) the unloaded sample was
significantly lower to the T (0) control (35%±3.18 vs. 74% ±5.60, p<0.05), while
mechanical stimulation resulted in a trend towards an increase in osteocyte viability when
compared to unloaded, with no statistically significant differences noted (52%±4.56 vs.
35%±3.18, p>0.05) Similarly rhPTH treatment showed a trend towards an increase in
osteocyte viability in the absence or presence of mechanical stimulation when compared
to unloaded, with no statistically significant differences noted (48 %±4.27, 52%±5.79 vs.
35%±3.18, respectively, p>0.05). In Patient 3 (P3) (Figure 4.8C), in the absence of
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mechanical stimulation osteocyte viability was significantly decreased when compared to
T(0) control (23%±4.23 vs. 77%±8.46, p=0.03) while in the presence of mechanical
stimulation osteocyte viability was increased compared to unloaded (55%±12.8 vs.
23%±4.23, p=0.09). rhPTH treatment in the presence of mechanical stimulation
significantly increased osteocyte viability compared to unloaded samples (60%±10.2 vs.
23%±4.23, p=0.012) while in the absence of mechanical stimulation no statistically
significant differences were noted (35%±5.81vs. 23%±4.23, p>0.05) . Across all three
patients the general trend observed at the distance of 1mm is that osteocyte viability is
increased in the presence of mechanical stimulation whether rhPTH is present or not
when compared to unloaded samples.
As shown in figure 4.8(D-F) at 2.5mm for PI (Figure 4.8D) osteocyte viability in the
unloaded sample was significantly lower to the T (0) control (27%± 2.62 vs. 70%± 7.73,
p=0.001), while mechanical stimulation significantly increased osteocyte viability when
compared to unloaded (52%± 7.01 vs. 27%± 2.62, p=0.001). rhPTH treatment
significantly increased osteocyte viability in the absence of mechanical stimulation when
compared to unloaded (77%± 10.7 vs. 27%± 2.62, p=0.001), while rhPTH in combination
with mechanical stimulation increased osteocyte viability compared to unloaded however
no statistically significant differences were noted ( 42%± 5.08 vs. 27%± 2.62,
p>0.05).For P2 (Figure 4.8E) osteocyte viability was significantly higher in the T (0)
control compared to unloaded (83.1% ±3.43 vs. 42.8%±5.04, p<0.001). Mechanical
stimulation resulted in a trend towards an increase in osteocyte viability when compared
to unloaded; with no statistically significant differences noted (54%±4.22 vs. 43%±5.04,
p>0.05), however significant differences were observed in the presence of rhPTH
treatment alone (36%±5.02 vs. 54%±4.22, p=0.027). rhPTH treatment in the presence of
mechanical stimulation significantly increased osteocyte viability when compared to
rhPTH treatment only (59%±4.7 vs. 36%±5.02, p=0.037). In P3 (Figure 4.8F), in the
absence of mechanical stimulation osteocyte viability was significantly decreased
compared to T (0) control (20%±3.6 vs. 83%±5.2, p=0.001) while in the presence of
mechanical stimulation osteocyte viability was increased compared to unloaded
(59%±6.2 vs. 20%±3.6, p=0.001). rhPTH treatment in the presence or absence of
mechanical stimulation significantly increased osteocyte viability compared to unloaded
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(37%±5.7 vs. 20%±3.6, p=0.006, 52%±4.47 vs. 20%±3.6, p=0.002, respectively). At the
distance of 2.5 mm the trend observed across the three patients is that in that following
rhPTH treatment in the presence or absence of mechanical stimulation osteocyte viability
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Figure 4.8 The percentage of LDH positive osteocytes in the presence or absence of
mechanical stimulation and rhPTH. Bone cores from PI, P2 and P3 were maintained
in the bioreactor for 7 days in the presence or absence of mechanical stimulation and the
presence of rhPTH with mechanical or no mechanical stimulation. The T (0) controls
were frozen as described above at the time of harvesting. Frozen sections collected at 1
(A-C) and 2.5 (D-F) mm and were examined for LDH activity in osteocytes (A-F).In the
absence of mechanical stimulation for all patients osteocyte viability was significantly
decreased compared to the T (0) controls, while mechanical stimulation increased
osteocyte viability. rhPTH treatment increased osteocyte viability in while rhPTH in
combination with mechanical stimulation had a more pronounced effect compared to
rhPTH only. Results are expressed as the percentage of LDH positive osteocytes ±
S.E.M * = p<0.05 and ** = p<0.001.
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Figure 4.9 Histochemical reaction of LDH enzyme in sections of human bone
explants cultured in the Zetos™ system for 7 days. Osteocyte lacunae showed either
strong reaction with LDH indicating viable osteocytes or no reaction indicating empty
lacunae or non viable osteocytes. Representative images from A. the T (0) control B. the
mechanically stimulated sample C. the unloaded sample. Black arrow identifies a viable
LDH-positive osteocyte. Bar represents 100pm.
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4.3.2 The effect of mechanical loading on osteocyte apoptosis in the
presence or absence of rhPTH.
Bone cores treated with rhPTH in the presence or absence of mechanical stimulation
were also analyzed for osteocyte apoptosis at the distance of 2.5 mm (Figure 4.11).
Application of mechanical loading reduced osteocyte apoptosis in all three patients
compared to unloaded samples. More specifically in PI (Figure 4.1 OA), osteocyte
apoptosis in the unloaded sample was significantly increased compared to the T (0)
control (0.94% ± 0.49 vs. 10% ± 1.89, p=0.005), while mechanical stimulation
significantly decreased osteocyte apoptosis compared to the unloaded (2% ± 0.60 vs.
10% ± 1.89, p=0.011). rhPTH treatment decreased osteocyte apoptosis compared to
unloaded, however no significant differences were noted (6% ±1.21 vs. 10% ± 1.89). On
the other hand rhPTH treatment in the presence of mechanical stimulation significantly
decreased osteocyte apoptosis compared to unloaded (1 % ± 0.46vs. 10% ± 1.89,
p=0.006) In P2 (Figure 4.10B), osteocyte apoptosis was significantly increased in the
absence of mechanical stimulation compared to the T (0) control (10% ±1.39 vs.0.77% ±
0. 47, p=0.006). Mechanical stimulation significantly decreased osteocyte apoptosis
compared to unloaded (2 % ± 0.49 vs. 10% ±1.39, p=0.025), while rhPTH treatment in
the presence of mechanical stimulation significantly decreased osteocyte apoptosis
compared to unloaded (1% ± 0.46 vs. 9 % ± 1.39, p=0.027). In P3 (Figure 4.10C)
similar to PI and P2, osteocyte apoptosis in the unloaded sample was significantly
increased compared to the T (0) control (11% ± 1.89 vs. 0.75% ± 0.31, p=0.015), while
mechanical stimulation significantly decreased osteocyte apoptosis compared to the
unloaded (3% ± 0.75 vs. 11% ± 1.89, p=0.026). Similarly mechanical stimulation in
combination with rhPTH treatment significantly decreased apoptosis compared to
unloaded (2 % ± 0.54 vs. 11% ± 1.89, p=0.006). The general trend observed across all
three patients is that mechanical stimulation significantly decreased osteocyte apoptosis
compared to unloading conditions.
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Figure 4.10 In situ evidence of DNA fragmentation in osteocytes subjected to
mechanical stimulation in the presence or absence of rhPTH. Sections obtained from
the 2.5mm distance were analyzed for osteocyte apoptosis using the in situ nick
translation technique. (A-C). Treatment of cores under unloading conditions alone
significantly increased the percentage of osteocyte apoptosis compared to the other
treatments and the T (0) controls in PI (A), P2 (B) and P3 (C). Combination treatment of
rhPTH and mechanical stimulation in PI (A), P2 (B) and P3 (C) significantly decreased
osteocyte apoptosis compared to unloading conditions. Results are expressed as the
percentage of osteocytes displaying positive staining for fragmented DNA over their total















Figure 4.11 In situ evidence of DNA fragmentation in osteocytes subjected to
mechanical stimulation in the presence or absence of rhPTH. The percentage of
osteocyte apoptosis was quantified in sections at the distance of 2.5mm. Representative
images of apoptotic osteocytes (FITC) and the corresponding total cell count (DAPI) in
A. T (0) control, B. Unloaded samples, C. Unloaded samples in the presence of rhPTH,
D. Loaded samples and E. Loaded samples in the presence of rhPTH. Arrow indicates
apoptotic osteocytes. Bar represents 100pm.
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4.3.3. The effect of mechanical loading on the percentage of alkaline
phosphatase labeled bone surfaces in the presence or absence of rhPTH.
Bone cores treated with rhPTH in the presence or absence of mechanical loading were
analyzed for indices of osteoblast activity at the distance of 2.5 mm. Cryostat sections
were stained for alkaline phosphatase as described in the methods section (Figure 4.13).
All three patients show a higher percentage of ALP positively labelled bone surface in the
T (0) controls compared to both loaded and unloading conditions either presence or
absence of rhPTH . As shown in figure 4.12(A-C) at 2.5mm for PI (Figure 4.12A) T (0)
control was statistically significant different to unloaded, loaded, and rhPTH treated
samples in the absence or presence of mechanical stimulation (5%± 1.21 vs. 2%± 0.63,
2%± 0.43, 1 %± 0.39, 1.50%± 0.67, respectively, p<0.05), however no statistically
significant differences were noted between other treatment groups. For P2 (Figure 4.12B)
the percentage of positively labelled ALP bone surface was found to be significantly
higher in the T (0) control compared to unloaded, loaded, and rhPTH treated samples in
the absence or presence of mechanical stimulation (5%±0.92 vs. 0.92%±0.18,
0.59%±0.14, 1 %±0.43, 1%±0.37, respectively, p<0.001), while combination treatment of
rhPTH and mechanical stimulation significantly increased ALP positively labelled
surface compared to unloading conditions (1%±0.37 vs. 0.92%±0.18, p=0.05). In P3
(Figure 4.12C) the percentage of ALP labelled area was significantly higher in the T (0)
control compared to unloaded (3%±0.61 vs. 2%±0.73 p=0.026). rhPTH treatment in the
presence or absence of mechanical stimulation was also found significantly different to
























































Figure 4.12 The percentage of alkaline phosphatase positive area in the presence or
absence of mechanical stimulation and PTH. Frozen sections collected at the distance
of 2.5mm obtained from bone cores from patients PI, P2 and P3 were examined for
osteoblast activity indices in loading and unloading conditions in the presence or absence
of rhPTH (A-C). In PI (A) the percentage of positively labeled surface was found to be
higher in the T (0) controls compared to the other treatment groups, while the presence of
mechanical stimulation or rhPTH did not affect ALP expression. In P2 (B) the percentage
of positively labeled bone surface was significantly higher in the T (0) control compared
to the other treatment groups, while combination treatment of rhPTH and mechanical
stimulation significantly increased ALP positively labeled surface compared to unloading
conditions (p=0.05). In P3 (C) the percentage of positively labeled bone surface was
higher in the T (0) control compared to unloading conditions in the presence or absence
of rhPTH (p<0.05). Results are expressed as the percentage of ALP positively labelled




Figure 4.13 Histochemical reaction of alkaline phosphatase positive bone surfaces in
sections of human bone explants cultured in the Zetos™ system for 7 days. ALP was
stained using standard techniques, the ALP positive surfaces stain as purple.
Representative images from A. the T (0) control. B. the mechanically stimulated sample
C. the unloaded sample. Arrow indicates alkaline phosphatase positive stained surfaces.
Bar represents 100pm.
177
4.3.4 The effect of rhPTH on osteocyte sclerostin expression in the
presence or absence of mechanical stimulation.
Bone cores from the three patients treated with rhPTH in the presence or absence of
mechanical stimulation were analyzed for sclerostin expression (Figure 4.14 A-C). For
PI, P2 and P3 there were no significant differences noted between samples that where
treated either in the presence or absence of mechanical stimulation as well as the presence
or absence of rhPTH in the percentages of osteocytes expressing sclerostin. In more detail
for P1 (A) in the absence of mechanical stimulation compared to the T (0) control (40% ±
1.20 vs. 43% ± 1.21, p>0.05) no difference was observed. Similarly in the presence of
rhPTH in both loaded and unloaded conditions no reduction in the percentage of
sclerostin positive osteocytes compared to the unloaded (39 % ± 0.57, 39 % ± 0.77 vs. 40
% ± 1.20, p>0.05) was observed. In P2 (B) similar observations to PI were made with the
presence of rhPTH in both loaded and unloaded conditions not affecting the percentage
of sclerostin positive osteocytes (38% ± 0.30, 38%± 0.70 vs. 40 ± 0.52, p>0.05).
Similarly loaded samples showed no difference in the percentage of sclerostin positive
osteocytes when compared to samples in the presence of rhPTH in both unloaded and
loaded conditions (40% ± 0.54 vs. 38% ± 0.30, 38% ± 0.70, p>0.05). Similar
observations to PI and P2 were made for P3 (C) with the presence of rhPTH in both
loaded and unloaded samples showing no reduction in the percentage of sclerostin
positive osteocytes compared to the unloaded (39%± 0.80, 39% ± 0.89 vs. 40% ± 0.60,














































T(0) unloaded loaded Unloaded+PTH Loaded+PTH
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T(0) unloaded loaded Unloaded+PTH Loaded+PTH
P2
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Figure 4.14 The percentage of sclerostin positive osteocytes in human trabecular
explants in the presence or absence of mechanical stimulation and rhPTH. Sections
obtained from the 2.5 mm distance for all three patients were analyzed for sclerostin
expression on osteocytes (A-C). For PI (A), P2 (B) and P3 (C) treatment of bone cores
with rhPTH either in the presence or absence of mechanical stimulation had no effect on
the percentages of osteocytes expressing sclerostin.. Results are expressed as the
percentage of sclerostin positive osteocytes ± S.E.M
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4.3.5 The effect of rhPTH on SOST gene expression in the presence or
absence of mechanical stimulation.
Total RNA from bone cores from the three different patients was extracted and
transcribed into cDNA which was then subjected to quantitative real-time PCR to
measure the mRNA levels of SOST in samples subjected to mechanical stimulation in the
presence or absence of rhPTH (Figure 4.15A-C). In all three patient samples SOST gene
expression was significantly higher in the T (0) controls compared to both loaded and
unloaded conditions in the presence or absence of rhPTH. In more detail in PI
mechanical stimulation in the presence or absence of rhPTH reduced SOST mRNA levels
(A) compared to T (0) control (3 ± 5.4 vs. 33 ± 5.9, p=0.03, vs. 66 ± 5.4, p<0.001).
Absence of mechanical stimulation in the presence or absence of rhPTH also reduced the
mRNA levels of SOST (3 ± 1.63 vs. 29± 2.41, p=0.12). In P2 (B) similar observations to
PI were made with the presence of rhPTH in both loaded and unloaded conditions
reducing the levels of SOST mRNA (1 ± 3.13 vs. 2 ± 0.81, p>0.05), however no
statistically significant differences were noted. A reduction in SOST mRNA levels was
observed in the presence or absence of mechanical stimulation compared to the T (0)
control (3 ± 3.41 vs. 2± 2.41 vs. 30± 0.19, p<0.001). Similarly in P3 (C) the presence of
rhPTH in loaded and unloaded conditions resulted in a reduction in SOST mRNA levels
(2 ± 4.07 vs. 3 ± 0.63, p>0.05), with no statistically significant differences noted, as did
the presence or absence of mechanical stimulation when compared to T (0) control (12 ±
0.81 vs 21 ± 0.10 vs. 96 ± 7.27, pO.001).
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Figure 4.15 SOST gene expression in human trabecular explants subjected to
mechanical stimulation in the presence or absence of rhPTH. RNA was extracted
from whole bone cores using TRIZOL and subjected to cDNA synthesis used for
quantitative real-time PCR for the SOST gene (A-C). For PI (A) mechanical stimulation
in the presence or absence of rhPTH reduced SOST mRNA levels as did the absence of
mechanical stimulation in the presence or absence of rhPTH when compared to T(0)
controls. Similarly in P2 (B) the presence of rhPTH in both loaded and unloaded
conditions reduced the levels of SOST mRNA as did the presence or absence of
mechanical stimulation compared to the T (0) control. Similar observations to P1 and P2
were made for P3 (C) in which the presence of rhPTH in loaded and unloaded conditions
reduced SOST mRNA levels as did the presence or absence of mechanical stimulation
when compared to T(0) control. Results are expressed as the SOST gene expression
relative to human 18s ± S.E.M * = p<0.05 and ** = p<0.001 denote significant
differences of T (0) to the other treatments.
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4.4 Discussion
Data presented in previous chapters demonstrated a protective effect of rhPTH on the
viability of rat osteocytes in vivo and murine osteocytes in vitro. The study presented in
this chapter investigated the potential effects of rhPTH on the viability of human
osteocytes ex vivo following 7 days in culture using the Zetos1M bioreactor, in the
presence or absence of physiological loading.
Over the years a line of evidence has accumulated to demonstrate the anabolic effects of
mechanical loading within the physiological range of strains to bone (Mosley et al. 1997,
Lanyon 1992) while unloading conditions induced bone resorption and bone loss. Organ
and cell culture systems have provided important insights regarding the response of bone
cells to mechanical stimulation or to growth factors and hormones (Rawlinson et al.
1995, Cheng et al. 1996, Zaman et al. 1997). However it has not been possible to
maintain the tissue viable due to the inability of these systems to mimic the in vivo bone
microenvironment (Jones et al. 2001) resulting in tissue necrosis mainly in the centre of
the organ culture (Jones et al. 2001, Davies et al. 2004). Due to these difficulties, little is
known regarding the viability of osteocytes, considered to be the mechanosensors
(Lanyon 1993, Zhang et al. 1997, Noble et al. 2003) and transducers in bone (Lean et al.
1996, Aarden et al. 1996, Duncan and Turner 1995, Klein Nulend et al. 1995, Yellowley
et al. 2000) based on the current ex vivo organ culture systems. In the study presented
here the 3-D bioreactor system (Zetos™) was used to investigate the effects of rhPTH on
human osteocytes from three patients over a seven day period in the presence or absence
of mechanical stimulation.
For the determination of osteocyte viability following extraction from the patient,
osteocytes were examined by means of their LDH activity in the T (0) controls. The
distance analyzed was at 1 and 2.5 mm, in order to determine possible effects of the
drilling process on osteocyte viability. It was observed that higher percentages of viable
osteocytes were observed at 2.5 mm compared to 1mm in the T (0) cores possibly
suggesting that the drilling process might have induced the loss of osteocytes observed in
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the latter this finding is in line with previous work (Mann et al. 2006). Despite the loss of
2 2
osteocytes at 1mm, the density of osteocytes per mm (125-150 osteocytes per mm" at
1mm and 180-250 osteocytes per mm2 at 2.5mm) was found to be within the range of
viable osteocytes per mm2 reported for human trabecular bone in the literature
(Mullender et al. 1996, Tomkinson et al. 1998, Qiu et al. 2002, Mann et al. 2006).
Because osteocyte viability at 2.5mm from the surface of the cores was higher than at the
1 mm distance all further analysis was earned out at this region of interest within each
core.
Although the viability of osteocytes in the T (0) controls was found to be within the
lowest range of viable osteocytes reported in human control samples (Mullender et al.
1996, Tomkinson et al. 1998, Qiu et al. 2002), maintenance of bone cores under
unloading conditions in the bioreactor resulted in a decrease in the percentage of viable
osteocytes, which was between 20-45% after 7 days in culture. However the viability of
osteocytes was improved by almost 1.5 fold upon application of mechanical loading
compared to the unloaded samples. Although in other ex vivo organ cultures such as the
one in the study by Takai and colleagues (2004) it was shown that mechanical stimulation
could not maintain osteocyte viability in bovine bone explants after 22 days in culture,
possibly due to insufficient nutrient perfusion to osteocytes. In contrast to these findings
in this system as it was shown by Mann and colleagues (2006) following 3, 7 and 27 days
in culture, as well as by the experiments presented in this study there is sufficient and
possibly homogeneous supply of feeding media throughout the thickness of the bone
cores, as evidenced by the fact that osteocyte viability did not drop towards the centre of
the bone cores.
The viability of osteocytes was examined by means of their metabolic activity. In more
detail, the metabolic activity of the LDH enzyme was monitored following the addition of
tetrazolium salts to cells as described in the methods section, which are reduced in viable
cells to a coloured product by the action of dehydrogenases (Tisserat and Manthey 1996,
Verleysen et al. 2004). On the basis of this assay only the living cells were coloured,
since the colour observed is a product of metabolic activity in cells, whereas the non-
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coloured cells were considered dead (Widholm 1972). In the current study this viability
assay demonstrated that the non-viable cells were not detected due to the loss of enzyme
activity, suggesting that only metabolically active cells were included in the measurement
of viable cells. However, as described above necrotic cells would be excluded from the
measurements, it may be possible that apoptotic cells would be included in the viable cell
measurements, due to the fact that apoptosis is an active, ATP-dependent process (Kerr
1972) and therefore cells of the early apoptotic stages would still be metabolically active
and would possibly show LDH activity. For these reasons the response of osteocytes to
different treatments was further characterized by examining apoptotic indices using the in
situ nick translation technique.
Apoptotic osteocytes were estimated based on DNA fragmentation, in the T (0) samples
levels of apoptosis were similar to those reported in the literature for control human
samples (Tomkinson et al. 1997, Mann et al. 2006). Culturing of bone explants in the
absence of mechanical loading resulted in a 4 fold increase of osteocyte apoptosis
compared to the T (0) samples. Similar findings has been previously reported by other
studies showing that the absence of mechanical loading resulted in an increase in
osteocyte apoptosis (Noble et al. 2003, Bakker et al. 2004, Basso et al. 2006, Mann et al.
2006). Moreover application of mechanical loading within the known osteogenic range
(Mann et al. 2006) reduced osteocyte apoptosis compared to the unloaded samples. These
findings are in accordance with previous studies that have demonstrated that application
of mechanical stimulation within the physiological range is beneficial for osteocyte
viability in rat bone either in vivo (Noble et al. 2003) or ex vivo (Lozupone et al. 1996) as
well as for osteocyte viability and apoptosis in human bone.
Furthermore, following 7 days in culture and the application of loading in the presence or
absence of rhPTH in the bioreactor there was an increase in alkaline phosphatase activity
as indicated from the percentages of positively labeled bone surface compared to
unloading conditions. These findings indicated that the mechanical strains or improved
fluid flow produced by the bioreactor (Knothe et al., 2000) induced an osteogenic
response in the bone cores. Although no fluorescent markers of bone formation had been
administered due to the short duration of the experiments and no secure assessment of the
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degree of bone formation could be formulated, the application of mechanical stimulus
alone and in combination with rhPTH in patients 2 and 3 increased the percentage of
ALP positive bone surfaces demonstrating a significant mechanoresponsiveness in the
bioreactor system, these observations are in agreement with previous work done in our
lab (Mann et ah, 2006). On the other hand ALP positive bone surface was reduced in the
unloaded samples.
It was shown previously that intermittent administration of PTH increases bone mass and
improves bone structure in vivo (Li et ah, 2003, Rosen et ah, 2004). In light of these
observations, rhPTH in the present study was administered intermittently as well. Both
osteocytes and osteoblasts possess receptors for PTH (Dobnig and Turner, 1995), while
osteoblasts are considered to be the primary target of PTH actions on bone (Jilka et al.
1999). The percentage of ALP positive labeled surfaces was increased in the presence of
rhPTH in the presence or absence of mechanical stimulation suggestive of a synergistic
effect of these two parameters on the osteoblast. Increased ALP activity has also been
shown in other studies when osteoblasts were subjected to mechanical stimulation as well
as in response to PTH treatment (Nasu et al. 200, Winter et al. 2003). Moreover SOST
mRNA levels were decreased in patients 1 and 3 in response to rhPTH treatment as well
as mechanical stimulation, which may further explain the enhanced osteoblast function as
indicated by ALP staining.
Expression of sclerostin, the protein produced exclusively by osteocytes, was tested in
this study via means of immunostaining and quantitative real-time PCR for SOST gene
expression. Following rhPTH treatment in the presence or absence of mechanical
stimulation sclerostin positive osteocyte numbers did not change when compared to T (0)
and unloaded controls. However it should be noted that compared to rat bone as
presented in chapter 3, the numbers of sclerostin positive osteocytes were higher in
human bone. These findings may be due to the fact that sclerostin is a delayed secreted
product of osteocytes, since newly embedded osteocytes will secrete sclerostin only after
the local onset of mineralization, as such only matured osteocytes will secrete sclerostin
(Poole et al. 2005). Another reason may be the fact that there was not a concentrated
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region of cells that are affected enough to detect a change at the protein level using
immunohostochemistry and possibly a more sensitive technique such as in situ
hybridization would provide more information. On this basis it has been speculated that
sclerostin functions as a final signal to osteoblasts (via osteocyte canaliculi) or to lining
cells, when mineralization of the osteocyte surrounding matrix is completed, in order to
limit osteoblast activity (Poole et al. 2005). Moreover only a subpopulation of osteocytes
has PTH receptors in human bone, and newly embedded osteocytes do not express those,
in order for them to be a PTH target (Langub et al. 2001).
On the other hand SOST mRNA levels were significantly reduced in response to rhPTH
treatment in the presence or absence of mechanical stimulation, moreover loading and
unloading conditions reduced the levels of SOST mRNA expression. Data presented here
demonstrates that administration of intermittent rhPTH in the presence or absence of
mechanical stimulation has downregulated SOST mRNA levels, demonstrating an
rhPTH/loading-mediated effect on the regulation of SOST mRNA expression. However
as mentioned SOST mRNA did not drop under unloading conditions as in murine
models, possibly due to species-related differences, and it can be speculated that in
human bone only PTH administration could prove effective in reducing sclerostin
production. There is controversial data reported in the literature regarding the effects of
intermittent PTH administration on SOST mRNA. Data presented in this study is in line
with those of Keller and Kneissel (2005), Silvestrini et al (2007) who have reported a
SOST mRNA reduction in mice and rat respectively, treated with PTH daily. Also
Robling et al (2006) reported a decrease in SOST mRNA in response to mechanical
loading in the rodent ulna loading model. On the other hand Bellido et al. (2005) have
reported a fall in SOST mRNA in response to continuous infusion of PTH in vivo and in
vitro while they failed to detect any changes in response to intermittent administration to
PTH. In the presence of mechanical stimulation data presented here implicates SOST as a
mechanically suppressed signal. With its known inhibitory effects of Lrp function and
bone formation, it provides a possible regulatory mechanism that permits, enhanced Wnt
signaling upon mechanical stimulation (Robling et al. 2006). Wnt signaling is important
for the mechanotransduction cascade, as it was reported that Lrp5 deficient mouse
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skeleton is unable to respond anabolically to mechanical stimulation (Sawakami et al.
2006). Intermittent PTH attenuates, while chronic administration does not affect
osteoblast apoptosis (Bellido 2003) and reduces SOST mRNA (Bellido et al. 2005) in
osteocytes; such that the precise role of SOST in intermittent PTH administration is not
clear. SOST is clearly influenced by mechanical stimulation, as it is by PTH, and in the
data presented here these two parameters in combination possibly exert a synergistic
effect. PTH administration has also been shown to rapidly reduce sclerostin mRNA and
protein production in osteocytes in vitro and in bone in vivo (Keller and Kneissel 2005,
Silvestrini et al. 2007), raising the possibility that transient reduction of sclerostin output
by osteocytes in response to intermittent PTH could mediate enhanced osteoblast
differentiation and bone formation (Van Bezooijen et al. 2005), and reduced osteoblast
apoptosis (Sutherland et al. 2004).
The beneficial bone responses to PTH therapy as well as mechanical stimulation are well
known. In vitro studies using stretched osteocytes demonstrated that PTH and mechanical
loading elevated IGF-I mRNA (Sekiva et al. 1999, Miyauchi et al. 2000). Such
observations are suggestive of a potential mechanism between PTH signaling and
mechanotransduction pathways. In the study by Chow et al. (1998) in normal and
thyroparathyroidectomized rats, PTH (1-34) administration before or after mechanical
stimulation restored the osteogenic response in the thyroparathyroidectomized rats
suggesting that physiological levels of PTH are necessary for the mechanical
responsiveness of bone. Similar findings were reported by Hagino et al. (2001) where a
synergistic effect of mechanical loading and PTH administration was shown with bone
formation increased by 4-point bending as well as by PTH administration with a
significant interaction between loading and PTH.
In this study mechanical stimulation in the presence and more interestingly in the absence
of rhPTH decreased the numbers of apoptotic osteocytes compared to unloading
conditions in the absence of rhPTH. The anti-apoptotic effects of PTH have been
demonstrated both in vivo and in vitro by Jilka and colleagues (1999) as well as in the
previous chapter in this thesis were the anti-apoptotic effect of rhPTH on osteocytes in
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vivo was highlighted. Frost (1988, 1992) proposed a strain threshold, called the 'set point'
above which bone modeling and remodeling are activated. According to this theory
hormones act to adjust the skeletal 'set point' that regulates bone mass relative to
customarily encountered loading stimuli. The observations made in this study indicate
that intermittent administration of rhPTH lowers this 'set point' such that identical
loading stimuli are perceived as more intense in the rhPTH treated samples than in the
controls. It has been shown in this study that rhPTH possibly acts synergistically with
mechanical stimulation to decrease osteocyte apoptosis. Moreover rhPTH has been
shown to exert its anti-apoptotic effects even in the absence of mechanical stimulation as
demonstrated in the samples treated as such. In the study by Sakai et al (1999) it was
reported that intermittent PTH (1-34) administration at 40pg/kg five times per week
prevents immobilization related bone loss at the proximal tibia in the sciatic
neurectomized mouse model (Sakai et al. 1999).
To my knowledge no other study exists in the literature to have reported the use of an ex
vivo bioreactor to apply mechanical loads in the presence or absence of rhPTH. However
in this study only a single dose of rhPTH was administered and the subsequent
observations made should be interpreted with caution. Therefore it would be useful to
conduct further studies to determine the dose-dependency of the effects of rhPTH on
human osteocytes in response to mechanical stimulation. This study was based on
samples obtained from three different patients and that can explain the variability
observed in some of the treatment groups, however all three showed similar responses to
loading and rhPTH in all parameters examined. This patient variability can be explained
by the different genetic backgrounds, health problems and treatment received by each
individual, alterations in the environment, age, nutrition, different trabeculae architecture
and tha fact that males respond differently to load compared to females. Moreover
findings of other studies examining indices tested here were reported in rat and mouse
bone and there are potential species-related differences that should be acknowledged
before comparing to human bone. Furthermore, it should be taken into account that the
samples used were coming from patients undergoing elective hip arthoplasty and
responses should be interpreted accordingly. The individuals were receiving various
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prophylaxes for pain management but to my knowledge none was receiving any
treatments in the form of HRT known to affect bone turnover. The degree of between-
patient variability seen here is in agreement with previous work in our lab (Mann et al.
2006) and others (Tomkinson et al. 1997, Dunstan et al 1993) in which a range of
variabilities in terms of apoptosis, viability as well as alkaline phosphatase positive
surfaces are reported.
In summary this study has provided evidence that osteocytes undergo apoptosis in
response to unloading which could be improved following application of mechanical
stimulation within physiological levels in the Zetos1M bioreactor in the presence or
absence of rhPTH. Application of mechanical loading in the presence or absence of
rhPTH induced an osteogenic response in terms of alkaline phosphatase positively
labelled bone surfaces. Finally application of loading in the presence or absence of
rhPTH decreased the mRNA levels of SOST gene expression, providing an indication of
how loading and/ or rhPTH may be acting to enhance bone formation. However after
PTH treatment in the presence or absence of mechanical stimulation, no differences were
detected in sclerostin-positive osteocyte percentages in the different treatment groups;
this data is in line with the data reported by Poole et al. (2005) who recorded no statistical
differences between numbers of sclerostin-positive osteocytes in cortical and in
cancellous normal human bone. Similar data was obtained for sclerostin positive rat
osteocytes in vivo following rhPTH treatment as presented in chapter 3. An alternative
explanation to this finding may provide future studies of protein expression using
Western blots.
The use of the Zetos™ system has enabled us to study the response of human osteocytes
in response to mechanical stimulation in the presence or absence of rhPTH, since it
would be difficult due to ethical issues to obtain human biopsies pre- and post-exercise in
response to hormone treatment. The molecular mechanisms by which mechanical
stimulation and rhPTH treatment increased osteocyte viability and decreased apoptosis in
this system has not been the subject of investigation in this study. It is possible that the
reduction in apoptosis is a product of increased nutrient supply and oxygen or due to an
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CHAPTER 5
Differential Gene Expression Between Osteoblastic Populations




Anabolic treatments such as PTH and GH have been proposed to exert their effects
selectively and specifically on the osteoblastic population at the periosteal and endosteal
sites of bone. However, the cellular and molecular mechanisms by which these agents
regulate osteoblastic cell behavior remain poorly understood. In the present study an
attempt to unravel potential mechanisms of their actions on the osteoblast is presented.
For the identification of genes of interest as potential drug targets for age related bone
loss laser capture microdissection (LCM) technology, and gene microarray was used.
Thirty virgin female Sprague-Dawley rats at the age of 15 months were divided into five
treatment groups. The control group received vehicle by gavage (n=6), treatment groups
received rhPTH (1-34) once daily at a dose of 50 gg/kg (n=6), rhGH once daily at a dose
of 2.5 mg/kg (n=6) by subcutaneous injection, Compound A twice daily by gavage at a
dose of lOOmg/kg (n=6), and Compound B once daily by gavage at a dose of 200mg/kg
(n=6). Compounds A and B are of unknown nature (provided by NOVARTISj.The
duration of the experiment was 14 days at the end of which tissue sections from the tibias
of these animals where subjected to LCM to isolate pure osteoblastic cell populations.
The tissue collected was then used for total RNA isolation.
In this study a technique for generating cryosections of native bone and the preparation of
homogeneous osteoblast populations representing the state they adopt in their in vivo
environment is presented. Gene expression analysis is presented for a limited number of
samples and methodological pitfalls in the original study design as well as the
methodology to solve these issues are discussed.
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5.1 Introduction
In the previous chapters evidence has been presented regarding the protective effects of
rhPTH and rhGH on murine osteocytes in vitro, rat osteocytes in vivo and human
osteocytes ex vivo and their potential use as anabolic treatments to treat bone loss has
been discussed. Osteocytes are derived from osteoblasts that become incorporated during
bone remodelling. Recently anabolic agents have received lots of attention as they have
been demonstrated to act by inducing bone formation by osteoblasts and/ or by inhibition
of osteoblast apoptosis (Jilka et al., 1999). Both PTH and GH have the potential to be
used as anabolic treatments (Allen et al, 2004). Thus exploring their bone forming
activity may provide identification of novel molecules and mechanisms that may prove to
be advantageous for osteoporosis treatment (Raouf and Seth, 2002, Onyia et al., 2005,
Gonovi et al., 2006). In spite of the approval of rhPTH (1-34) produced by Lilly referred
to as teriparatide as a therapeutic anabolic agent that increases bone mass, the discovery
of other safe alternative therapies against osteoporosis continues to be a need. PTH
results in increased osteoblast numbers and activity either via increased differentiation or
survival or due to the ability to increase IGF-I and IGF-II in osteoblasts (Jilka et al. 1999,
Robinson et al. 2006). GH on the other hand has been shown to up regulate bone
formation markers as well as serum concentrations of IGF-I (Fernholm et al., 2000,
Hedstorm et al. 2004) acting either directly on osteoblasts or indirectly via the stimulation
and release of IGF-I (Govoni et al. 2006). Studies have shown differences in the
osteogenic responses these agents elicit at different anatomical sites of bone (Andreassen
and Oxlund, 2000) and it has been proposed, that each cell population responds
differently both qualitatively and quantitatively to hormones and growth factors (Allen et
al. 2004). Compared to endosteal, periosteal osteoblasts exhibit greater
mechanosensitivity to strain, lower responsiveness to osteogenic compounds such as PTH
and GH, more estrogen alpha receptors and higher levels of protein expression such as
periostin, which is present in greater abundance in periosteum compared to other
locations in bone (Allen et al. 2004). Such findings suggest that selective targeting of
either periosteal or endosteal bone surfaces where osteoblasts reside could prove useful;
however such an approach would require the identification of genes and proteins unique
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to those sites or present in greater concentrations. However the interactions between
periosteal and endosteal surfaces and the role that mechanical compensation plays in
periosteal and/or endosteal expansion should not be undervalued, and necessitates more
in-depth study. There is the possibility that specific drug targets are present within those
sites that can possibly be activated independently. However the relatively small quantities
of periosteum and endosteum at given sites as well as thinning of it with ageing, present
hurdles that may be overcome by the use of laser capture microdissection (LCM)
combined with molecular biology assays and tissue arrays. In the present chapter a pilot
study looking into the gene expression of endosteal and periosteal osteoblastic
populations in response to rhPTH and rhGH treatment using LCM is presented.
Bone is a compact, analytically difficult to handle mineralized tissue that undergoes
continuous remodelling. Osteoblasts - the bone forming cells are synthesizing and
secreting bone matrix proteins during remodelling, until about 10-20% of their population
reaches the final differentiation stage that of osteocytes and eventually become embedded
in bone matrix. It is clear that the osteoblast serves very important functions which are
under the influence of a number of transcription factors (e.g., Cbfa-l/Runx-2), growth
factors (e.g., TGF-(3) and hormones (e.g., PTH, GH) (Mackie, 2003); and contributes to
the interactions between bone cells under normal and pathological conditions; but the
molecular physiology of the osteoblast is poorly understood. The maturation of the
osteoblast is a complex process that involves a number of genotypic changes and
although it is desirable to identify these changes for advancing diagnostic and therapeutic
measures of diseased bone, there are very few reliable in vivo and in vitro studies in cell
lines, particularly due to the difficulties in handling native bone tissue (Raouf and Seth,
2002, Onyia et al., 2005, Gonovi et ah, 2006).
Transcript profiling appears to be a useful tool to study the global gene expression from
tissues and cell lines (Shaffer et al., 2002, Nakazono et al. 2003) and could provide
valuable information that would help towards the development of new drug targets for
treating pathological bone conditions. However to apply this technology cells that exist in
heterogeneous tissues, surrounded by other cell types, it is necessary to minimize
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contamination of unwanted cells. LCM is a new tool that makes it possible, which allows
the identification of cells, followed by their excision and subsequent RNA extraction.
Successful microarray hybridization depends on the quality of the RNA samples
subjected to analysis. The tissue preparations used in bone investigations are an
unsatisfactory source of RNA; with the typical ones including formalin fixation,
decalcification and paraffin embedding which generate chemically modified RNA
molecules as well as affecting their integrity (Goldsworthy et al. 1999, Finkelstein et al.
1999, Srinivasan et al. 2002). Cryosections of bone are thought to provide the best source
for obtaining intact RNA (Goldsworthy et al., 1999). However preparation of
homogeneous populations of osteoblasts from frozen, undecalcified bone sections has
proven to be difficult due to the low numbers of osteoblasts in the highly calcified tissue.
Typically a minimum of lOOng of total RNA is required for indirect or direct labeling of
cDNA to perform hybridization on one microarray chip to analyze gene expression
(Xiang et al. 2002). Yields of this magnitude are usually not viable from typical LCM
derived samples and as such amplification to make microarray analysis possible is
required (Wang et al 2006). Collection of high quality RNA using LCM requires the
application and optimization of various methodological steps including sectioning,
staining, laser microdissection and successful RNA isolation; since it has not been
determined to what extent each of the steps in LCM sample processing damages the
RNA.
In the study presented here a short proof of concept study was undertaken to establish the
feasibility of the Novartis study. For this study 2-3 months female virgin rats were used
and ~ 10,000 periosteal and endosteal cells were collected using LCM and RNA
extraction. These samples were evaluated and osteoblast lineage specific genes were
identified. Following this study the Novartis study was initiated as discussed in this
chapter.
In this chapter a pilot study is presented for the preparation of homogeneous osteoblast
populations from cryosections of native rat bone, using laser microdissection
196
technology.Limited gene expression data is also presented and indicates methodological
pitfalls in the original study design as well as the methodology to solve these issues.
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5.2 Materials and Methods
All chemicals were purchased from Sigma, UK, unless otherwise stated. All LCM
consumables were purchased from P.A.L.M. Microlaser Technologies.
5.2.1 Animals
The experimental design for the animals used in this study has been described 3.2.1; in
the study described in chapter 3 only three groups where analyzed. In this study the
second tibias of all five groups as outlined in diagram 5.1 where analyzed. More
specifically the second tibias of all five animals from each of the five groups were
sectioned and used for laser microdissection (LCM). Briefly animals were randomized
into five treatment groups. The control group received vehicle by gavage using a stomach
tube. The second group received synthetic recombinant human parathyroid hormone
fragment 1-34 (rhPTH) (provided by NOVARTIS) once daily at a dose of 50 pg/kgbody
weight via subcutaneous injection, dissolved in 0.15M saline. The third group received
recombinant human growth hormone (rhGH) (provided by NOVARTIS) once daily at a
dose of 2.5 mg/kg body weight via subcutaneous injection, dissolved in distilled water.
The fourth and fifth group received compounds A and B of unknown nature (provided by
NOVARTIS),compound A was administered twice daily by gavage using a stomach tube
at a dose of lOOmg/kg body weight and compound B was administered once daily by
gavage using a stomach tube at a dose of 200mg/kg body weight. The duration of the
experiment was fourteen days, at the end of which all animals were killed by
exsanguination, the tibias were harvested and dissected free of muscle, briefly immersed
in 5% polyvinyl alcohol and chilled to -70°C in super cooled hexane (BDH, UK), prior





















































Diagram 5.1: Flow Diagram of in vivo experimental design. Thirty female animals
were randomized in five treatment groups and tibias were subjected to cryosectioning and
LCM.
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5.2.3 Preparation of cryostat sections
Following their removal, bone specimens were immediately snap-frozen in hexane under
RNase-free conditions. The sample was mounted on a chuck using polyvinyl alcohol in a
freezing bath and was placed in the cryostat (Bright Instruments, Co. Ltd) to acclimatize
at -26 to -28° C for 30 minutes prior to sectioning. Sectioning was performed using a
tungsten carbide blade (Bright Instruments, Co. Ltd) at a thickness of 10 microns. For the
identification of mid-diaphysis sections were examined every 20 sections following
identification of the growth plate under the microscope. The absence of trabecular bone
indicated the start of the diaphysis and sections were collected from that area of bone.
Prior to LCM one slide (i.e. 4 sections) was stained with DAPI nuclear stain. Placed on
the PALM microscope and number of cells per area (endosteum and periosteum) were
counted per section and an average taken over the 4 sections in order to determine
number of sections/area required to be LCM.
Subsequent sections were fixed by physical pressure on 1.35 pm thick PEN membrane
slides (PALM). The slides were pre-treated to ensure RNAse free conditions, by dipping
in RNase Away for 5 seconds and then washed twice in DEPC treated water; allowed to
dry at room temperature prior to UV treatment for 30minutes at 254nm to polymerize the
adhesive. Cryosections were stored at -80°C.
Prior to initiation of the Novartis study, preliminary studies as described in §5.3.2.1 were
carried out to establish the techniques to be used. For these studies 2-3 month old female
rat tibias were used for estimation of cell numbers using DAPI stain, to establish the best
settings and conditions for laser microdissection and finally establish the most successful
RNA extraction method, due to the difficulty to obtain animals of similar age as these of
the in vivo study. The animals of the in vivo study were at the age of 18 months and the
numbers of cells where found to be significantly lower compared to the younger animals
of the preliminary studies (Figure 5.1).
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Figure 5.1. Representative images of periosteal and endosteal surfaces of young and
old female rat tibias. DAPI stained and bright field periosteal surface of a 3 month old
female rat tibia from the preliminary studies, with about 50 cells found on that surface
(A, C), DAPI stained and bright field periosteal surface of an 18 month old female rat
tibia from the in vivo study, with about 20 cells found on that surface (B, D). Bright field
images of periosteal and endosteal surface from an 18 month old animal from the in vivo
study (E, F).Bar represents 100pm.
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5.2.4 Fixation and Staining of sections
Cryosections on slides were immediately fixed in pre-cooled 70% ethanol for 5 minutes
followed by a 1 minute dip in eosin solution followed by washing in DEPC treated water.
Cryosections were dehydrated by increasing grades of ethanol from 70% to 95% up to
100% for 15 seconds each. Cryosections were then allowed to dry at room temperature;
when no leftover ethanol was obvious on the slides they were stored at -80°C until further
use.
5.2.5 Micro Laser Dissection
LCM of the cryosections was performed using a 337-nm pulsed UVa-nitrogen laser
(P.A.L.M Instruments, Germany) built in an inverse Zeis Axiovert 200/200m microscope
(Figure 5.2). A pulsed ultra-violet (UV-A) laser of high beam quality is interfaced into
the microscope and focused through an objective to a beam spot size of less than 1
micrometer in diameter for the cutting action. The principle of laser cutting is a locally
restricted ablative process without heating of the adjacent material and results in a clear
cut gap between the desired sample area and the surrounding tissue. After
microdissection is complete, the isolated specimens are ejected out of the object plane
and catapulted directly into a microfuge tube in a non-contact manner and such without
the introduction of contamination (PALM MicroLaser Systems).
For collection of tissue 70pl of lysis buffer (10 mi's of RLT buffer (Qiagen) + 100 pi P-
mercaptoethanol (Invitrogen)) were added into an eppendorf tube cap and the section was
examined at x5 magnification to locate the area of interest. Upon identification of the
area of interest laser dissection was performed using the PALM Robo software at 20 x
magnifications with the laser energy and focus settings optimized according to the
respective absorption behavior of the microdissected specimens (Figure 5.3, Figure 5.4).
At the end of each collection the eppendorf cap was examined at x5 to ensure that laser
dissection and catapulting were successful. The tube containing the laser dissected
material was then centrifuged at 10, 000 rpm for 15 seconds to collect the sample at the
bottom of the tube and stored at -80°C until further use.
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Laser
Figure 5.2. Zeiss/PALM system used for laser capture microdissection. Laser capture
microdissection microscopy (LCMM) utilizes a UV laser pulsed micro beam for







Pulsed ultra-violet (UV-A) laser is
interfaced into the microscope and
focused through an objective to a
beam spot size
Figure 5.3. Principle of LCM. A pulsed ultra-violet (UV-A) laser is interfaced into the
microscope and focused through an objective to a beam spot size for the cutting action.
The principle of laser cutting is a locally restricted ablative process without heating of the
adjacent material and results in a clear cut gap between the desired sample area and the
surrounding tissue. After microdissection, the isolated specimens catapulted directly into







Periosteum prior LCM x20 Periosteum post LCM x20
Endosteum prior LCM x20 Endosteum post LCM x20
Figure 5.4. Preparation of osteoblasts from bone cryosections using laser
microdissection. Tibial mid-diaphysis specimens were dissected using a pulsed UVa-
nitrogen laser. (A) Microdissection of periosteal osteoblasts prior LCM and (B) after
LCM. (C) Microdissection of endosteal osteoblasts prior LCM and (D) after LCM. LCM
was performed on fixed 10pm thick cryostat sections. Bar represents 100pm.
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5.2.6 RNA Isolation
The RNA samples from which microarray data was obtained as described in §5.2.4 were
extracted using the Qiagen Micro RNeasy Kit- for isolation of total RNA from
microdissected tissue following manufacturer's protocol. In each case approximately
50,000 cells were LCM and RNA extracted. Limited microarray data was obtained from
a small number of samples from the first set of RNA sent. No data was obtained from the
second set of RNA samples as these were determined to be either sub-optimal or no RNA
detectable. Therefore a number of RNA extraction methods and modifications trials were
initiated using 50,000 LCM cells to try and improve the RNA quality. Four methods were
used:
1) Proteinase K - Introduction of a Proteinase K digestion step to RNA extraction using
Qiagen RNeasy Micro Kit.
2) Trizol (Invitrogen) following manufacturers protocol with two modifications (a)
following homogenisation stage in Trizol solution samples were incubated for 10 minutes
at room temperature with rotation prior to the addition of chloroform, (b) Glycogen
carrier (20pg) was added to the aqueous phase prior to precipitation with isoprpanol.
3) Decalcification - Sections were de-calcified 10 minutes at room temperature in the
decalcification mixture. Sections then underwent LCM and RNA extraction using either
(a) Qiagen RNeasy Micro Kit or (b) Trizol followed by Qiagen Micro Kit Clean-up.
4) Arcturus Pico Pure - RNA was extracted from 50,000 LMD cells following Pico
Pure RNA Isolation Kit Arcturus following manufacturer's protocol.
Total RNA was purified according to protocols provided by the suppliers as described
below. Microdissected tissue was captured and lysed in buffers according to individual
protocols.
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5.2.6.1 Qiagen Micro RNeasy Kit - for isolation of total RNA from
microdissected tissue
RNA was extracted from the micro dissected tissue using the RNeasy Micro Kit (Qiagen,
UK). All the collections were pooled together into a single eppendorf tube at a 350 pi
volume. The samples were then homogenized by passing through a 29 gauge (29G)
needle. 350pl of 70% ethanol were added to the lysate and mixed by pipetting. The
mixture was then applied onto an RNeasy MinElute Spin Column, and centrifuged
(eppendorf Centrifuge 5415D) for 15secs at >8,000xg and another 350pl buffer RW1
were added to wash the column. To remove any genomic DNA contamination lOpl of
DNasel stock solution were added to 70pl buffer RDD and pipetted directly onto the
membrane for 15 minutes at room temperature. To wash away the DNasel mix, 350pl of
buffer RW1 were pippeted onto the membrane.
The column was then transferred into a new collection tube and 500pl of buffer RPE was
added onto the column to wash it further. Then 500pl of 80% ETOH was added to the
column and centrifuged for 2 minutes at >8,000xg to dry the membrane. To elute the
RNA the column was transferred into a 1.5 ml collection tube and 18pl of RNase free
water was pippeted onto the membrane; the tube was then centrifuged for a minute at




The tissue was collected in TRIZOL reagent (Invitrogen, UK) and stored at -80 °C until
all collections were complete. The tissue was then pooled together into a single tube at a
500 pi volume and ground using a mortar and pestle for 1 minute. The homogenized
sample was then incubated for 5 minutes at room temperature to allow the dissociation of
nucleoproteins. The mix was then centrifuged (eppendorf centrifuge 5417R) to remove
any debris and the supernatant was transferred to a new tube. 200 pi of chloroform was
added and the samples vortexed for 15 seconds and incubated at room temperature for 2-
3 minutes prior to centrifugation at 4°C for 15 minutes at 12,000 x g. The mixture then
separates into a lower phenol-chloroform phase containing the DNA, an interphase that
contains protein and a colorless upper aqueous phase containing the RNA. The upper
aqueous phase was carefully aspirated into a new tube taking care to avoiding the
interphase. An equal volume of room temperature isopropanol was added and the sample
placed at -20 °C for a minimum of 20 minutes in order to precipitate the RNA. Following
centrifugation at 12,000 x g for 10 minutes at 4°C the RNA was visible as a gel-like pellet
at the bottom of the tube. The supernatant was then removed and the pellet washed three
times with 1ml of 75% ethanol at 7,500 x g for 5 minutes at 4°C. All leftover ethanol was
removed after the final wash and the pellet was allowed to air-dry for approximately 10
minutes. The RNA pellet was then dissolved in 15 pi of RNAse free water. The RNA
sample was then transferred on ice and stored immediately at -80°C.
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5.2.6.3 Qiagen Micro RNeasy Kit clean up
RNA samples extracted using the Trizol method were subjected to a clean up using the
Qiagen Micro RNeasy kit, when there was an indication of co-contaminants in the
samples. The sample was adjusted to lOOpl with RNase-free water and 350pl of RLT
buffer along with 250pl of 100% ethanol added and mixed thoroughly by pipetting. The
sample was then loaded onto a column and centrifuged for 15 seconds at >8,000g. The
flow through was then discarded and the column washed with 350pl of buffer RW1
centrifuged at >8,000g for 15 seconds. The flow through was then discarded and 500pl of
buffer RPE was applied on to the column and centrifuged at >8,000g for 15 seconds.
Another wash with 80% ethanol followed for 2 minutes at >8,000g. After the final wash
the flow through was discarded and the column dried via centrifugation at full speed for 5
minutes. To elute the RNA 14pl of RNase free water were added to the column and
centrifuged for 1 minute at maximum speed.
5.2.6.4 Arcturus Pico Pure RNA Isolation Kit
RNA was extracted from microdissected tissue using the Pico Pure RNA Isolation Kit by
ARCTURUS (Arcturus, UK). The tissue was collected in 50 pi of extraction buffer
provided with the kit into a microcentrifuge tube. At the end of each collection the tube
was centrifuged and the collected cell extract was incubated at 42°C for 30 minutes and
then stored at -80 0 C until all collections were completed and ready for the RNA
extraction..
For the RNA isolation all collections were pooled together into one single eppendorf tube
at a 250 pi volume. The column was pre-conditioned with 250pl of conditioning buffer
for 5 minutes and then centrifuged at 16,000 g for 1 minute. The cell extract was then
mixed with 70% ethanol and pippeted on the purification column, centrifuged at lOOg for
2 minutes followed by an immediate centrifugation at 16,000g for 30 seconds. The
column was then washed with 100 pi of wash buffer one and centrifuged at 8000g for 1
minute, followed by 100 pi wash with wash buffer two followed by centrifugation at
16000g for 2 minutes. After washing, the column was transferred into a new tube and 11
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pi of the elution buffer was pippeted onto the column and incubated for 1 minute at room
temperature prior to centrifuging at 1,000 g for 1 minute followed by an immediate
centrifugation at 16,000g for 1 minute. The RNA sample was then transferred on ice and
stored immediately at -80°C.
5.2.7 De-calcification of sections
Sections were de-calcified for the removal of hydroxyapatite. Following cryosectioning
sections were incubated for 10 minutes at room temperature in the de-calcification
mixture (50mM Tris/HCL containing 0.25mM EDTA at pH 7.4). Following de¬
calcification sections were gently washed with PBS followed by fixation and staining.
5.2.8 RNA quality and Quantity tests
In order to obtain successful microarray results both the quantity and quality of RNA are
very important parameters. The RNA extracted in this study was tested both on the
NanoDrop1M 1000 (Thermo Scientific) which is one of the most developed
spectrophotometers, for quantity and the Agilent bioanalyser 2100 (Agilent, Palo Alto,
CA, USA) for quality.
5.2.8.1 NanoDrop™ 1000
The NanoDrop™ 1000 Spectrophotometer (Thermo Scientific) enables highly accurate
UV analyses of 1 pi samples. 2 pi of the RNA sample were loaded at the bottom pedestal
of the instrument and then the other pedestal was lowered. Once a column was formed
between the pedestals, using the NanoDrop™ software the quantity of RNA was
measured and also the 260/280 and 260/230 ratios were given (Figure 5.6). At the end of
the measurement the pedestals were washed with water. The 260/280 ratio is used to
assess the purity of the nucleic acid. A ratio of -2.0 is generally accepted as 'pure' for
RNA preparations. If the ratio is lower that might indicate contamination of protein,
phenol or salts. The 260/230 ratio was used as a secondary measure of purity and is
usually higher than the 260/280 ratio. It is commonly in the range of 1.8-2.2. If this ratio
is lower it is indicative of the presence of co-purified contaminants.
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5.2.8.2 Agilent Bioanalyzer 2100
The Agilent 2100 bioanalyzer (Agilent Techonologies) is a microfluidics-based platform
used for the analysis of DNA, RNA, proteins and cells. The data is generated within 30
minutes and indicates the quality and quantity of nucleic acids mainly by the RNA
integrity number (RIN), scale from N/A to 10 which helps to estimate the integrity of the
RNA not by the ratio of the ribosomal bands but by the entire electrophoretic trace of the
RNA sample (Figure 5.7). RNA that was not degraded should have two clear bands
representing the 28S and 18S rRNA, with ratios of 28S/ 18S absorbance exceeding 1.5.
In addition, the RNA sample should be low in genomic DNA contamination, which
would appear as bands larger than 28S rRNA. In the present study the pico chip was
used, due to the low amounts of RNA obtained, the quantity of RNA detected with a pico
chip is within 200-5000 pg/pl.
All the solutions were left at room temperature to equilibrate for half an hour. 1 pi of the
dye concentrate was added in the filtered gel; vortexed and spun down to remove any
residual dye. A pico chip was placed in the chip priming station and 9 pi of the gel-dye
mix were pippeted in the designated well. The plunger was then held by the clip to evenly
spread the gel throughout the chip and after 30 seconds it was released. Another 9pl of
the gel-dye mix were added in the designated well. 9 pi of the conditioning buffer
(providing the mixture with conditioning factors) were added in the appropriate well and
1 pi of the pico marker was added in the well marked as ladder. 1 pi of the samples to be
tested were pippeted into each of the 10 wells. The chip was then vortexed in an adapter
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Figure 5.5 Typical analysis outcome of an RNA sample measurement with the
NanoDrop™ 1000. A column with the RNA sample is formed between the pedestals and
by using the NanoDrop™ software the quantity of RNA is measured and also the
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Figure 5.6 Typical analysis outcome of an RNA sample measurement with the
Agilent 2100 bioanalyzer. The Agilent bioanalyzer is a microfluidics-based platform
that provides information of the quality and quantity of nucleic acids, via an estimation of
the RIN number which helps to estimate the integrity of the RNA not by the ratio of the
ribosomal bands but by the entire electrophoretic trace of the RNA sample
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5.2.9 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
For RT-PCR successful reverse transcription depends on the integrity and purity of the
RNA used as the template. Superscript1 M III First Strand Synthesis System for RT-PCR
(Invitrogen) was used to synthesize first strand cDNA. Superscript can copy DNA
sequences from an oligo(dT) 16-18 primer which will anneal to mRNA poly-A tail. As
per manufacturers instructions a 10 pi reaction was set up as follows:
lpl dNTP
1 pi oligo (dT)
2pl RNA (20ng/pl)
6pl DEPcFhO
This mixture was heated at 65°C for 5 minutes before cooling on ice for >1 min, and
addition of the following:
2pi lOxRT buffer
4pl MgCl2
2pi 0.1 M DTT
lpl RNase OUT
This mixture was then heated to 42°C for 2 minutes and 1 pi of Superscript mix was
added directly into the mixture. It was then incubated at 42°C for 50 minutes and 70°C
for 15 minutes on a thermocycler. The tube was then centrifuged and 1 pi of RNase H was
added directly into the mixture followed by incubation at 37 °C for 20 minutes. The
resulting cDNA was then stored at -20°C until further use.
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5.2.10 Polymerase Chain Reaction (PCR)
PCR is used to amplify specific regions of a DNA strand, which can be a single gene or
part of a gene. The basic components of a PCR are a DNA template, one or more primers
which are complementary to the DNA regions at the 5' and 3' ends of the DNA region, a
DNA polymerase, deoxynucleoside triphosphates (dNTPs) which are the building blocks
from which the DNA polymerases synthesizes the new DNA strand, a buffer solution that
provides a suitable chemical environment for optimum activity and stability of the DNA
polymerase, divalent cations, more commonly magnesium (Pavlov et al. 2004). Primers
for use in PCR for the detection of actin were all designed in house. The sequences of the
primers were:
P-actin: forward primers, 5'-ATCGTGGGGCGCCCCAGGCACC-3'
580 bp
reverse primers, 5'-CTCCTTAATGTCACGCACGATTTC-3'
The PCR reaction was carried out in a 25pl volume by first preparing a master mix as









The reaction was performed by incubating the samples in an automatic DNA Thermal
Cycler (Peltier Thermal Cycler, MJ Research PTC-200,) at appropriate temperatures
corresponding to the three steps of the reaction of amplification-denaturation, annealing
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PCR products were visualized on agarose gels containing ethidium bromide and sized by
running size markers.
5.2.11 Agarose Gel Electrophoresis
Agarose gels were made using SeaKem GTG Agarose (FMC Bioproducts). For the
separation of products 1.2% agarose gels were cast. The required amount of agarose was
dissolved in TBE buffer (89mM Tris Base, 89mM Boric Acid, 2mM EDTA sterilized
with autoclaving), and the mixture was heated in a microwave oven for approximately 2
minutes until all agarose had dissolved. Agarose was cooled under running tap water for
about 3 minutes. On cooling of the agarose 5 pi ethidium bromide (lOmg/ml) was added
and stirred, prior to gel being cast in the electrophoresis gel cast system. When the gel
was set, the electrophoresis tank was filled with TBE buffer and samples were loaded
using 3 pi of Orange G loading dye (1% w/v in dFEO). 100 volts were applied across the
gel until the dye front had migrated 2/3 from the end of the gel. Gels were visualized
using a UV transilluminator (Uvidoc, UVItec, BTS-20-M). Ethidium bromide has the
ability to bind to DNA/RNA and visibly fluoresces under UV light. The product size was
measured relative to size markers (2 pi of Tracklt™ lOObp DNA ladder (Invitrogen))
which were run alongside samples.
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5.2.12 Microarray and Bioinformatics
All microarray and bioinformatics analysis was carried out by the Novartis Genomics
Unit (Basel, Switzerland). For cDNA synthesis since the stalling total RNA was in the
range of 10-100 ng per reaction, the 2-cycle cDNA amplification according to Affymetrix
protocol was followed. For labeling and subsequent hybridizations to the arrays standard
Affymetrix protocols were followed. The U34A oligonucleotide array (Affymetrix) was
used for the microarray analysis. In figure 5.8, a summary of the steps involved in the
two-cycle cDNA synthesis is presented.
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DAY 1
Total RNA (100 ng)
I
First Strand cDNA Synthesis using T7- oligo dT primer
I
(2)
Second Strand cDNA Synthesis
I
In vitro Transcription using unlabelled ribonucleotides ' '
DAY 2
Clean-up of cRNA ^
I
First Strand cDNA Synthesis using random primers (5)
I
Second Strand cDNA Synthesis using T7-oligo dT primer (6)
1
Clean-up of Double Stranded cDNA ^
I




Fragmentation and Hybridisation n ...
Carried out by MaC
Figure 5.7 Diagrammatic representation of the steps involved in the two-cycle cDNA
synthesis for small samples. The process of the cDNA synthesis for small samples as
per Affymetrix standard protocol.
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5.2.12.1 Small Sample Protocol using the Affymetrix Two-Cycle Labelling
Reagents First Cycle, First strand cDNA synthesis
Reagents were supplied by Affymetrix in the GeneChip Two-Cycle cDNA synthesis kit,
the GeneChip IVT labelling kit, the GeneChip Sample Cleanup Module and Ambion in
the MEGAscript High Yield Transcription Kit.
In more detail for step 1: (lOOng) Total RNA - 2.5 pi
(5pmol/.l) diluted T7 Oligo d(T) primer 2pl
Diluted PolyA+ Cocktail 0.5 pi
Nuclease free dH20. 0 pi
Made up to a total of 5 pi. Mixed by pipetting, spun briefly as necessary and then
incubated at 70 °C for 6 minutes in a thermal cycler with a heated lid. The sample was
cooled at 40 °C for 2 minutes; and spun briefly.
For the master mix: (5x) First Strand Buffer 2 pi
(O.IM)DTT 1 pi
(lOmM) dNTPs 0.5 pi
RNase Inhibitor 0.5 pi
Superscript II 1 pi
5 pi of master mix were added to each reaction tube. Mixed by pipetting, spun briefly and
incubated at 42 °C for 1 hour in a thermo-cycler with a heated lid. The reaction was
incubated at 70 °C for 10 minutes in a thermo-cycler with a heated lid to inactivate the
enzyme.The samples were cooled at 4 °C for 2 minutes and proceed immediately to "First
Cycle, Second strand cDNA synthesis".
Step 2: Prepare a master mix: Nuclease free dH20 4.8 pi
(17.5 mM) Freshly diluted MgC12 4.0 pi
(lOmM) dNTPs, 0.4 pi
E. coli DNA Pol I, 0.6 pi
RNase H, 0.2 pi
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Mixed by pipetting and spun briefly. 10 pi of the master mix were added to each of the
first strand reaction tubes mixed by pipetting and incubated at 16 °C for 2 hours in a
thermo-cycler without a heated lid, at 75 °C for 10 minutes and at 4 °C for 2 minutes.
Following incubation tubes were placed on ice and proceed to "First Cycle, IVT
Amplification of cRNA".
For step 3: Prepare a master mix: 1 OX Reaction buffer 5 pi
Mixed by pipetting and spun briefly. 30 pi of the master mix were added to the double-
stranded cDNA from the previous reaction, and mixed thoroughly by pipetting. Tubes
were then incubated at 37 °C for 16 hours in a thermo-cycler, spun briefly and proceed to












For step 4: The samples were transferred to 1.5 ml microfuge tube and 50 pi of
Nuclease free dH20 and 350 pi of IVT cRNA Binding Buffer were added and mixed
thoroughly by pipetting. 250 pi of 100% ethanol were added and mixed by pipetting. The
samples were then applied to an IVT cRNA Cleanup Spin Column and centrifuged at
>8,000g for 15 seconds. The column was then transferred to a fresh 2ml collection tube
and 500 pi of IVT cRNA Wash Buffer was added onto the spin column and spun at
>8000g for 15 seconds. The collection tube was then emptied and 500 pi of 80% ethanol
were added onto the spin column and spun at >8000g for 15 seconds. The collection tube
was then emptied and the cap of the spin column opened and centrifuged at maximum
speed for 5 minutes to completely dry the membrane. The spin column was transferred
into a new 1.5ml collection tube and the sample was eluted by placing 13 pi of nuclease-
free water directly onto the middle of the spin column membrane. The column was
incubated at room temperature for 2 minutes and centrifuged at maximum speed for 1
minute. An aliquot of 2 pi was reserved for quality assessment and the remainder was
used for the second cycle.
For step 5: A mix of the following was prepared:
600ng purified cRNA (from previous step) - x pi
(0.2ug/ul) diluted Random Primers. 2 pi
Nuclease free dH20 - x pi
Make up to a total of 11 pi
Mixed by pipetting and spun briefly. The mix was then incubated at 70 °C for 10 minutes,
at 4 °C for 2 minutes and kept on ice.
For the master mix: (5x) First Strand Reaction Mix 4 pi
Mixed by pipetting and spun down briefly. 9 pi of the master-mix were added to the










incubated at 42 °C for 1 hour in a thermo-cycler with a heated lid, cooled at 4 °C for 2
minutes, and spun briefly. 1 pi of RNase H was added to each sample mixed by pipetting
and incubated at 37 °C for 20 minutes in a thermo-cycler with a heated lid, at 95 °C for 5
minutes cooled at 4 °C for 2 minutes, spun briefly and placed on ice.
Step 6: 4 pi of diluted T7 Oligo dT primer were added (5pmol/ pi) to each sample and
mixed by pipetting. The samples were then incubated at 70 °C for 6 minutes in a thermal
cycler with a heated lid and cooled at 4 °C for 2 minutes.
For the master mix: RNase free dH20 88 pi
5x 2nd Strand Reaction Mix 30 pi
(lOmM)dNTPs 3 pi
(10 U/ pi) E. coli DNA Pol I 4 pi
The master mix was then mixed by pipetting and 125 pi of the master mix were added to
each sample for a final volume of 150ml.The mix was then incubated at 16 °C for 2 hours
in a thermal cycler followed by addtitin of 2ml of T4 DNA polymerase. The mix was
then incubated at 16 °C for 10 minutes and at 4 °C for 2 minutes. It was then placed on
ice prior to the next step.
Step 7: The samples were transferred to a 1.5ml microfuge tube and 600 pi of cDNA
Binding Buffer were added to the cDNA reaction. The samples were then applied to the
cDNA Cleanup Spin Column and centrifuged at >8000g for 1 minute. The collection tube
was then emptied and the column reloaded with the remaining cDNA mixture and
centrifuged at >8000g for 1 minute. The column was then transferred into a new 2ml
Collection tube and 750 pi of cDNA Wash Buffer were added onto the spin column and
centrifuged at >8000g for 1 minute. The collection tube was emptied and the cap of the
spin column was opened and centrifuge at maximum speed for 5 minutes, to completely
dry the membrane. It was then transferred to a fresh 1.5ml collection tube. And the
samples eluted by adding 14 pi of cDNA Elution Buffer directly onto the middle of the
spin column membrane and incubated at room temperature for 1 minute followed by
centrifugation at maximum speed for 1 minute.
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Step 8: To prepare a master mix of the IVT reagents the following were mixed together:
Nuclease free dH20 8 pi
(lOx) IVT labelling buffer 4 pi
Labelled NTP mix 12 pi
IVT labelling enzyme mix 4 pi
The mix was mixed by pippeting and 28 pi of master-mix were added to the double
stranded cDNA for a final volume of and mixed by pipetting. The mix was the incubated
at 37 °C for 16 hours and then at 4 °C for 2 minutes in a thermal cycler.
Step 9: The samples were transferred to a 1.5ml microfuge tube and 60 pi of nuclease
free dH20 and 350 pi of IVT cRNA Binding Buffer were added into the sample and
mixed thoroughly by pippetting. 250 pi of 100% ethanol were added and the sample was
applied to an IVT cRNA Cleanup Spin Column and centrifuged at >8,000g for 15
seconds. The spin column was then transferred to a fresh 2ml collection tube and 500 pi
of IVT cRNA Wash Buffer were added onto the spin column and spun at >8000g for 15
seconds. The collection tube was emptied and 500 pi of 80% ethanol were added onto the
spin column and spun at >8,000g for 15 seconds. The collection tube was emptied and
the cap opened and centrifuged at maximum speed for 5 minutes to completely dry the
membrane. The spin column was then transferred into a new 1.5ml Collection tube and
the sample eluted by placing 11 pi of nuclease-free water directly onto the middle of the
spin column membrane. Incubated at room temperature for 2 minutes and centrifuged at
maximum speed for 1 minute.
Step 10: For the fragmentation of cRNA in each tube x pi of cRNA (20pg), 4pi 5X
fragmentation buffer and x pi RNase free dH20 were added in the same tube to a final
0
volume of 20pl. The mix was then incubated at 95 C for 35 minutes. During incubation
of cRNA, 20x eukaryotic hybridization controls and control oligonucleotide B2 were
O
heated at 65 C for 5 minutes and mixed gently by vortexing. After incubation, the
microfuge tubes containing the cRNA were spun briefly to remove condensation from lid
and 15 pi of each replicate of the fragmentation reactions for each sample were transferred
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into a clean tube. For the cocktail master mix, for each tube containing 15 pg fragmented
2X cRNA the following were added:
hybridization buffer 150pl
control oligonucleotide B2 (3nM) 5 pi
20X eukaryotic hybridization controls 15pl
herring sperm DNA (lOmg/ml) 3 pi
acetylated BSA (50mg/ml) 3 pi
DMSO (99.5% GC) 30pl
RNase free dH O
2 79pl
The master mix was pulsed-vortexed for 30 seconds and 285 pi of master mix were added
to each 15 pi fragmented cRNA sample and mixed thoroughly.
For Hybridization:
1. Target Hybridization
The probe array was equilibrated to room temperature immediately before use and the
array was wet by filling it through one of the septa with 200 pi of IX MES hybridization
0
buffer using a micropipetor. The probe was incubated at 45 C for 10-15 minutes with
O
rotation. The hybridization cocktail was heated to 99 C for 5 minutes and then
0
transferred to 45 C for 5 minutes. The hybridization cocktails were spun at maximum
speed in a microcentrifuge for 5 minutes to remove any insoluble material from the
hybridization mixture. After 10-15 minutes of prehybridization, the buffer solution was
removed from the probe array cartridge. The probe array was filled with 200 pi of the
cocktail, avoiding any insoluble matter at the bottom of the tube and the probe array was
placed in hybridization oven, loaded in balanced configuration around axis and rotated at
60rpm for 16 hours.
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2. Post-hybridization wash and stain
The hybridization cocktail was removed from the probe array and set aside in a fresh
eppendorf tube. The probe array was filled completely with non-stringent wash buffer.
The SAPE (Streptavidin-Phycoerythrin) stain solution was prepared (always fresh):
Final concentration Volume (pi) X
2XMES stain buffer IX 600
DI H20 540 pi
Acetylated BSA 50 mg/ml 2mg/ml 48 pi
SAPE 1 mg/ml 10 pg/ml 12 pi
For the antibody solution:
Final concentration Volume (pi) X
2XMES stain buffer IX 300
Dl H20 266.4 pi
Acetylated BSA 50 mg/ml 2mg/ml 24 pi
Normal goat IgG 10 mg/ml 0.1 mg/ml 6 pi
Biotinylated antibody 0.5 mg/ml 3pg/ml 3.6 Pi
Target sequences for each chip were downloaded from the Affymetrix website and then
compared to NCBI genome builds, to Uni-Gene and to RefSeq transcripts with BLAT.
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5.3 Results
5.3.1 Proof of concept study
5.3.1.1 Optimization of staining and laser dissection
To improve laser dissection staining of tissues is helpful for the laser-excitation for
cutting. Ethanol fixation and eosin staining were used in this study following reports by
Schutze and Lahr (1998) and Goldsworthy and colleagues (1999) as it was found to be
the stain with the least negative effect on RNA integrity along with ethanol fixation. To
assess whether the use of staining with eosin affected the integrity of RNA, samples
isloated from sections with or without eosin stain were analyzed. The quality of RNA as
can be seen in figure 5.9 was similar in both cases indicating that staining had no
negative effect in the quality of isolated RNA. RNA degradation as indicated by the
degradation smears as well as by the RIN numbers (figure 5.9), appeared in both stained
and unstained samples compared to RNA isolated from tissue culture cells, and therefore
could not be attributed to the presence of eosin.
5.3.1.2 Isolation of RNA
For RNA isolation the Qiagen Micro RNeasy Kit for microdissected tissues was used as
described in the §5.2.6.1. Both periosteal and endosteal osteoblasts were dissected using a
337-nm pulsed UVa-nitrogen microbeam laser built in an inverse microscope. Total RNA
isolated was subjected to RT-PCR for cDNA synthesis followed by PCR. The PCR
products were run on a 1.2% agarose gel. As can be seen in figure 5.10, in lanes 6 and 5
there is a visible product for actin in samples of laser micro-dissected (LMD) osteoblasts
from periosteal and endosteal bone surfaces. Whole bone rat cryosections and 10,000
cultured osteoblasts and MLO-Y4 osteocyte-like cells were also subjected to RNA
extraction and RT-PCR to provide the positive controls for the PCR. These results
indicate the successful isolation of total RNA from 10,000 LMD periosteal and endosteal
osteoblast samples and the expression of actin. The same samples were evaluated by the
Novartis Genomics Unit and applied to microarray chips. Successful microarray data was
obtained indicating the expression of genes of the osteoblast lineage (data not available).
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(A) (B) (C)
Figure 5.9 Effect of eosin staining and ethanol fixation on RNA integrity. Total RNA
was prepared from mid-diaphysis tibial periosteal osteoblast microdissected material
(10,000 cells) from a 3 month old animal. RNA was extracted using the RNeasy Micro kit
(Qiagen) following manufacturers guidelines and analyzed by Agilent bioanalyzer,
characterising RNA integrity on the basis of 18s and 28s rRNAs recovery by
electrophoresis-gel-like images. (A) Control RNA, R1N: 9.3 from cultured osteoblasts






Lane 1: 100 bp DNA ladder
Lane 2: Actin with H2O (cDNA negative control)
Lane 3: Actin with 1 rat section
Lane 4: Actin with cultured human osteobalsts (positive control)
Lane 5: Actin with 10 rat sections
Lane 6: Actin with 10,000 LMD endosteal osteoblasts
Lane 7: Actin with 10,000 LMD periosteal osteoblasts
Lane 8: Actin with MLO-Y4 (positive control)
Figure 5.10. Expression of actin in osteoblast preparations. The expression of actin
was determined by RT-PCR in periosteal and endosteal osteoblast populations (lanes 6
and 7) as indicated by the arrows. RNA extracted from whole rat sections and 10,000




5.3.2.1 RNA Isolation from the Control Group
Following the protocols developed for the proof of concept study, which indicate that the
methods developed were successful for isolation of total RNA, the Novartis study
samples from the in vivo experiment, were analyzed following the same protocols. Tibias
were subjected to cryosectioning and LMD. For both periosteal and endosteal osteoblast
samples -50,000 cells were collected from either side and total RNA was isolated
following the RNeasy Micro Kit extraction protocol. For the control group the
NanoDrop profiles can be seen in Table 5.1 and the electropherogram in figure 5.11.
Despite the fact that all samples extracted using the RNeasy Micro Kit provided a reading
on the NanoDrop, we were unable to obtain an Agilent profile for some of the samples.
As can been seen in table 5.1 260/230 ratios are low indicative of RNA degradation or
co-contaminants, however the 260/280 ratios were close to 2 indicating that the RNA was
clear of protein and DNA. Also as can be seen in figure 5.11, we were unable to obtain a
profile on the Agilent bionalyzer on some samples indicative of no or very little RNA
present; and for the samples that 18S and 28S peaks were detected degradation smears
were observed as indicated by the intermediate bands in between the peaks and the low or
non-applicable (N/A) numbers.
227
ng/pl 260/280 260/230 Total RNA
ANIMAL 1
PERIOSTEUM 1.4 ng/jj.1 1.72 0.35 16.8 ng
ENDOSTEUM 1.9 ng/^1 1.85 0.10 22.8ng
ANIMAL 2
PERIOSTEUM 1 ng/jal 1.86 0.11 12 ng
ENDOSTEUM 1.2 ng/jal 1.78 0.37 16.8 ng
ANIMAL 3
PERIOSTEUM 1.7 ng/pl 1.83 0.33 20.4 ng
ENDOSTEUM 1.9 ng/pl 1.87 0.37 22.8 ng
ANIMAL 4
PERIOSTEUM 1.2 ng/pl 1.79 0.19 14.4 ng
ENDOSTEUM 2.2 ng/pl 1.84 0.13 26.4 ng
ANIMAL 5
PERIOSTEUM 1.2 ng/pl 2.05 0.15 14.4 ng
ENDOSTEUM 1.9 ng/pl 1.77 0.33 22.8 ng
Table 5.1 NanoDrop readings for the control group RNA samples. 2 pi of the RNA
samples were used for the NanoDrop. The 260/280 ratios were close to 2 indicative of
RNA samples free of DNA and protein contamination but the 260/230 ratios were low
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L: Ladder
1. Control MLO-Y4 cells RNA
2. Periosteal sample Animal 1
3. Endosteal sample Animal 1
4. Periosteal sample Animal 2
5. Endosteal sample Animal 2
6. Periosteal sample Animal 3
7. Endosteal sample Animal 3
8. Periosteal sample Animal 4
9. Endosteal sample Animal 4
10. Periosteal sample Animal 5
11. Endosteal sample Animal 5
Figure 5.11 Agilent Bioanalyzer electropherogram and peaks of control total RNA
isolation samples. Clear 18S and 28S peaks were observed for a few experimental
samples, however degradation of these samples was observed as indicated by the low
RIN numbers.
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5.3.2.2 RNA Isolation from the Compound A
Tibias from the five animals that recived compound A twice daily at a dose of lOOmg/kg
were subjected to cryosectioning and LMD. Total RNA was isolated from these samples
as described above for the control group. For compound A treatment group the NanoDrop
profiles can be seen in Table 5.2 and the electropherogram in figure 5.12. Despite the fact
that all samples extracted using the RNeasy Micro Kit gave a reading on the NanoDrop,
we were unable to get an Agilent profile for all of the samples. Similarly to the control
group RNA samples, the 260/280 ratios were close 2 but the 260/230 ratios were low,
indicative of degradation or presence of co-contaminants. Moreover as can be seen in
figure 5.12, we were unable to obtain a profile on the Agilent bionalyzer for most of the
samples indicating that no or very little RNA, that is undetectable is present; for those
samples in which 18S and 28S peaks were detected considerable degradation was




PERIOSTEUM 2.5 ng/pl 1.74 0.01 30 ng
ENDOSTEUM 3.0 ng/pl 1.72 0.24 36 ng
ANIMAL 2
PERIOSTEUM 1.4 ng/pl 1.74 0.01 16.8 ng
ENDOSTEUM 2.3 ng/pl 1.67 0.25 27.6 ng
ANIMAL 3
PERIOSTEUM 1.5 ng/pl 1.68 0.02 18 ng
ENDOSTEUM 3.1 ng/pl 1.75 0.18 37.2 ng
ANIMAL 4
PERIOSTEUM 2.3 ng/pl 1.80 0.18 27.6 ng
ENDOSTEUM 4.8 ng/pl 2.1 0.01 57.6 ng
ANIMAL 5
PERIOSTEUM 1.4 ng/pl 1.78 0.03 16.8 ng
ENDOSTEUM 1.2 ng/pl 1.65 0.01 14.4 ng
Table 5.2 NanoDrop readings for the Compound A group RNA samples. 2 pi of the
RNA samples were used for the NanoDrop. For some of the samples the 260/280 ratios
were close to 2 indicative of RNA samples free of DNA and protein contamination,
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L: Ladder
1. Control MLO-Y4 cells RNA
2. Periosteal sample Animal 1
3. Endosteal sample Animal 1
4. Periosteal sample Animal 2
5. Endosteal sample Animal 2
6. Periosteal sample Animal 3
7. Endosteal sample Animal 3
8. Periosteal sample Animal 4
9. Endosteal sample Animal 4
10. Periosteal sample Animal 5
11. Endosteal sample Animal 5
Figure 5.12 Agilent Bioanalyzer electropherogram and peaks of Compound A total
RNA extraction samples. Clear 18S and 28S peaks were observed for a few
experimental samples, however degradation of these samples was observed as indicated
by degradation smears and low or N/A RIN numbers.
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5.2.3.3 RNA Isolation from the Compound B
Tibias from the five animals receiving compound B once daily at a dose of 200mg/kg
were subjected to cryosectioning and LMD. Total RNA was extracted as described above
for the other treatment groups. For compound B treatment group, the NanoDrop profiles
can be seen in Table 5.3 and the electropherogram in figure 5.13. Despite the fact that all
samples extracted using the RNeasy Micro Kit gave a reading on the NanoDrop, we were
unable to get an Agilent profile for all of the samples. Similarly to the RNA samples
discussed above the 260/280 ratios were close to 2 but the 260/230 ratios were low,
indicative of degradation or presence of co-contaminants. Also as can be seen in figure
5.13, we were unable to obtain a profile on the Agilent bionalyzer for most of the samples
indicating that no or very little RNA, that is undetectable is present; for the samples that
18S and 28S peaks were detected considerable degradation was observed.
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ng/pl 260/280 260/230 Total
ANIMAL 1
PERIOSTEUM 2.2 ng/pl 1.80 0.22 22ng
ENDOSTEUM 1.3 ng/jul 1.90 0.44 15.6ng
ANIMAL 2
PERIOSTEUM 1.0 ng/pl 1.68 0.03 12 ng
ENDOSTEUM 1.1 ng/jul 1.80 0.01 15.4 ng
ANIMAL 3
PERIOSTEUM 1 .Ong/jal 1.68 0.25 14 ng
ENDOSTEUM 1.8ng/pl 1.85 0.01 25.2 ng
ANIMAL 4
PERIOSTEUM 1.2 ng/pl 2.01 0.01 16.8 ng
ENDOSTEUM 1.2 ng/jal 2.1 0.02 16.8 ng
ANIMAL 5
PERIOSTEUM 1.1 ng/pl 2.01 0.03 15.4 ng
ENDOSTEUM 1.8ng/pl 1.81 0.06 25.2 ng
Table 5.3 NanoDrop readings for the Compound B group RNA samples. 2 pi of the
RNA samples were used for the NanoDrop. Most of the experimental samples had high
260/280 ratios, however the 260/230 ratios similarly to other experimental samples from
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L: Ladder
1. Control MLO-Y4 cells RNA
2. Periosteal sample Animal 1
3. Endosteal sample Animal 1
4. Periosteal sample Animal 2
5. Endosteal sample Animal 2
6. Periosteal sample Animal 3
7. Endosteal sample Animal 3
8. Periosteal sample Animal 4
9. Endosteal sample Animal 4
10. Periosteal sample Animal 5
11. Endosteal sample Animal 5
Figure 5.13 Agilent Bioanalyzer electropherogram and peaks of Compound B total
RNA extraction samples. Clear 18S and 28S peaks were observed for the control
sample, but no RNA was detectable for all experimental samples of Compound B as no
18S or 28S peaks were detected.
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5.2.3.4 RNA Isolation from the rhPTH Group
Tibias from the five animals receiving rhPTH once daily at a dose of 50ug/kg were
subjected to cryosectioning and LMD. As for the treatment groups discussed above total
RNA was isolated and tested on Agilent and NanoDrop. For the PTH treatment group the
NanoDrop profiles can be seen in Table 5.4 and the electropherogram in figure 5.14.
Despite the fact that all samples extracted using the RNeasy Micro Kit gave a reading on
the NanoDrop, we were unable to obtain an Agilent profile for all of the samples.
Similarly to RNA samples discussed above the 260/280 ratios were close to 2 but the
260/230 ratios were low, indicative of degradation or presence of co-contaminants. Also
as can be seen in figure 5.14, we were unable to obtain a profile on the Agilent bionalyzer
for most of the samples indicating that no or very little RNA, although 18S and 28S
peaks are present degradation of the samples was observed as indicated by the
degradation smears and the low or N/A RIN numbers.
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ng/jul 260/280 260/230 Total
ANIMAL 1
PERIOSTEUM 2.0 ng/pl 1.90 0.05 28 ng
ENDOSTEUM 1.9ng/pl 1.75 0.01 22.8ng
ANIMAL 2
PERIOSTEUM 3.2 ng/pl 2.01 0.04 44.8 ng
ENDOSTEUM 3.4 ng/pl 1.68 0.15 47.6 ng
ANIMAL 3
PERIOSTEUM 3.1 ng/pl 1.83 0.15 43.4ng
ENDOSTEUM 2.9 ng/pl 1.87 0.08 40.6 ng
ANIMAL 4
PERIOSTEUM 2.3 ng/pl 1.79 0.17 32.2 ng
ENDOSTEUM 2.1 ng/pl 1.84 0.22 29.4 ng
ANIMAL 5
PERIOSTEUM 3.4ng/pl 1.82 0.13 47.6 ng
ENDOSTEUM 3.2 ng/pl 1.77 0.46 44.8 ng
Table 5.4 NanoDrop readings for the rhPTH group RNA samples. 2 pi of the RNA
samples were used for the NanoDrop. Similarly to the RNA samples isolated from the
other treatment groups in the rhPTH group samples had 260/280 ratios close to 2,
however the 260/230 ratios similarly to the other experimental samples remain low
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L: Ladder
1. Periosteal sample Animal 1
2. Endosteal sample Animal 1
3. Periosteal sample Animal 2
4. Endosteal sample Animal 2
5. Periosteal sample Animal 3
6. Endosteal sample Animal 3
7. Control MLO-Y4 cells RNA
8. Periosteal sample Animal 4
9. Endosteal sample Animal 4
10. Periosteal sample Animal 5
11. Endosteal sample Animal 5
Figure 5.14. Agilent Bioanalyzer electropherogram and peaks of rhPTH group total
RNA extraction samples. Clear 18S and 28S peaks were observed for the control sample
as well as 18S and 28S peaks for some of the experimental samples with degradation
smears present and low RIN numbers.
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5.2.3.4 RNA Isolation from the rhGH Group
Tibias from the five animals receiving rhGH once daily at a dose of 2.5mg/kg were
subjected to cryosectioning and LMD. As for other treatment groups as described
previously total RNA was extracted and subjected to Agilent and NanoDrop testing. For
the rhGH treatment group the NanoDrop profiles can be seen in Table 5.5 and the
electropherogram in figure 5.15. Despite the fact that all samples extracted using the
RNeasy Micro Kit gave a reading on the NanoDrop, we were unable to get an Agilent
profile for all of the samples. As for the RNA samples discussed previously the 260/280
ratios were close to 2 but the 260/230 ratios were low, indicative of degradation or
presence of co-contaminants. Also as can be seen in figure 5.15, we were unable to obtain
a profile on the Agilent bionalyzer for most of the samples. However samples that 18S
and 28S peaks were detected considerable degradation was observed with obvious
degradation smears in between peaks.
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ng/pl 260/280 260/230 Total
ANIMAL 1
PERIOSTEUM 1.5 ng/pl 1.90 0.53 21 ng
ENDOSTEUM 1.9 ng/pl 1.75 0.04 22.8ng
ANIMAL 2
PERIOSTEUM 2.2 ng/pl 1.77 0.32 30.8 ng
ENDOSTEUM 2.4 ng/pl 1.68 0.05 33.6 ng
ANIMAL 3
PERIOSTEUM 3.6 ng/pl 1.93 0.10 50.4 ng
ENDOSTEUM 2.1 ng/pl 2.01 0.07 29.4 ng
ANIMAL 4
PERIOSTEUM 3.4 ng/pl 1.79 0.07 47.6 ng
ENDOSTEUM 2.1 ng/jal 1.84 0.12 29.4 ng
ANIMAL 5
PERIOSTEUM 1.5ng/pl 1.79 0.07 21 ng
ENDOSTEUM 2.1 ng/pl 1.79 0.12 29.4 ng
Table 5.5. NanoDrop readings for the rhGH group RNA samples. 2 pi of the RNA
samples were used for the NanoDrop. Similarly to the RNA samples extracted from the
other treatment groups, rhGH RNA samples had 260/280 ratios close to 2, however the
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L: Ladder
1. Periosteal sample Animal 1
2. Endosteal sample Animal 1
3. Periosteal sample Animal 2
4. Endosteal sample Animal 2
5. Periosteal sample Animal 3
6. Endosteal sample Animal 3
7. Periosteal sample Animal 4
8. Control MLO-Y4 cells RNA
9. Endosteal sample Animal 4
10. Periosteal sample Animal 5
11. Endosteal sample Animal 5
Figure 5.15. Agilent Bioanalyzer electropherogram and peaks of rhGH group total
RNA extraction samples. Clear 18S and 28S peaks were observed for the control
sample, and faint peaks for a few experimental samples with low RIN numbers and
degradation smears present.
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5.2.4 Preliminary Microarray data
All the RNA samples discussed above, extracted using the RNeasy Micro Kit (Qiagen)
were evaluated by the Genomics Unit of Novartis (Basel, Switzerland). 5 animals from
each group, 5 samples from each site (endosteal vs. periosteal) were arrayed. From the
first set of samples which included the control and the rhPTH groups microarray data was
obtained from a small number of samples, for the endosteal envelope (table 5.6) since
most of them were found to be of sub-optimal quality to be further processed. No data
was obtained from the second set of samples including the rhGH and Compounds A and
B as these RNA samples were determined to be of either sub-optimal quality or no RNA
detectable. No further RT-PCR was carried out to check for consistency to the data
presented here, because of the small volume of the samples. Therefore a number of RNA
extraction methods and modifications trials were initiated using -50,000 LCM cells in an
attempt to improve the RNA quality. These methods and the data obtained are discussed
below. All trials discussed were performed at least three times each.
5.2.5 Gene expression in response to rhPTH treatment at the endosteal
envelope
In order to identify genes regulated by rhPTH, rhGH and Compounds A and B at the
endosteal and periosteal envelopes of old female rats the in vivo experiment as described
in § 5.2.1 was set up. RNA samples from these treatment groups as well as the control
group were tested by the Novartis Genomics Unit and only a few samples were found to
be of optimal quality to be used for microarray analysis. Limited microarray data was
obtained from the rhPTH and the control group for the endosteal envelope. Genes whose
expression was changed by two-fold or more in response to rhPTH treatment compared
to the control at the endosteal envelope of the rat tibia are listed in table 5.6. The genes
showing most evident changes belong to mainly three categories: bone development,
binding, catalysis and cell cycle.
Additional genes involved in signal transduction, apoptosis, cytokinesis and cell
migration, cell proliferation as well as structural proteins and transcription factors were



























Gene Title Fold Change
(rhPTH/Control)
interferon regulatory factor 45.97
Wolf-Hirschhorn syndrome 11.89
candidate 1 -like 1
Polymerase (DNA directed), 33.7
epsilon 2 (p59 subunit)
lamimin, gamma 2 18.63
Vacuolar protein sorting 54 18.07
SRY-box containing gene 6 8.292
distrobrevin binding protein 1 6.596
LSM 16 homolog 13.45
zinc finger protein 91 4.744
leucine-rich and death domain 14.7
containing
baculoviral LAP repeat-containing 2.359
3
regulator of chromosome 12.23
condensation 2
dedicator of cytokinesis 5 2.329
trefoil factor 1 6.73
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Fuca2 fucosidase, alpha-L-2, plasma 6.761
Pde8b Phosphodiesterase 8B 39.64
Signaling
Rgsl4 regulator of G-protein signaling 14 2.292
TbcldlOa TBC1 domain family, member 10a 2.235
Table 5.6 Gene expression changed two-fold or more in response to rhPTH
treatment at the endosteal envelope of the rat tibia. The genes whose expression
changed in response to rhPTH treatment mainly belong to three categories: bone
development, binding, catalysis and cell cycle.
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5.2.6 Improvement of RNA Quality
5.2.6.1. Qiagen RNeasy Micro RNA Isolation with addition of Proteinase K
-50,000 endosteal and periosteal osteoblast were LMD in lysis buffer (RLT + P-
mercaptoethanol). For the control RNA 50,000 cultured osteoblasts were extracted using
the RNeasy Micro kit method. For RNA isolation the manufacturer's protocol as
described in the methods section was used with the introduction of a proteinase K step,
known to inactivate the RNases and DNases in nucleic acid extractions. 5 pi (lOOpg) of
proteinase K were added to the sample following homogenization in lysis buffer and then
incubated at 55°C for 10 minutes prior to addition on an equal volume of 70% ethanol.
The RNA samples were tested on the NanoDrop and the Agilent bionalyzer for quantity
and quality (figure 5.16). As can be seen in figure 5.16 the 260/280 and 260/230 ratios
were both low indicative of the presence of co-contaminants and on the Agilent profile no
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Figure 5.16. Agilent Bionalyzer profiles and NanoDrop data for total RNA samples
of -50,000 cells isolated using RNeasy Micro kit and addition of Proteinase K.
50,000 cells from periosteum and endosteum were LMD and RNA was isolated using the
RNeasy Micro kit method with the addition of lOOpg proteinase K. The 260/280 and
260/230 ratios were low for both samples indicative of co-contaminants. In the Agilent
profiles no 18S and 28S peaks were detected for both samples while clear peaks were
observed for the cultured osteoblast control sample indicative of degraded samples.
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5.2.6.2. Trizol (Invitrogen) RNA isolation
-50,000 periosteal osteoblasts were LMD in trizol, which served as the lysis buffer. For
the control RNA 50,000 cultured osteoblasts were lysed in trizol for RNA isolation,
followed by the Qiagen clean-up. For RNA isolation the manufacturer's protocol as
described in §5.2.6.2 was followed. The samples were then homogenized using a syringe
and needle by passing 5-10 times through 29G needle attached to a sterile plastic syringe.
The manufacturer's protocol was then followed for the extraction with two modifications:
a) On addition of Trizol reagent samples were left at room temp with rotation for 10
min's prior to addition of chloroform.
b) After aqueous layer was collected Glycogen earner (20pg) was added prior to
precipitation with isopropanol.
Following extraction 5pl of the sample were reserved for Nano-drop and Agilent analysis
and the remaining sample was subjected to clean-up with Qiagen Micro Kit as described
in §5.2.6.3. The RNA samples were tested on the NanoDrop and the Agilent bionalyzer
for quantity and quality (figure 5.17). As can be seen in figure 5.17 the 260/280 and
260/230 ratios were both low indicative of the presence of co-contaminants while on the
Agilent profile clear 18S and 28S peaks were detectable, indicative of RNA present,
however low RIN numbers indicated RNA degradation. When the trizol extracted sample
was subjected to clean-up considerable loss of RNA was observed with no significant
improvements in either the 260/280, 260/230 ratios or RIN number.
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Figure 5.17 Agilent Bionalyzer profiles and NanoDrop data for total RNA samples
of -50,000 cells isolated using Trizol and addition of glycogen carrier. -50,000 cells
from periosteum were LMD and RNA was isolated using Trizol with addition of 20pg of
glycogen. The 260/280 and 260/230 ratios were low for both trizol and clean-up samples
as can be seen from the NanoDrop reading indicative of co-contaminants. As can be seen
in the Agilent profiles there are clear 18S and 28S peaks; however degradation was
detected as the RIN number were low. Following clean-up of the sample there was no
improvement in RNA quality with significant reduction in yield.
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5.2.6.3 Section de-calcification followed by (a) Qiagen RNeasy Micro Kit
and (b) Trizol followed by Qiagen Clean-up.
Although the trizol method improved the RNA quality significantly, further improvement
was necessary for successful microarray analysis. In table 5.7 a summary of the RNA
isolation methods discussed above is presented; with the modification of de-calcification
of sections prior to LMD and RNA isolation using either a)the RNeasy Micro Kit or
b)Trizol followed by the Qiagen clean-up. As can be seen from table 5.7 from the varying
combinations tested there was no improvement in the 260/230 ratio. These samples were
also tested using the Agilent and no profiles were obtained, demonstrating poor quality
RNA unsuitable for further analysis. It can be concluded that the de-calcification step did
not improve the RNA quality and resulted in significant reduction of RNA yield.
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Extraction method 260/280 260/230 ng/pl
Qiagen+decalcifi cation
Periosteum 1.40 0.69 5.1
Endosteum 1.38 0.52 6.6
Qiagen No
decalcification
Periosteum 1.41 0.49 4.5
Endosteum 1.44 0.05 6.5
Trizol+decalcification
Periosteum 1.39 0.33 12.5
Endosteum 1.45 0.42 22.5
Trizol No
decalcification
Periosteum 1.36 0.32 10.1
Endosteum 1.39 0.34 13.7
Clean up
Trizol+decalc.
Periosteum 1.54 0.45 6.9
Endosteum 1.49 0.13 8.3
Clean up Trizol No
decalcification
Periosteum 1.46 0.47 15.2
Endosteum 1.37 0.06 5.3
Table 5.7. Summary of RNeasy Micro Kit and Trizol total RNA isolation with or without
de-calcification.
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5.2.6.4. Arcturus Pico-Pure (Arcturus) RNA isolation
The Arcturus Pico-Pure RNA isolation method was tested, since it has been postulated to
be more sensitive with small LCM samples. -50,000 periosteal osteoblasts were LMD in
the lysis buffer provided by the supplier. Prior to extraction the sample was split in two
samples each containing -25,000 LMD osteoblasts. The extraction was carried out as
described in §5.2.6.4. For the control RNA 1,000 cultured osteoblasts were used. The
RNA samples were tested on the NanoDrop and the Agilent bionalyzer for quantity and
quality. As can be seen in figure 5.18 the 260/280 and 260/230 ratios were low indicative
of the presence of co-contaminants. The Agilent profiles showed clear 18S and 28S peaks
for the control sample which was 25,000 cultured osteoblasts as well as for sample A1
but not for sample A2; with no real improvement in the RNA integrity as indicated by the












































Figure 5.18. Agilent Bionalyzer profiles and NanoDrop data for RNA samples of
roughly 4,000 cells isolated using Arcturus Pico Pure RNA isolation kit. -25,000
cells from periosteum of a 15 month old animal were LMD and RNA was isolated using
the Arcturus Pico-Pure method. The 260/280 and 260/230 ratios were higher for the
sample A1 compared to A2. As can be seen in the Agilent profiles there were clear 18S
and 28S peaks for A1 but not for A2; however the samples were degraded as indicated by
the low RIN numbers.
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5.4 Discussion
Osteoblasts are the cells responsible for bone formation and have been proposed to
respond differently to osteotropic agents at different anatomical sites, but the functional
significance of such findings is not clear. One obstacle in understanding the response of
osteoblasts to different anabolic treatments is that the cells are not accessible for study in
vivo. Although it is possible to extract and culture osteoblasts from bones, the responses
of such cells might be different from those in vivo. In the present study a technique to
investigate osteoblast gene expression in vivo, in female rats previously treated with
rhPTH, rhGH and Compounds A and B over an experimental period of 14 days using
laser microdissection of bone tissue cryosections has been developed. The principle of
this method is that only specific cell populations from heterogeneous tissues are isolated
and RNA isolation can follow. Using this method, an attempt to investigate the gene
expression in osteoblastic cells from the rat tibia at the endosteal and periosteal sites was
made. Although limited gene expression was obtained, this technique forms the basis for
future studies to investigate gene expression of specific cell populations.
In the present study female rats were subjected to rhPTH and rhGH treatment for 14 days.
The animals used in this study were virgin 18 months of age females, which represents
the female ageing skeleton; providing a good model for quiescent bone surfaces. During
ageing, osteoblasts have a shorter life span and are more prone to apoptosis which may
account for the deficit in bone formation observed in age-related osteopenia (Chan and
Duque, 2002). The concept of apoptosis prevention in osteoblasts may explain the
anabolic action of PTH and GH in ageing bone (Whitfield, 2006); however more research
in terms of understanding the molecular profiles for such actions is necessary so that any
differences in response to anabolic treatment could be documented and potentially be
used for the design of drugs to prevent age-related bone loss.
Compact calcified bone, creates an analytically difficult to handle tissue. This is mainly
the reason why the majority of the available data on osteoblasts stem from cell culture
studies using cell lines, since obtaining pure populations of primary osteoblasts is
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demanding. However such studies cannot provide much information regarding gene
expression at the different anatomical sites of bone (periosteal vs. endosteal). To
overcome these difficulties a powerful tool becoming more widely used is LCM, which
allows the sampling of specific cell populations from heterogeneous tissues. In this study
fixed cell samples were collected by LCM, however they differed in several aspects from
fresh cells; as fixation introduced difficulty in the isolation of high quality RNA from
these cells. It has been reported in other studies that RNA isolated from
parafonnaldehyde fixed, paraffin embedded cells was less reliable than RNA isolated
from frozen ethanol fixed cells (Finke et al. 1993, Foss et al. 1994, Karlsen et al. 1994,
Shibutani et al. 2000, Macabeo-Ong et al. 2002, Eisenberger et al. 2004). Ethanol fixation
has been reported to introduce less chemical modifications, as it preserves nucleic acids
through denaturation; in contrast to formalin which causes cross-linking of nucleotides
and proteins, with subsequent poor RNA quality (Goldsworthy et al. 1999, Williams et al.
1999). In the present study the isolated RNA was to be used for microarray analysis,
therefore it was necessary to minimize the potential modifications from fixation, as they
would interfere with the amplification process. Furthermore, tissue was snap frozen in
cold hexane, as it has been generally considered to be the best source of intact RNA, as
well as maintaining better tissue morphology. To assess whether the stain of choice
affected the integrity of RNA, sections fixed in 70% ethanol were subjected to staining or
no staining, followed by LCM and RNA isolation. Following RNA examination it was
found that staining and fixing generally affected the integrity of RNA to a certain extent
when compared to RNA samples from fresh cells. Due to the study design it would not
have been possible to perform the study without staining since it significantly improved
the laser dissection process, as it helped laser-excitation for cutting. Although the
morphology of sections was satisfactory and the regions of interest were well defined, it
was troublesome to obtain such sections. For this reason it would be useful to consider
using commercially available tape-transfer systems such as CryoJane for future studies,
as it has been reported to produce frozen sections, fully intact and bonded to the
microscope slide in less than 3 minutes that is ready for fixation and staining. The value
of such systems is highlighted by the report of Eisenberger and colleagues (2004) of
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successful isolation of intact osteocyte RNA using a tape-transfer system; however it may
still need further testing and improvment.
Even when successfully isolated, RNA could have been subject to RNA degradation.
RNases are present and active at fixation, however the tissues used in this study were
immersion fixed in cold hexane and as such this possibility is remote. On the other hand
the conditions pre and post fixation can introduce RNA degradation, these would include
pre-fixation time, tissue processing; which would include cryosectioning, fixation and
staining to LCM. To minimize the chances of RNA degradation, tissues, following
surgical removal, were immediately fixed and all further processing from cryosectioning
to LCM was performed under strict RNase free conditions with all solutions being
RNase/DNase free as well as performing all steps in the minimum time necessary. During
LCM, the room and microscope used were isolated and cleaned after each use to avoid
introduction of RNases as well as minimizing the time of laser dissection to 30 minutes
per slide, although it is possible to LCM tissues if completely dry for up to 2 hours.
Moreover the DNase treatment for removal of any residual genomic DNA present in the
RNA sample as well as phenol/chloroform based extraction methods for example Trizol
RNA isolation employed in this study may further reduce the final RNA yield
considerably (Srinivasan et al. 2002). However in this study DNase treatment was a pre¬
requisite for subsequent microarray studies and thus could not be avoided. On the other
hand RNA isolation using trizol did give some successful results; which unfortunately
were not reproducible and the RNA yield was similar to the other RNA isolation methods
employed in this study.
To determine whether LCM led to the expected collection of osteoblasts the presence of
the actin gene was tested by PCR. Actin was found to be expressed in both the periosteal
and endosteal preparations indicating successful isolation of osteoblastic populations with
minimal contamination from the border regions when guiding the microdissection laser.
Since the pilot study which was performed using young animals of about 3-5 months of
age was successful, the same technique was applied in the animals of the study which
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were 18 months of age. However the reproducibility was poor between different sets of
samples, with RNA integrity being severely compromised in the tissues derived from the
study samples. In an attempt to improve on the quality of the RNA various capturing
media for microdissected material and RNA isolation methods were assessed. The
RNeasy micro kit RNA isolation method which was the method of choice was proven
successful as indicated by the limited microarray data obtained, however extensive
degradation was detected. In an attempt to improve the method, a modification with the
addition of proteinase K, which is known to inactivate RNases and DNases in nucleic
acid extractions was introduced, with no improvement in the RNA quality as it was
shown on the Agilent bionalyzer and poor 260/280, 260/230 ratios when quantified with
the NanoDrop.
The next method that was tested was phenol based isolation of RNA using trizol with
addition of glycogen carrier because of the low amounts of RNA present in these
samples. For the removal of any carryover phenol a clean up step was performed, which
did not improve the quality of the sample and resulted in significant yield reduction.
Although the trizol method improved the quality of RNA extracted compared to the
RNeasy method, the 260/280 and 260/230 ratios were low indicative of co-contaminants
that were not removed following clean up of the samples as well as low RIN numbers
indicative of RNA degradation.
Both RNeasy and trizol were viable methods for the purposes of this study, however
there was clear evidence of co-contaminants and RNA degradation present. The 260/230
ratios were low, with absorption at 230 nm indicating salt contamination. As mineralized
tissues are rich in hydroxyapatite and salts a de-calcification step with EDTA prior to
fixation and staining was introduced. RNA was isolated using trizol and RNeasy micro
kit, with no improvement in RNA quality as indicated by the 260/280 and 260/230 ratios
as well as the inability to obtain Agilent profiles. These data may be explained by the fact
that EDTA has been reported to compromise integrity and yield of nucleic acids
(Williams et al. 1999), in future studies it would be useful to test other methods such as
water or possibly shorter incubation times.
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Finally RNA was extracted using the Arctums pico pure RNA isolation method. This
commercially available kit is hypothesized to successfully isolate RNA from as little as
100 cells. This RNA isolation method was found not to improve the integrity of RNA
when compared to the other isolation methods. Although fewer cells were used for these
extractions compared to the other methods it can be concluded that this method may be
viable for studies of this nature, however it was found not to be reproducible.
Limited microarray data from the rhPTH treated group at the endosteal envelope was
obtained. Genes whose expression was strongly elevated in response to rhPTH treatment
were broadly grouped as being associated with development; binding, catalysis and cell
cycle; other genes affected to a lesser extent by rhPTH treatment were categorized as
being associated with signal transduction, apoptosis, cytokinesis and cell migration, cell
proliferation as well as structural proteins and transcription factors. However no RT-PCR
was performed to check for constistency due to time limitations, a major limitation which
should be, addressed in future studies. PTH is known to regulate the expression of genes
in these families (Qin et al. 2003), and similar findings have been reported in vivo and in
vitro by other researchers (Onyia et al. 2005, Qin et al. 2003). However no other data is
currently available in the literature regarding microarray data derived from different
anatomical sites of bone and as such no direct comparisons to the data presented here can
be made. These genes belong to different families based on their function, therefore
further evaluation of the regulation and function of these genes is necessary to clarify
their role in bone. It should be noted that this study is far from a complete representation
of all PTH regulated genes and thus further investigations are necessary.
Osteoblasts pose receptors for both PTH (Fermor and Skerry, 1995) and GH (Lobie et al.
1992) and are thus directly stimulated by these hormones. It has been reported that the
osteoblast and its progenitors are the primary in vivo targets for PTH action (Dempster et
al., 1993), where stimulation of bone formation occurs primarily on endocortical surfaces
(Oxlund et al., 1993). In vitro studies have shown that PTH promotes the commitment of
osteoblast precursors (Ishizuya et al., 1997) and inhibits osteoblast apoptosis (Jilka et al.,
1999). GH on the other hand has been shown to increase bone formation markers as well
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as serum concentrations of IGF-I (Fernholm et al., 2000, Hedstorm et al. 2004). It is well
known that GH either acts directly on specific tissues or by binding to its receptors and
stimulating the release of IGF-I, however the interdependence of GH and IGF-I makes it
difficult to independently assess the contribution of each compound to bone accretion
(Govoni et al. 2006). The molecular events responsible for the different skeletal
responses to PTH and GH are poorly understood. Therefore an attempt to ascertain the
molecular networks responsible for the effects of these hormones, by identifying gene
expression patterns and pathways associated with their processes in bone was undertaken.
In conclusion the data obtained and presented herein was not reproducible between
different sets of samples. Although considerable effort over 36 months was put into this
study, possibly due to the long term storage of the samples and the delays in analyzing
data, might have affected the RNA integrity, since the first set of samples provided
successful, though limited microarray data, compared to the second set of samples. While
the older animals were the best model for a quiescent bone surface at the start of the
experiment, obtaining high quality and quantity RNA from this age group was proving to
be problematic and the quality and quantity of RNA obtained was inconsistent across the
groups. This may have been due to the thinning of the periosteum and endosteum that
occurs with ageing, which affects the number and activity of cells present at those sites,
and therefore less RNA present and available to isolate. Finally during the laser
dissection process in order to avoid contamination of the sample with extraneous tissue
the muscle for the periosteal site and bone and bone marrow for the endosteal site were
avoided, so it is a possibility that the area of interest undergoes damage as a result of the
laser action when the width of periosteum to laser width ratio becomes to low which
leads to increased tissue degradation. Although a challenging study with many
difficulties, substantial work has been undertaken to provide the basis for future studies to
assess how different hormonal and growth factors influence periosteal and endosteal
cells. It's been long speculated that there are selective and specific drug targets within the
periosteum and endosteum that can be independently activated, to improve bone strength
and reduce fracture risk and studies like the one presented in this chapter highlight the
importance of research that needs to be undertaken to identify these targets.
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CONCLUSIONS AND FUTURE STUDIES
Conclusions and future work
The aim of this thesis was to provide support of the hypothesis, that rhPTH and rhGH can
protect osteocytes from apoptosis and control differently osteoblastic cell populations at
different anatomical sites. To examine this hypothesis a number of different experiments
were carried out in vitro using the MLO-Y4 osteocyte-like cell line, in vivo using aged
female rats and ex vivo using human bone cores in the presence or absence of mechanical
stimulation. It has long been speculated that anabolic treatments can be used in the future
to treat bone diseases. More specifically parathyroid and growth hormones have long
been under investigation and associated with the prevention of osteocyte apoptosis and
osteoblast actions to improve bone structure and integrity. However their effects and
molecular mechanisms controlling these processes on osteocytes and osteoblasts have not
been studied in response to injury, ageing or human ex-vivo explants.
In the second chapter of this thesis evidence has been presented of the protective effects
rhPTH and rhGH exert on osteocytes in a cell wounding model in vitro using the
osteocyte-like cell line MLO-Y4s, taken to represent microdamage in vivo. The data
presented in chapter 2 may provide us with an insight of how osteocytes sense and
respond to injury as well as the potential of therapeutical compounds to maintain
osteocyte viability in disease and ageing. However studies in primary osteocytes rather
than cell lines would be of more interest to explore their response to these hormones as
well as injury. Further studies will be useful to establish the long-term fate of the
wounded cells, since it is clear that is not necrosis of cells but we cannot rule out the
possibility of apoptosis and the relation of such a response to rhPTH and rhGH. Finally
the Zetos™ bioreactor discussed in chapter 4 may be useful to induce microcracks in
human bone and study the osteocyte response to cell wounding in its 3D dimensions in its
native environment, since such a study would be difficult to design in vivo. The Zetos™
bioreactor could be a useful system because it would allow the perfusion of growth
factors as well as hormone treatments and perfusion of dyes to study histologically the
fate and response of primary osteocytes to microdamage.
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As ML0-Y4s are osteocyte-like cells they do not represent primary osteocytes and their
responses during ageing. To study these parameters rhPTH and rhGH were administered
in aged female rats as presented in chapter 3 to study their effects on the ageing
osteocytic cell population. Evidence has been presented to show their protective effects
on these cells as well as improving bone architecture as evidenced by micro-CT analysis.
The effect of rhGH was not as pronounced as that of the rhPTH but these differences may
be partially explained by the fact that osteocytes possess receptors for PTH but not for
GH. Therefore GH treatment exerts indirect effects to the osteocytes possibly through the
GH/IGF-I axis. Although the exact anti-apoptotic signaling pathways were not
investigated in this thesis, sclerostin immunostaining may provide limited information as
to the hormonal regulation of bone remodeling mediated by the osteocytes; further
studies are however required to elucidate the possible involvement of sclerostin in other
processes such as apoptosis or cell differentiation.
However studying the effects of anabolic compounds on osteocytes and osteoblasts in
animal models is not representative of the in vivo situation in human bone. Therefore, to
investigate the effects of rhPTH in the presence or absence of mechanical stimulation,
following reports that they have synergistic effects on osteocyte viability and osteoblast
indices in human trabecular bone explants, the Zetos™ culture system was used. rhPTH
in the presence or absence of mechanical stimulation decreased SOST gene expression,
which supports the hypothesis of an anabolic effect of this hormone via the osteocyte.
Possibly rhPTH prevented osteocyte SOST production and promoted osteogenesis by the
rhPTH-stimulated apoptosis resisting osteoblasts in the BMUs of bones. However still
more studies are required to elucidate the role of SOST and sclerostin in such systems
and their biological significance in osteocyte-osteoblast communication. This system
might prove to be valuable for the prolonged maintenance of bone samples in culture and
questions regarding the time course of osteocyte or osteoblast apoptosis as well as the
interactions of these cells might be answered by its use. Future work should explore
whether rhPTH and rhGH, exert beneficial effects on osteocytes and osteoblasts and in
combination with molecular biology techniques it might provide useful insights into the
mechanisms and pathways employed by mechanical stimulation and/or rhPTH or rhGH
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in the maintenance of osteocyte viability in human bone. Also the use of
histomorphometric indices in longer duration experiments may provide useful
information with regard to osteocytes and osteoblasts and their response to mechanical
stimulation and growth factors. Due to time and compound availability limitations no
experiments were carried out to study the effects of rhGH in this system. GH and exercise
have been reported to increase osteogenesis at the periosteal envelope of bone (Kalu et al.
2000) and GH has been found to affect cortical and cancellous bone, however the
complexity of the GH/IGF-I system as well as the effects of GH on muscle which may
explain the enhanced mechanical properties of bone have made it hard to study these
parameters together, the Zetos™ may provide direct information as to the effects of these
two parameters separately and in combination.
Finally both PTH and GH have been reported to exert anabolic actions by inducing bone
formation by the osteoblasts and/or by inhibition of osteoblast apoptosis. The
mechanisms by which they exert their anabolic effects remain unknown. However, the
differences observed in the osteogenic responses these agents elicit at different
anatomical sites of bone, suggest that selective targeting of either periosteal or endosteal
bone surfaces would prove useful. This hypothesis served as the aim of the study in
chapter 5 where an attempt to study the gene expression of osteoblasts using LCM has
been presented. A number of pitfalls have been identified but this study could be the basis
for the design of future studies to look into the molecular profiling of the osteoblast
which is directly stimulated by rhPTH and rhGH and provide useful information that
could serve towards the development of new drug targets for treating pathological bone
conditions.
The data presented in this thesis highlights the protective effects of rhPTH and rhGH on
osteocytes in vitro, in vivo and ex vivo. Also an attempt to study the osteoblast molecular
profiling and its response to hormone treatment was made; unfortunately limited
microarray data was obtained, in response to rhPTH treatment at the endosteal envelope
that could form the basis for follow-up studies. Both rhPTH and rhGH exert complex
actions on bone, and future studies are necessary to elucidate the mechanisms of these
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lamimin, gamma 2
Similar to Factor VIII associated protein (predicted)
peroxisomal biogenesis factor 11A III peroxisomal
biogenesis factor 11A
Vacuolar protein sorting 54 (yeast)
similar to RIKEN cDNA 2500002L14; EST C77350
leucine-rich and death domain containing (predicted)
LSM16 homolog (EDC3, S. cerevisiae) (predicted)
Solute carrier family 16 (monocarboxylic acid
transporters), member 6
regulator of chromosome condensation 2 (predicted)
similar to RIKEN cDNA 5730453116
Wolf-Hirschhorn syndrome candidate 1 -like 1 (predicted)
solute carrier family 22 (organic cation transporter),
member 5
Pannexin 1
SRY-box containing gene 6
fucosidase, alpha-L- 2, plasma
trefoil factor 1
distrobrevin binding protein 1
CDNA clone IMAGE:7380769
zinc finger protein 91
similar to Zinc finger protein ZIC 3 (Zinc finger protein of
the cerebellum 3) (predicted)
similar to Expressed sequence AW060207





































HGF-regulated tyrosine kinase substrate
phosphoglucomutase 3 (predicted)
Ras homolog gene family, member G
LUC7-like 2 (S. cerevisiae) (predicted)
Hypothetical LOC295483 (predicted) III Similar to Rho
GTPase activating protein 20 (predicted)
Transcribed locus, strongly similar to NP_075738.1
yippee-like 1 [Mus musculus] III Transcribed locus,
strongly similar to NP_075738.1 yippee-like 1 [Mus
musculus]
Similar to RIKEN cDNA 2610019F03
similar to mKIAA1757 protein (predicted)
similar to KIAA2026 protein
baculoviral IAP repeat-containing 3 III baculoviral IAP
repeat-containing 3
dedicator of cytokinesis 5 (predicted)
regulator of G-protein signaling 14
Transcribed locus, strongly similar to XP_574462.1
PREDICTED: similar to hypothetical protein C230069C04
[Rattus norvegicus]
TBC1 domain family, member 10a
Transcribed locus
serine/arginine repetitive matrix 1 (predicted)
chromodomain helicase DNA binding protein 2 (predicted)
Transcribed locus
Transcribed locus
Transcribed locus, strongly similar to NP_032322.1 heat
shock factor 1 [Mus musculus]
Similar to Lmnb2 protein (predicted)
similar to 2610027C15Rik protein (predicted)
polymerase (DNA-directed), epsilon 4 (p12 subunit)
(predicted)
Transcribed locus
Thymoma viral proto-oncogene 1
aurora kinase A interacting protein 1
SUMO/sentrin specific peptidase 6 (predicted)
STEAP family member 3 III STEAP family member 3
Casein kinase 1, alpha 1
ubiquitin C III ubiquitin C
Similar to 4921517L17Rik protein
ras homolog gene family, member A III ras homolog gene
family, member A
similar to 3-oxoacid CoA transferase 1 III similar to 3-
oxoacid CoA transferase 1
Beta-2 microglobulin
Transcribed locus
GATA zinc finger domain containing 2A
similar to Cd300D antigen
Transcribed locus
similar to stromal membrane-associated protein 1
































RNA binding motif protein 18 (predicted)
Inositol (myo)-1(or 4)-monophosphatase 1
glutamate dehydrogenase 1
COMM domain containing 3
ribosomal protein S2 III similar to ribosomal protein S2
(predicted) III similar to 40S ribosomal protein S2 III
similar to 40S ribosomal protein S2 III similar to 40S
ribosomal protein S2
ubiquinol-cytochrome c reductase hinge protein III
ubiquinol-cytochrome c reductase hinge protein




similar to Probable serine/threonine-protein kinase
KIAA1811 (predicted)
Transcribed locus
presenilin enhancer 2 homolog (C. elegans)
Asparagine-linked glycosylation 3 homolog (yeast, alpha-
1,3-mannosyltransferase)
Transcribed locus, strongly similar to XP_215477.3
PREDICTED: similar to RIKEN cDNA 1500031M22
[Rattus norvegicus]
Similar to IQ motif and WD repeats 1 (predicted)
protein tyrosine phosphatase, receptor type, f polypeptide
(PTPRF), interacting protein, alpha 1 (predicted)
low density lipoprotein receptor-related protein 1 III low
density lipoprotein receptor-related protein 1
profilin 1
similar to TAFI95
spastic paraplegia 21 homolog (human)
similar to RIKEN cDNA 1810018L05 III similar to motile
sperm domain containing 1
Similar to male sterility domain containing 1 (predicted)
v-ral simian leukemia viral oncogene homolog B
CD59 antigen
solute carrier family 38, member 2
nuclear factor, erythroid derived 2, like 2 III nuclear factor,





etoposide induced 2.4 mRNA
Transcribed locus
similar to KIAA2010 protein (predicted)
Fc receptor, IgG, low affinity 111 III Transcribed locus,
weakly similar to XP_421392.1 PREDICTED: similar to
Protein phosphatase 1, regulatory (inhibitor) subunit 13B
[Gallus gallus]






































eukaryotic translation elongation factor 2 III eukaryotic
translation elongation factor 2
SAC1 (suppressor of actin mutations 1, homolog)-like (S.
cerevisiae)
Transcribed locus, moderately similar to XP_580018.1
PREDICTED: hypothetical protein XP_580018 [Rattus
norvegicus]
similar to RIKEN cDNA 0610037P05
ribosomal protein L23
LRRGT00193
Transcribed locus, strongly similar to NP_695208.1
serine/threonine protein kinase 6 [Rattus norvegicus]
similar to PHD finger protein 20-like 1 isoform 1
SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 4
syntaxin binding protein 3
ribosomal protein L19
bicaudal D homolog 2 (Drosophila)
heterogeneous nuclear ribonucleoprotein
methyltransferase-like 3 (S. cerevisiae) III heterogeneous
nuclear ribonucleoprotein methyltransferase-like 3 (S.
cerevisiae)
cofilin 1, non-muscle
superoxide dismutase 1 III superoxide dismutase 1
protein phosphatase 1, regulatory (inhibitor) subunit 2
similar to product is unknown-seizure-related gene
(predicted) III similar to Ornithine decarboxylase antizyme
2 (ODC-Az 2) (AZ2)
coronin, actin-binding protein, 1B
prefoldin 1 (predicted)
ribosomal protein L28
guanine nucleotide binding protein (G protein), gamma 11
similar to CG13957-PA (predicted)
acidic ribosomal phosphoprotein PO
zinc finger protein 592 (predicted)
Transcribed locus
integrin beta 3 binding protein (beta3-endonexin)
PDZ and LIM domain 1 (elfin)
ribosomal protein L26
succinate dehydrogenase complex, subunit D, integral
membrane protein III succinate dehydrogenase complex,
subunit D, integral membrane protein
Rho guanine nucleotide exchange factor (GEF) 3
(predicted)
RAB28, member RAS oncogene family
ribosomal protein S13 III similar to ribosomal protein S13
III similar to ribosomal protein S13
deoxyribonuclease 1 -like 1
similar to Ski protein (predicted)
ubiquitin A-52 residue ribosomal protein fusion product 1
CDC23 (cell division cycle 23, yeast, homolog)
protein tyrosine phosphatase, receptor type, F
mediator of RNA polymerase II transcription, subunit 31
Adh4 III Gtf2h4






























Alcohol dehydrogenase 4 (class II), pi polypeptide III
General transcription factor II H, polypeptide 4
pyruvate dehydrogenase E1 alpha 1 III similar to Pyruvate
dehydrogenase E1 component alpha subunit, somatic
form, mitochondrial precursor (PDHE1-A type I) III similar
to Pyruvate dehydrogenase E1 component alpha subunit,
somatic form, mitochondrial precursor (PDHE1-A type I)
similar to RIKEN cDNA 2410166105
ribosomal protein L7a (predicted)
similar to KIAA0853 protein (predicted)
carbonic anhydrase 3 III carbonic anhydrase 3
Transcribed locus
calmodulin 1 ///calmodulin 1
suppressor of initiator codon mutations, related sequence
1 (S. cerevisiae) (predicted) III similar to Eukaryotic
translation initiation factor 1 (elF1) (predicted) III similar to
suppressor of initiator codon mutations, related sequence
1 (predicted) III similar to suppressor of initiator codon
mutations, related sequence 1 III similar to suppressor of
initiator codon mutations, related sequence 1 III similar to
suppressor of initiator codon mutations, related sequence
1
Iroquois related homeobox 3 (Drosophila) (predicted)
similar to RIKEN cDNA 6330509G02
polymerase (DNA directed), epsilon 3 (p17 subunit)
Transcribed locus, strongly similar to XP_214253.3




similar to 2310002F18Rik protein
GrpE-like 1, mitochondrial
ADP-ribosylation factor 3
prolyl 4-hydroxylase, beta polypeptide
ribosomal protein L27a (predicted)
similar to MYLE protein (Dexamethasone-induced protein)
(predicted)
chromosome segregation 1 -like (S. cerevisiae) (predicted)
Carcinoembryonic antigen-related cell adhesion molecule
3 III Transcribed locus, strongly similar to XP_216910.3
PREDICTED: similar to Methionine-tRNA synthetase
[Rattus norvegicus]
Ssu72 RNA polymerase II CTD phosphatase homolog
(yeast)
chromodomain helicase DNA binding protein 4
Transcribed locus
similar to EMI domain containing 1
Transcribed locus, strongly similar to XP_238334.3
PREDICTED: similar to putative homeodomain








































3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 III 3-
hydroxy-3-methylglutaryl-Coenzyme A synthase 1
proteasome (prosome, macropain) subunit, alpha type 2
III proteasome (prosome, macropain) subunit, alpha type
2
Similar to mKIAA0934 protein (predicted)
Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 3 (predicted)
WD repeat domain 41 (predicted)
ribosomal protein L14
Similar to Enhancer of rudimentary homolog
ribosomal protein L34 (predicted) III similar to ribosomal
protein L34 III similar to ribosomal protein L34
cell division cycle 42 homolog (S. cerevisiae)
NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
4, 15kDa
dolichol-phosphate (beta-D) mannosyltransferase 1
(predicted)
B-cell leukemia/lymphoma 6 (predicted)
ADP-ribosylation factor-like 2 binding protein
similar to hypothetical protein D12Ertd771e
Zinc finger protein 212




Transcribed locus, strongly similar to XP_340756.1
PREDICTED: similar to tumorous imaginal discs protein
Tid56-like protein long form; TID1L; mTid-1L [Rattus
norvegicus]
similar to RIKEN cDNA 2900010J23
transgelin 2
Transcribed locus




GNAS complex locus III XLas protein
Transcribed locus
actin, beta
profilin 2 III profilin 2
ribosomal protein L35
Cell death-inducing DNA fragmentation factor, alpha
subunit-like effector A (predicted)












































sine oculis-related homeobox 5 homolog (Drosophila)
(predicted)
Transcribed locus
Discs, large homolog 1 (Drosophila)
similar to Adenosine deaminase CG11994-PA
LOC500651
Transcribed locus
Zinc finger protein 281
Transcribed locus
endothelial differentiation-related factor 1 (predicted)
similar to DKFZP547E1010 protein
eukaryotic translation initiation factor 3, subunit 9 (eta)
protein kinase C and casein kinase substrate in neurons 2
Protease, serine, 35 III Protease, serine, 35
hypothetical protein LOC683839 III hypothetical protein
LOC688495
ddx5 gene
proteasome (prosome, macropain) subunit, beta type 7 III
proteasome (prosome, macropain) subunit, beta type 7
Transcribed locus
peroxiredoxin 1 III peroxiredoxin 1
ribosomal protein L22 like 1 (predicted)
interferon induced transmembrane protein 2 (1-8D)
armadillo repeat containing 1 (predicted)
follistatin-like 3
similar to 60S ribosomal protein L18a




ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
transmembrane protein 55A
Numb gene homolog (Drosophila)
similar to protein kinase/endoribonuclease(IRE1) alpha
(predicted)
PR domain containing 15 (predicted)
similar to Erbb2 interacting protein isoform 2 (predicted)
dermal papilla derived protein 6
isochorismatase domain containing 1
FK506 binding protein 1a
similar to transcription elongation factor A 1 isoform 2
similar to RIKEN cDNA 1300002A08
inositol 1,4,5-triphosphate receptor 1
eukaryotic translation initiation factor 3, subunit 5 (epsilon)
(predicted)
chymase 1, mast cell
stromal interaction molecule 1 (predicted)
Similar to Notch-regulated ankyrin repeat protein



































similar to Vps41 protein (predicted)
oxysterol binding protein-like 5
Vimentin-type intermediate filament associated coiled-coil
protein
Down syndrome critical region homolog 2 (human)
(predicted)
MAP kinase-interacting serine/threonine kinase 2
ribosomal protein S15a
basigin





CDC42 effector protein (Rho GTPase binding) 4
(predicted)
poliovirus receptor-related 3 (predicted)
similar to Solute carrier family 35, member E3 (predicted)
hypothetical protein LOC687090
similar to T-Brain-1 III similar to T-Brain-1
aquaporin 1
Transcribed locus
ring finger protein 25
docking protein 4 (predicted)
similar to Ski protein (predicted)
synaptotagmin binding, cytoplasmic RNA interacting
protein
Transcribed locus
Solute carrier family 26 (sulfate transporter), member 1
zinc finger protein, subfamily 1 A, 5 (predicted)
adaptor-related protein complex 1, sigma 2 subunit
(predicted)
cysteine and glycine-rich protein 1
serine (or cysteine) peptidase inhibitor, clade B, member
6a
similar to Myeloid/lymphoid or mixed-lineage leukemia
protein 3 homolog (Histone-lysine N-methyltransferase,
H3 lysine-4 specific MLL3) III similar to Myeloid/lymphoid
or mixed-lineage leukemia protein 3 homolog (Histone-
lysine N-methyltransferase, H3 lysine-4 specific MLL3)
phosphatidylethanolamine binding protein 1
similar to nucleolar protein family A, member 3 III similar
to nucleolar protein family A, member 3
zinc finger protein 142 (clone pHZ-49) (predicted)
Transcribed locus, moderately similar to XP_529790.1
PREDICTED: hypothetical protein XP_529790 [Pan
troglodytes]
Similar to CDNA sequence BC024561 (predicted)
heat shock factor 2



































Acidic (leucine-rich) nuclear phosphoprotein 32 family,
member E
similar to hypothetical protein CG003 (predicted)
ribosomal protein SA
proline/serine-rich coiled-coil 2
tetratricopeptide repeat domain 3 (predicted)
RAB1, member RAS oncogene family
Transcribed locus
FK506 binding protein 3 (predicted)
Transcribed locus
endothelial cell adhesion molecule
similar to HSPC288 (predicted)
hypoxia induced gene 1
TBC1 domain family, member 2B
PRP4 pre-mRNA processing factor 4 homolog (yeast)
glutathione peroxidase 4 III glutathione peroxidase 4
WW domain binding protein 5 (predicted)
eukaryotic translation elongation factor 1 gamma
dystroglycan 1
Fatty acid amide hydrolase
GATA binding protein 4
Transcribed locus
v-rel reticuloendotheliosis viral oncogene homolog A
(avian) III v-rel reticuloendotheliosis viral oncogene
homolog A (avian)
similar to EST AA792894
Transcribed locus
Transcribed locus
heat shock 70kDa protein 14
Transcribed locus
expressed in non-metastatic cells 2 III expressed in non-
metastatic cells 2
similar to RNA binding motif, single stranded interacting
protein 3 isoform 1
Transcribed locus, weakly similar to XP_359938.1
hypothetical protein MG11009.4 [Magnaporthe grisea 70-
15]
RAB12, member RAS oncogene family
Transcribed locus
similar to ubiquitin-conjugating enzyme E2D 1, UBC4/5
homolog
similar to protein 7 transactivated by hepatitis B virus X
antigen
ubiquitin specific peptidase 9, X chromosome (predicted)
Programmed cell death protein 11 (predicted) III CDNA
clone IMAGE:7933354, with apparent retained intron
Transcribed locus
RGD1565641 (predicted)
ATP-binding cassette, sub-family E (OABP), member 1
myotubularin related protein 4 (predicted)
similar to hypothetical protein BC015148 (predicted)





Sim ilarto glucocorticoid induced gene 1 (predicted)
Transcribed locus, strongly similar to XP_230983.3
PREDICTED: similar to MLTK-beta [Rattus norvegicus]
programmed cell death 5 (predicted)
similar to D-glucuronyl C5-epimerase (predicted)
Transcribed locus, strongly similar to NP_722482.1 BCL2-
















TM2 domain containing 3 (predicted)
Transcribed locus
chemokine orphan receptor 1
Transcribed locus III Transcribed locus
ribosomal protein S2
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 11 (predicted)
proteasome (prosome, macropain) 28 subunit, alpha
ubiquitin-conjugating enzyme E2A, RAD6 homolog (S.
cerevisiae)
leucine-zipper-like transcriptional regulator, 1 (predicted)
SEC31-like 1 (S. cerevisiae)
Fc receptor, IgG, low affinity III
similar to CG6105-PA
Activity and neurotransmitter-induced early gene 11 (ania-
11) mRNA, 3' UTR
Transcribed locus
PR domain containing 15 (predicted)
similar to formin-like 2 isoform B (predicted)
Transcribed locus
myc target 1 (predicted)
similar to RIKEN cDNA 2810409H07

















ubiquitin specific protease 12 (predicted) III similar to
ubiquitin specific protease 12 (predicted) III similar to
ubiquitin specific protease 12
crystallin, alpha B III crystallin, alpha B
plectin 1




similar to DNA segment, Chr 1, Brigham & Womens
Genetics 0212 expressed (predicted)
syndecan 4
ring-box 1 III ring-box 1
ephrin B3 (predicted)
WD repeat protein 1
deoxyribonuclease II





























MTERF domain containing 2
Transcribed locus
hypothetical protein LOC686471 III hypothetical protein
LOC690263
NADPH oxidase organizer 1 (predicted)
Transcribed locus, strongly similar to XP_578163.1
PREDICTED: similar to hypothetical protein, expressed
[Rattus norvegicus] III Transcribed locus, strongly similar
to XP_578163.1 PREDICTED: similar to hypothetical








vacuolar protein sorting 28 (yeast) (predicted)
Transcribed locus
asparagine-linked glycosylation 12 homolog (yeast, alpha-
1,6-mannosyltransferase) (predicted)




sterile alpha motif domain containing 4B
two pore segment channel 2 (predicted)
similar to amyloid beta (A4) precursor protein-binding,
family B, member 2 (predicted)
similar to RIKEN cDNA 1200014J11 (predicted)
profilin 2
mitochondrial ribosomal protein L24
similar to RIKEN cDNA B930096L08 (predicted)
similar to RIKEN cDNA 4933428G09 (predicted)
glutaminase
Similar to Transmembrane anchor protein 1
similar to AT motif-binding factor (predicted)
Transcribed locus
Transcribed locus, strongly similar to XP_343327.2
PREDICTED: similar to Myeloid/lymphoid or mixed-
lineage leukemia protein 2 (ALL1-related protein) [Rattus
norvegicus]
similar to 5730405l09Rik protein (predicted)
similar to DNA segment, Chr 4, Brigham & Womens
Genetics 0951 expressed
Transcribed locus
epithelial membrane protein 2
Guanine nucleotide binding protein, alpha q polypeptide
tripartite motif protein 2
Gm963_predicted
Wdr20
Gene model 963, (NCBI) (predicted)
Transcribed locus
Transcribed locus









Rho family GTPase 2
similar to RIKEN cDNA 1810020E01
ELAV (embryonic lethal, abnormal vision, Drosophila)-like
1 (Hu antigen R) (predicted)
Transcribed locus
Transcribed locus
similar to glutathione transferase GSTM7-7






















mitochondrial ribosomal protein L49
crystallin, gamma D
Transcribed locus
Potassium channel tetramerisation domain containing 12
(predicted)
Retinoblastoma binding protein 5 (predicted)
Transcribed locus
similar to RIKEN cDNA 6720467C03 (predicted)
Similar to transmembrane protein 44 isoform a (predicted)
carboxypeptidase D
Neural precursor cell expressed, developmentally down-
regulated gene 4A
kinesin heavy chain family, member 2
leucine rich repeat containing 17
hypothetical protein LOC686179
calcium channel, voltage-dependent, beta 4 subunit
calcium/calmodulin-dependent protein kinase II gamma
protein O-fucosyltransferase 2 (predicted)
similar to Protein C20orf29 (predicted)
heterogeneous nuclear ribonucleoprotein F
similar to RIKEN cDNA 1700023M03
Transcribed locus
Taxi (human T-cell leukemia virus type I) binding protein
3
myelin and lymphocyte protein, T-cell differentiation
protein











































homeo box C6 III homeo box C6
similar to TAFA5 (predicted)
similar to Sec1 family domain containing protein 2
(Syntaxin binding protein 1 -like 1) (Neuronal Sec1)
similar to hypothetical protein FLJ38984 (predicted)
Phosphatidylinositol 3-kinase, regulatory subunit,
polypeptide 1
LIM domains containing 1 (predicted)
similar to 8430411 H09Rik protein (predicted)
Transcribed locus III Transcribed locus
similar to angiopoietin-like 1 III similar to angiopoietin-like
1
zinc finger protein 496 (predicted)
Transcribed locus
similar to procollagen C-endopeptidase enhancer 2 III




Ly6-C antigen III similar to Ly6-C antigen gene (predicted)
tripartite motif protein 28
scavenger receptor class B, member 1
hypothetical LOC311134
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-
linked
WAP four-disulfide core domain 1
synaptojanin 2 binding protein
Transcribed locus
FtsJ homolog 3 (E. coli)






potassium channel tetramerisation domain containing 6
(predicted)
Transcribed locus
similar to RIKEN cDNA 4930521E07 (predicted)
matrix metallopeptidase 3 III matrix metallopeptidase 3
similar to CGI-94 protein (predicted)
Transcribed locus
seven in absentia 2
excision repair cross-complementing rodent repair
deficiency, complementation group 8 (predicted)




similar to RIKEN cDNA 4833435D08


























region, candidate 13 (predicted) III amyotrophic lateral
sclerosis 2 (juvenile) chromosome region, candidate 13
(predicted)
periostin, osteoblast specific factor (predicted) III
periostin, osteoblast specific factor (predicted)
Transcribed locus
syntaphilin (predicted)
Trf (TATA binding protein-related factor)-proximal protein
homolog (Drosophila) III similar to ubiquitin specific
protease 49 (predicted)
Transcribed locus
Similar to RIKEN cDNA 2310005N03 gene
protein phosphatase 2 (formerly 2A), regulatory subunit A
(PR 65), alpha isoform
gap junction membrane channel protein alpha 7
5' nucleotidase, ecto
similar to intracellular protein transport like (XM453)
(predicted)
similar to COX10 homolog, cytochrome c oxidase
assembly protein, heme A: farnesyltransferase III similar
to COX10 homolog, cytochrome c oxidase assembly
protein, heme A: farnesyltransferase
sema domain, seven thrombospondin repeats (type 1 and
type 1 -like), transmembrane domain (TM) and short
cytoplasmic domain, (semaphorin) 5B (predicted)
Rho guanine nucleotide exchange factor (GEF) 15
(predicted)
similar to RIKEN cDNA 2510005D08 (predicted)
similar to Homeobox protein Flox~D9 (Hox-4.4) (Hox-5.2)
similar to OTTHUMP00000018508 (predicted)
Transcribed locus
microfibrillar-associated protein A III microfibrillar-
associated protein 4
Transcribed locus, weakly similar to XP_580018.1
PREDICTED: hypothetical protein XP_580018 [Rattus
norvegicus]
Similar to Transcription factor GATA-5 (GATA binding
factor-5)
similar to hypothetical protein MGC52110 (predicted)
Transcribed locus
Transcribed locus
similar to E2-induced gene 2 protein (predicted)
plasticity-related protein PRG-2
Transcribed locus
similar to RIKEN cDNA 1700052N19
similar to protein Tyr phosphatase III similar to protein Tyr
phosphatase
similar to lipoma HMGIC fusion partner-like 3 (predicted)
zinc finger protein 537 (predicted)


























kelch-like 22 (Drosophila) (predicted)
translocated promoter region
Fibronectin type III domain containing 5
RGD1563912 (predicted)
Protein tyrosine phosphatase, receptor type, K,
extracellular region
protocadherin 3
Aldo-keto reductase family 1, member B4 (aldose
reductase)
Transcribed locus
WD repeat domain 50 (predicted)
protein S (alpha) III protein S (alpha)
Unknown (protein for MGC:72614)
serine (or cysteine) peptidase inhibitor, clade A, member
3N III serine (or cysteine) peptidase inhibitor, clade A,
member 3N
solute carrier family 25 (mitochondrial deoxynucleotide
carrier), member 19




Similar to CD2-associated protein (predicted)
Transcribed locus
Similar to asporin precursor
CDC42 effector protein (Rho GTPase binding) 2 III
CDC42 effector protein (Rho GTPase binding) 2
similar to CG5500-PA
hypothetical protein LOC680687 III hypothetical protein
LOC687274
flavin containing monooxygenase 5 III flavin containing
monooxygenase 5
Transcribed locus
cysteine and glycine-rich protein 2













Transcribed locus, strongly similar to XP_341639.2
PREDICTED: similar to Nedd4-binding brain specific
protein BEAN [Rattus norvegicus]
Protein kinase, AMP-activated, beta 2 non-catalytic
subunit
Serine/threonine kinase 16 III Similar to BC026645
protein (predicted) III Similar to KIAA0954 protein
(predicted)















Similar to Homeobox protein Hox-D8 (Hox-4.3) (Hox-5.4)
polymerase (RNA) II (DNA directed) polypeptide C
stress-induced phosphoprotein 1
membrane-associated DHHC5 zinc finger protein
cysteine-rich secretory protein LCCL domain containing 2
tenascin N (predicted)
Transcribed locus, moderately similar to NP_084125.1
hypothetical protein LOC77043 [Mus musculus]
Transcribed locus, weakly similar to XP_575132.1
PREDICTED: similar to LRRGT00012 [Rattus norvegicus]
cell division cycle 26
Transcribed locus
hypothetical protein LOC678810 III hypothetical protein
LOC685448
coagulation factor C homolog (Limulus polyphemus)
(predicted) III coagulation factor C homolog (Limulus
polyphemus) (predicted)
similar to hypothetical protein MGC34760
Transcribed locus
similar to amyloid beta (A4) precursor protein-binding,
family B, member 2 (predicted)
